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ABSTRACT

O’Neal, Stefanie L. Ph.D., Purdue University, December 2015. Manganese Toxicity:
Accumulation in Bone, Effect on Neurochemistry, Impact on Adult Neurogenesis. Major
Professor: Wei Zheng.

Manganese (Mn) exposure is a growing public health concern as new evidence
continues to show that high level exposure to this essential metal is toxic. Chiefly toxic to
the central nervous system, it produces signs and symptoms resembling, but not identical
to idiopathic Parkinson’s disease. The hypothesis tested in this dissertation is that Mn
accumulation in body tissues produces subclinical changes in the central nervous system
altering neuronal repair mechanisms and leading to neurodegenerative damage. The
studies in this dissertation evaluated the extent of these changes in the central nervous
system. Changes in the toxicokinetic properties of Mn in bone affecting the parameters of
accumulation, distribution, and elimination were also identified. Importantly, the half-life
of Mn in bone was estimated to be approximately 8.6 years in humans, a finding which
will be essential in developing a biomonitoring system for Mn exposure. Significant
accumulation of Mn in brain and body tissues was observed along with significant metal
dyshomeostasis following Mn exposure. Several brain regions had altered

xv
neurochemistry, and as a consequence, impaired motor function was observed. The
subventricular zone (SVZ), one of two neurogenic niches in the adult brain, had the
largest magnitude of change. Therefore, effects of Mn exposure on cell proliferation and
differentiation in this region were investigated further. The processes involved in adult
neurogenesis were significantly altered following Mn exposure, particularly with regard
to cell proliferation. The full extent of the consequences resulting from Mn exposure in
the pathology of neurodegenerative disease remains unknown, but the results of these
studies demonstrate that although Mn exposure undoubtedly leads to several changes
observed early in neurodegenerative disease pathology, no overt neurodegeneration was
observed. The results of this work will help researchers studying the effect of metal
exposure on adult neurogenesis and will also help researchers studying neurodegenerative
disease and other disorders of the central nervous system.
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CHAPTER 1: INTRODUCTION AND BACKGROUND

1.1 Abstract
Exposure to manganese (Mn) causes clinical signs and symptoms resembling, but
not identical to, Parkinson’s disease. Since the last review on this subject by this group in
2004, the past decade has been a thriving period in the history of Mn research. This
chapter provides a comprehensive review on new knowledge gained in the Mn research
field. Emerging data suggest that beyond traditionally recognized occupational
manganism, Mn exposures and the ensuing toxicities occur in a variety of environmental
settings, nutritional sources, contaminated foods, infant formulas, and water, soil and air
with natural or man-made contaminations. Upon fast-absorption into the body via oral
and inhalation exposures, Mn has a relatively short half-life in blood, yet fairly long halflives in tissues. Recent data suggest Mn accumulates substantially in bone, with a halflife of about 8-9 years expected in human bones. Mn toxicity has been associated with
dopaminergic dysfunction by recent neurochemical analyses and synchrotron X-ray
fluorescence imaging studies. Evidence from humans indicates that individual factors
such as age, gender, ethnicity, genetics, and pre-existing medical conditions can have
profound impacts on Mn toxicities. In addition to body fluid-based biomarkers, other
biomarkers are now being considered, including Mn levels in finger and toenails,
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noninvasive measurement of Mn in bone, and functional alteration assessments. The
information provided in this chapter is intended to establish the importance of this
research. More specific background for research presented in each chapter will be
provided in the introduction sections of respective chapters.

1.2 Introduction
Manganese (Mn) is the 12th most abundant element on the earth (Nadaska et al.,
2012). As a transition metal, Mn exists in more than five valence states, with a majority
as Mn2+ or Mn3+ (Aschner et al., 1999). In the environment, it is found mainly in its
oxidized chemical forms, as MnO 2 or Mn 3 O 4 (Post, 1999). Mn is essential to human
health, acting as a co-factor in the active centers of various enzymes, and is required for
normal development, maintenance of nerve and immune cell functions, and regulation of
blood sugar and vitamins, among other functions (Aschner et al., 2007; Crossgrove and
Zheng, 2004; Guilarte, 2010). Overexposure to this metal, however, causes toxicity to
many organ systems and across different life stages. Clinically, this toxicity is termed
manganism.
In 2004, this group summarized the impact of Mn exposure on general human
health (Crossgrove and Zheng, 2004). At the time, a majority of evidence on Mn
intoxication came from occupational settings, because of high exposure levels. Over the
past decade, much progress has been made in the Mn research field, from toxicokinetics
to exposure assessment and from the mode of action to clinical therapeutic intervention.
Recent studies from this and other laboratories have indicated that low-level occupational
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exposure, with air Mn concentrations at or below occupational standards can also be
detrimental. Neurochemical, neurobehavioral, and neuroendocrine changes may occur
before structural damage occurs, and are linked to pathogenic conditions (Alessio et al.,
1989; Cowan et al., 2009a,b; Dydak et al., 2011; Lucchini and Zimmerman, 2009; Mutti
et al, 1996). In addition to the exposure level and duration, there are other unique factors,
such as age, gender, ethnicity, genetics, location, and pre-existing medical conditions that
may contribute to Mn toxicity.
This chapter seeks to provide a comprehensive review of the new insights into
environmental Mn exposure gained in the last decade. The current understanding of Mn
toxicokinetics and its distribution in brain by using advanced synchrotron X-ray
fluorescence imaging technique will be first introduced. The advantage and disadvantage
of using bone Mn levels as a potential indicator for Mn body burden will be addressed.
This will be followed by a general review of the updated knowledge on Mn systemic
toxicities including effects on brain, liver, and the cardiovascular system. Finally,
comments and recommendations will be made with regard to the diagnosis of Mn
intoxication and clinical intervention.

1.3 Absorption, Distribution, and Elimination
The highest concentrations of Mn are present in bone, liver, kidney, pancreas,
adrenal and pituitary glands (Rahil-Khazen et al., 2002). The normal concentration of Mn
in human tissues is 1 mg/kg in bone (Liu et al., 2014), 1.04 mg/kg in pancreas, and 0.98
mg/kg in kidney cortex (Rahil-Khazen et al., 2002). The normal blood Mn
concentrations range from 4-15 μg/L in humans (ATSDR, 2012). A recent survey among
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the general Chinese population suggests that women have a higher blood Mn level than
men (~28.6%) (Zhang et al., 2015). Mn is transported and regulated by several
macromolecules summarized in Table 1.
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Table 1. Proteins Involved in Maintaining Mn Homeostasis. Proteins required for
regulating Mn are shown in conjunction with the particular species bound and the
corresponding function.

Name and abbreviation
Divalent metal transporter
(DMT1/SLC11A2)
Transferrin (Tf)
Tf Receptor (TfR)

Mn
species
bound
Mn2+
Mn3+
Mn3+

Function

References

Mn2+
Mn2+
Mn2+

Mn uptake
Mn uptake
Mn uptake
Mn transport in blood brain
barrier
Mn uptake
Mn uptake

Mn2+

Mn uptake

Lucaciu et al., 1997

?

Mn uptake

Mn2+
?

Mn uptake
Mn efflux

Ferroportin (SLC40A1)
Metallothionein
Iron-responsive elementbinding protein (IRP1)

Mn2+
?

Ceruloplasmin

Mn2+

Mn efflux
storage protein
Mn can replace the 4th Fe in
the 4Fe-4S active center.
potentially oxidizes Mn(II) to
Mn(III)
oscillates between Mn(II) and
Mn(III) species

Kannurpatti et al., 2000
Crossgrove and Yokel,
2005
DeWitt et al., 2013
Madejczyk and Ballatori,
2012
Kobayashi et al., 2007

Citrate
ZIP8 (SLC39A8)
ZIP14 (SLC39A14)
Voltage regulated calcium
channels
Ionotropic glutamate receptor
calcium channels
Store-operated calcium
channels
SLC30A10

superoxide dismutase
Note: ? indicates uncertainty.

Mn2+

Au et al., 2008
Aschner and Gannon, 1994
Baker et al., 2015
Crossgrove et al., 2003
He et al., 2006
Fujishiro et al., 2012

Wang et al., 2006
Gibbons et al., 1976
Sheng et al., 2012
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1.3.1 Chemical Species of Mn in Body Fluids
In the human body, Mn exists primarily in two oxidized states, i.e., Mn2+ and
Mn3+. Mn2+ species in the blood are bound to high molecular mass fractions, such as
albumin and β-globulin as hydrated ions, and also in complexes with bicarbonate, citrate,
and other low molecular mass species (Harris and Chen, 1994; Reaney et al., 2002).
Nearly 100% of Mn3+ species are bound to transferrin (Tf), to form a more stable
complex (Michalke and Fernsebner, 2014). Mn molecules in tissues such as liver, kidney,
pancreas, bone, and brain exist primarily as Mn2+ (Crossgrove and Zheng, 2004).
In the cerebrospinal fluid (CSF), Mn2+ ions are bound to low molecular weight
compounds, such as Mn-citrate (Michalke and Fernsebner, 2014). This form is thus
thought to be transported by a citrate transporter (Yokel, 2009). More evidence, however,
suggests that Mn2+ species are transported mainly by the divalent metal transporter-1
(DMT1) as the primary influx route to brain, although the other transporting proteins
such as ZIP8 are suggested to mediate Mn transport into brain (Aschner et al., 2007;
Chua and Morgan, 1997). Evidence in literature has also suggested that Mn2+ can enter
the brain by store-operated calcium channels; but the extent of this route is much less
than that of transporter-mediated transports (Yokel, 2009). The other Mn species entering
the brain is Mn3+, which is complexed with transferrin and via the transferrin receptor
(TfR)-mediated process (Zheng, 2005, Table 1).

1.3.2 Absorption
The main route of Mn absorption is through the gastrointestinal tract; but the
absorption also occurs in the lungs following inhalation exposure (Nadaska et al., 2012).
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The intravenous injection of illegal narcotics containing Mn has recently provided a third
route of exposure (Sikk et al., 2011).
Inhalation exposure to airborne Mn is common among welders and smelters
(Jiang et al., 2006; Korczynski, 2000; Leavens et al., 2007). Inhaled Mn can by-pass the
liver to enter the blood stream; from there it can enter the brain via the olfactory tract
bypassing the blood brain barrier (Lucchini et al., 2012; Zoni et al., 2012). Studies in rats
demonstrate that Mn is rapidly transported along the evolutionarily conserved olfactory
pathway and is present within the olfactory bulb 8-48 hours after exposure. It is believed
that the trigeminal nerve may also play a role in delivering Mn from the nasal cavity to
the brain (Kanayama et al., 2005; Leavens et al, 2007; Zoni et al., 2012).
Oral exposure is another common route of exposure. Mn is required in small
quantities obtained through dietary intake. The average daily intake for many Western
diets is between 2.3 and 8.8 mg (EPA, IRIS); but this can be much higher. Consumption
of food or water contaminated with high levels of Mn has toxic consequences (Kondakis
et al., 1989). For example, the water supply in Bangladesh is contaminated with Mn up to
2.0 mg/L (Frisbie et al., 2002), which is 4-fold higher than the WHO standard for
drinking water of 400 µg/L (Khan et al., 2012). Studies among school children suggest
that increased levels of Mn in the drinking water in Bangladesh area are inversely
associated with students’ achievement scores in mathematics (Khan et al., 2013). High
levels of Mn in drinking water in Canada have been found to lead to significantly higher
levels of Mn in hair samples in school-age children. The increased hair Mn
concentrations are significantly associated with increased hyperactive behaviors
(Bouchard et al., 2007), impaired cognitive development (Khan et al., 2012), and a
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decrease in IQ points (Bouchard et al., 2011). In Italy, school-age children living near a
ferroalloy plant have been found to have significant impairment of motor coordination,
hand dexterity, and odor identification after exposure to excess levels of Mn in soils
(Lucchini et al., 2012). It is alarming that the high Mn concentration in drinking water is
not solely a public health issue unique to developing countries; approximately 5.2% of
the 2,167 wells surveyed across the United States exceeded the health benchmark of 300
µg/L (DeSimone et al., 2009).
Another potential source of oral exposure is from consuming milk- or soy- based
infant formulas, which contain high levels of Mn. The FDA sets a minimum nutritional
requirement of 5 μg/100 kcal for the amount of Mn infant formulas must contain; yet
there is no maximum established. According to the Institute of Medicine’s
recommendation, infants can consume about 3 µg Mn/day for 0-6 months. Infants can
drink up to a liter of formula a day. When formula is prepared according to the
manufacturer’s instructions, infants could consume from 32-51 µg of Mn per day, far
exceeding the aforementioned recommendation. Soy-based formulas contain more Mn
than cow-based formulas, and both contain much more Mn than does human breast milk
(Tran et al., 2002). Since only a small percentage of Mn is eliminated in human
breastmilk and because breastfed babies consume smaller volumes of milk than do bottlefed babies at each feeding (Stastny et al., 1984), feeding breastmilk is considered much
safer than feeding formulas to infants. It is also known that the concentrations of Mn in a
mother’s milk decrease as lactation progresses. Laboratory testing has shown that babies
who drink formulas had higher concentrations of Mn in hair samples than those who were
breast-fed (Collipp et al., 1983). The higher level of dietary Mn intake has been
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suggested to be associated with the risk of developing the attention deficit hyperactivity
disorder (Aschner and Aschner, 2005).
Recently, cases of Mn-induced Parkinsonism have been reported among
intravenous ephedrone abusers in Estonia, Turkey, Eastern Europe, the Baltic States and
Canada (Tuschl et al., 2013; Zheng, 2005). Mn is added to the drug cocktail as the
oxidizing agent potassium permanganate; the final Mn concentration can be as high as
0.6 g/L. Multiple injections per day can result in doses ranging from 60-180 mg/day by
intravenous administration. This amount far exceeds the 0.1 mg Mn/day recommended as
an intravenous supplement. Continued uses can lead to elevated Mn concentrations in
blood and urine, and patients have signs and symptoms such as impaired speech,
cockwalk, bradykinesia and ataxia (Sikk et al., 2011) Even after cessation of ephedrone
use, some of the motor symptoms continue to progress (Sikk et al., 2011; Tuschl et al.,
2013).

1.3.3 Distribution
Once Mn enters systemic circulation from either the small intestine or lung, it
mainly accumulates in liver (1.2-1.3 mg/kg), brain (0.15-0.46 mg/kg) and bone (1 mg/kg
up to 43%) (Krebs et al., 2014; Liu et al., 2014; Rahil-Khazen et al., 2002; Subramanian
and Meranger, 1985). Mn is detectable in the CSF before it is detectable in the brain
parenchyma, suggesting that it is transported through the choroid plexus (Schmitt et al.,
2011).
The brain is the target organ of Mn toxicity. In human subjects exposed to Mn in
the work place, MRI studies have established higher levels of Mn accumulation in the
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globus pallidus than in other brain structures (Dydak et al., 2011; Jiang et al., 207). Rapid
advancement in synchrotron X-ray fluorescence (XRF) imaging technique has made it
possible to illustrate the Mn distribution pattern in the brain. In rat brains, Mn
accumulates with the highest concentration in the globus pallidus, followed by substantia
nigra pars compacta, thalamus, caudate putamen, axon bundles, and cortex (Robison et
al., 2012). While the hippocampus does not contain more Mn than other brain regions in
control animals, Mn exposure in fact increases hippocampal Mn to the same level as
those in substantia nigra pars compacta and thalamus. Thus, it appears that the
hippocampus is susceptible to Mn toxicity. Moreover, the XRF data show that Mn tends
to accumulate in brain regions that also have a high iron (Fe) concentration (Robison et
al., 2013).
Mn concentrations are thought to be greater in astrocytes than in neurons (Tuschl
et al., 2013). However, the XRF data from single cells show a diffuse Mn distribution
pattern within cells of hippocampus CA3, which are likely neurons. Since only 30% of
astrocytes are saturated after Mn exposure, it seems unlikely that astrocytes serve as the
primary target of Mn accumulation in the rodent model (Robison et al., 2013).
In addition to brain and liver, Mn accumulates extensively in human bone under
normal physiological conditions (Pejovic-Milic et al., 2009). By examining the human
bone collected during autopsy, it is estimated that bone contains about 40% of the total
body burden of Mn (Schroeder et al., 1966). Our recent study in rats has shown that after
subchronic oral exposure to Mn, Mn accumulates in femur, tibia, humerus, and parietal
bone with accumulation reaching steady state concentrations after 6 weeks of dose
administration (O’Neal et al., 2014a).
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Mn is intracellularly distributed in red blood cells due to the presence of
transferrin receptor (TfR) and divalent metal transporter-1 (DMT1) in this cell type
(Crossgrove and Zheng, 2004; Jiang et al., 2007). Inside the cell, Mn acts on
mitochondrial complex I and disrupts energy production (Chen et al., 2001; Jiang and
Zheng, 2005; Zheng et al., 1998). But mitochondria may not be the major intracellular
organelles where Mn ions accumulate. Morello and colleagues (2008) used electron
spectroscopy imaging and demonstrated that the highest concentrations of Mn were
present in the heterochromatin and the nucleolus, followed by a lower concentration of
Mn in the cytoplasm, with the lowest levels in mitochondria. After chronic Mn exposure,
the highest levels of Mn were observed in the mitochondria (Morello et al., 2008).
In a comparative in vitro study utilizing choroidal epithelial Z310 cells, rat brain
endothelial RBE4 cells, dopaminergic N27 and PC12 cell lines, cells were fractionated to
separate nuclei and mitochondria. After Mn exposure, the highest levels of accumulation
were found in the PC12 and N27 neuronal cell types compared with the non-neuronal
brain barrier Z310 and RBE4 cell types. Most Mn was present within the nuclei, which
was true for all four cell lines; only limited accumulation was observed in mitochondria
(<0.5%) and microsomes (<2.5%) (Kalia et al., 2008). Nonetheless, the profound Mn
toxicity on mitochondrial function should not be underestimated.

1.3.4 Elimination
The primary route of Mn elimination is via the fecal hepatobiliary excretion with
limited urinary excretion (Klaassen, 1976). Some Mn-containing molecules such as MnDPDP and Mn nanoparticles show different elimination patterns from the metal Mn
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(Bellusci et al., 2014; Marchal et al., 1993; Zhu et al., 2014). Mn is also eliminated in
milk as mentioned above. However, this route of elimination does not constitute a major
route of Mn excretion. Similarly, very low levels of Mn are excreted in sweat
(Omokhodion and Howard, 1994).
In the brain parenchyma, Mn rapidly accumulates in brain structures such as the
superior and inferior colliculi, amygdala, stria terminalis, hippocampus, and globus
pallidus. The half-lives of Mn in these tissues are about 5-7 days, with the longest
retention in the periaqueductal gray, amygdala, and entorhinal cortex (Grunecker et al.,
2013). The elimination rate from brain tissue is expected to be slower than from either
liver or kidney. In the rat, the half-lives of 16 brain regions are between 52 and 74 days
(Crossgrove and Zheng, 2004).
In a study described in Chapter 2, we administered Mn by oral gavage at 50
mg/kg for 10 weeks. It was interesting to observe that by the fourth week of dose
administration, Mn in blood reached the steady-state concentration, which was
maintained for the duration of the study. Mn concentrations in the CSF, however,
continued to increase even at the 8th week. It is possible that a slow elimination of Mn
from the CSF may contribute to the high level of Mn in the brain (O’Neal et al., 2014a).
It is also possible that a redistribution of Mn from the bone compartment to the central
nervous system may account, at least partially, for the high level of Mn in the CSF. By
studying the elimination rate constant and half-lives, our data revealed that the half-lives
of Mn in various rat bones were between 77 and 690 days with an average of 143 days
for the whole skeleton (O’Neal et al., 2014a). A comparative study between human and
rat estimates that every 16.7 days of a rat’s life is equivalent to one human year
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(Sengupta, 2011). By using this figure, the range of Mn half-lives in the rat skeleton is
estimated approximately 4.6 – 41.3 years in humans with an average half-life of 8.6 years
for humans (O’Neal et al., 2014a).

1.4 Human Exposure to Mn
The primary source of clinically identified Mn intoxication is due to occupational
exposure. Neurotoxicity due to inhalation exposure to airborne Mn has been reported in
miners in Mn dioxide mines (Couper, 1837), workers in dry-cell battery factories (Keen
and Lönnerdal, 1995), smelters (Cowan et al., 2009a,b; Huang et al., 1989; Jiang et al.,
2006; Jiang et al., 2007), steel manufacturing workers or welders (Bowler et al., 2011; Lu
et al., 2005; Ono et al., 2002; Racette et al., 2012; Wang et al., 1989). Our own studies on
3,200 welders in 142 factories in the metropolitan area of Beijing reveal a significant
correlation between airborne Mn level and manganism among welders with an estimated
exposure dosages (calculated by the weight of welding rods) of 5-20 kg (containing 0.36% Mn) per working day per person (Crossgrove and Zheng, 2004; Want et al., 1998).
There are many environmental sources of Mn, which include eroded rocks, soils
and decomposed plants. Human activities expose individuals to additional sources
containing Mn, including the fungicides, Maneb and Mancozeb, medical imaging
contrast agents, and water purification agents. Additionally, several countries including
the United States, Canada, Argentina, Australia, Bulgaria, France, Russia, New Zealand,
China, and the European Union have approved use of the fuel additive
methylcyclopentadienyl manganese tricarbonyl (MMT) (Michalke and Fernsebner,
2014; Nadaska et al., 2012). Combustion of gasoline containing MMT releases Mn
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phosphates, sulphates and oxides into the air, especially where there is high traffic
density releasing particles within the respirable size range (Frumkin and Solomon, 1997;
Nadaska et al., 2012). Mn-containing emissions contaminate soil, dust and plants near
roadways, which introduces additional Mn to the environment (Lytle et al., 1995). Recent
projections of MMT use indicates the average person’s Mn absorption may increase by
several percent. It should be noted that this is an estimated average level of exposure;
therefore some people may be exposed more substantially than others (Frumkin and
Solomon, 1997).
Ultimately, Mn from these various sources ends up in the water supply. As Mn
filters down through the soil, it is reduced to the more soluble Mn2+ form where it can
easily make its way into ground and surface waters. Ground water has the highest
concentration of Mn; but surface water and water near mining operations contain high
levels of Mn as well (Nadaska et al., 2012).

1.5 Manganese-Induced Toxicities
Mn can be stored in organs such as the liver and bone with limited local effects,
but Mn targets multiple organ systems with severe consequences including the
cardiovascular, reproductive, and respiratory; the main target of Mn toxicity is the central
nervous system.

1.5.1 Mn-Induced Neurotoxicity
Cumulative evidence has established that Mn exposure induces signs and
symptoms similar but not identical to Parkinson’s Disease (Jiang et al., 2006; Racette et
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al., 2001; Racette et al., 2005; Rutchik et al., 2012a,b; Tuschl et al., 2013). Early
symptoms of Mn toxicity include cognitive deficits and psychiatric disturbances,
followed by motor symptoms including rigidity, postural impairment, and tremors
(Guilarte and Gonzales, 2015). A study on six manganism patients who were
occupationally exposed to Mn as welders or smelters in Guangxi, China suggested that
Mn exposure led to clinical manifestations of Parkinsonian syndromes with considerable
variations. One patient who had a classic presynaptic syndrome and responded to LDOPA was clearly Mn-intoxicated. Moreover, a case with 25-year Mn exposure showed
a syndrome of Parkinsonism at an early age with magnetic resonance imaging (MRI)
abnormalities bilaterally in the globus pallidus (Rutchik et al., 2012a,b). Thus, these
observations support an overlap in syndromes between Mn-induced movement disorder
and Parkinson’s disease (Racette et al., 2001; Racette et al., 2005; Rutchik et al. 2012a,b).
While the linkage between manganism and Parkinson’s disease is noteworthy,
animal studies suggest that dopaminergic neurons in the substantia nigra and their
terminals in the striatum, which are selectively lesioned in Parkinson’s disease, remain
intact after Mn intoxication (Guilarte, 2010). Additionally, following Mn toxicity,
patients are typically unresponsive to levodopa, the dopamine precursor (Guilarte and
Gonzales, 2015). Thus, changes in neurotransmission, rather than a massive dopamine
neuronal cell loss, likely underlie behavioral observations.
Reports of Mn exposure altering neurotransmitter and metabolite levels have been
published in literature (Gwiazda et al., 2007; Racette et al., 2012a). In Chapter 3, we
investigated changes in dopamine, dopamine metabolites, including 3,4dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as GABA,
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in rat brain after Mn exposure. Our data showed a significantly increased dopamine level
in the striatum; this increase was accompanied by increased levels of DOPAC and HVA
in the same region. In agreement with our report, Vorhees and colleagues (2015) recently
showed that Mn exposure increased striatal dopamine and HVA concentrations compared
to controls. They also observed an increased norepinephrine in the striatum and increased
dopamine, norepinephrine, and serotonin levels in the hippocampus. By utilizing various
ages of animals, these investigators reported that Mn exposure altered monoamines as a
function of age (Vorhees et al., 2015).
In a human study utilizing magnetic resonance imaging and spectroscopy (MRI/S)
to investigate changes in neurochemistry of smelting workers, increases in GABA and
decreases in myo-inositol were seen in the thalamus. Changes in thalamic GABA were
associated with reduced fine motor performance as assessed by the Purdue pegboard test
(Long et al., 2014).
Recent investigation of Mn neurotoxicity has also extended to the field of adult
neurogenesis, which takes place in two critical niche areas in brain, i.e., the
subventricular zone (SVZ) and the subgranular zone (SGZ). Application of the
synchrotron XRF imaging technique to study brain distribution of copper (Cu) and Fe
with or without Mn exposure has led to the unexpected discovery that Cu concentrations
in the SVZ are considerably higher than in any other brain regions (Pushkar et al., 2013).
Further in vivo studies revealed that subchronic Mn exposure in rats greatly increased the
cell proliferation in the SVZ and the associated RMS, but significantly reduced the Cu
levels in the SVZ (Fu et al., 2015). These observations raised the interesting question as
to what the role of Cu in adult neurogenesis may be. It is unknown how Mn transport,
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intracellular storage and trafficking may affect Cu homeostasis and ultimately alter
normal neuronal repair processes, which may contribute to the non-motor symptoms
characteristic of Mn-induced Parkinsonian disorder. The research presented in Chapter 4
was designed to study the effect of Mn toxicity on adult neurogenesis following
intranasal exposure.
Kikuchihara and colleagues (2015) further confirmed that oral Mn exposure
resulted in reduced numbers of local Pvalb+ GABAergic interneurons in the other
neurogenic niche, the SGZ of the dentate gyrus in the HP of mice (Kikuchihara et al.,
2015). Similar to the data published by our group, Kikuchihara’s group also observed a
reduced Cu level in the subgranular zone after Mn exposure, although differences in
animal species, exposure route, and duration between these two studies are evident. Since
Mn exposure results in reduced Cu levels in both neurogenic niches, these two
independent studies may suggest a similar molecular mechanism underlying Mn
neuropathology.

1.5.2 Mn-Induced Cardiovascular Toxicity
Despite a lack of epidemiological evidence, animal and human evidences support
the view that Mn exposure significantly alters cardiovascular function. Intravenous
injection of Mn at high dose (5-10 mg Mn/kg) caused a decreased heart rate and blood
pressure and increased P-R and QRS intervals (Charash et al., 1982). In perfused rat
hearts, an MRI contrast agent Mn-DPDP had similar, but reduced effects on cardiac
function as compared with Mn2+ (Vander et al., 1997). Limited data from human
populations are available; but it somewhat contradicts the data from animal studies. As
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opposed to the decreased blood pressure and heart rate observed in animal studies,
smelters showed significantly faster heart rates than control subjects. Additionally, while
animal studies showed increased P-R intervals, the reverse was true for the smelters,
although the QRS and T waves were wider and elevated in both male and female smelters
compared to controls (Jiang and Zheng, 2005).
Overexposure to the MRI enhancer Mn-DPDP causes flushed face and the head
and ears feeling hot. Postural hypotension has also been observed in Mn-DPDPoverdosed patients (Jiang and Zheng, 2005). Even when cardiac function is not
significantly altered, the mean diastolic blood pressure can be significantly lower, while
and diastolic hypotension can be significantly higher, in Mn-exposed workers as
compared to control subjects. Workers with the highest level of exposure to Mn exhibit
the lowest systolic blood pressure (Jiang and Zheng, 2005).
Despite differences in levels of exposure between human and animal studies, it
appears that Mn exposure inhibits myocardial contraction, dilates blood vessels and
induces hypotension, suggesting that Mn exposure has a significant effect on cardiac
function. The exact mechanism of cardiac toxicity remains unknown; it has been shown
that Mn has a direct effect on mitochondrial function resulting in a reduced myocardial
contraction, and causes vasodilation, leading to a decreased blood pressure following
acute exposure (Jiang and Zheng, 2005). However, the research evidence on whether and
how chronic low level Mn exposure causes cardiovascular toxicities from both human
and animal studies remains sparse. Future work to evaluate these effects is well
warranted.
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1.5.3 Mn Exposure and Infant Mortality
Increased Mn levels in water sources have been linked to increased infant
mortality. An analysis of groundwater concentrations in North Carolina reveals that
infant mortality increases by a factor of 2 per 1,000 live births for every log increase in
groundwater Mn concentration (Spangler and Spangler, 2009). Hafeman et al. (2007) also
report an increased mortality in the first year of life in infants in Bangladesh exposed to
Mn concentrations at or above the WHO’s standard of 400 µg Mn/L compared to
unexposed infants (Hafeman et al., 2007).

1.5.4 Mn Toxicity and Liver Function
Since the original report by Klaassen in 1976 describing the hepatobiliary
excretion of Mn from the liver (Klaassen, 1976) not much work has been done to
describe Mn-induced hepatotoxicity. The liver is a known storage organ for Mn; the
highest Mn uptake occurs in the liver, only second to brain uptake (Chua and Morgan,
1997). Hepatic Mn accumulation in mice intravenously injected with Mn nanoparticles
persisted significantly longer than other highly perfused tissues such as kidney and
spleen; however, no histopathological damage was observed (Bellusci et al., 2014).
Hepatobiliary excretion of Mn represents a primary route of Mn clearance from
the body, accounting for 80% of Mn elimination. Thus, severe liver damage, owing to
various chronic liver diseases, can result in an excessive accumulation of Mn in brain
with ensuing signs and symptoms clinically called Mn hepatic encephalopathy (Long et
al., 2009). With weakened liver function, there is also an increased risk of
neurodegeneration with continued Mn exposure (Squitti et al., 2009). In those patients
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with chronic hepatic encephalopathy, liver transplant has proven to be effective in
reducing brain Mn concentrations. When patients were re-examined 5 months after
transplant, the T1-weighted MRI signals in the basal ganglia were absent (Long et al.,
2009). These data suggest that the normal liver function is essential to maintain
homeostasis of Mn in the body, including the central nervous system (CNS).

1.5.5 Mn Toxicity and Individual Susceptibility
There are many factors that may predispose one individual to Mn toxicity over
another. These individual factors include age, gender, ethnicity, genetics, and pre-existing
medical conditions, such as chronic liver disease.
Age is a common factor which may influence an individual’s susceptibility to Mn
toxicity. Very young animals as well as humans have increased intestinal Mn absorption
(Vorhees et al., 2015) and also have increased accumulations of Mn in the CNS (Cahill et
al., 1980), due to increased permeability of neuronal barriers to Mn (Michalke and
Fernsebner, 2014). The young also have a reduced biliary excretion capacity (Aschner
and Aschner, 2005). The 2011-2012 National Health and Nutrition Examination Survey
(NHANES), a study of US residents, found higher Mn levels in the younger population,
with the highest levels in one year old infants (Oulhote et al., 2014). These age-related
factors can increase the risk of neurotoxicity following exposure.
Alternatively, the very old are a population of special concern, because of the
large number of people who develop idiopathic Parkinsonism. Brain regions such as the
globus pallidus, substantia nigra and striatum are involved in both Mn neurotoxicity and
Parkinsonism; thus it is possible that the elderly may have a subclinical pathology and
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could be “pushed over the edge” by increased doses of Mn (Mena et al., 1969). For
example, in one of our occupational exposure studies, we found that smelters without
clinical symptoms performed significantly worse on the Purdue Pegboard test, which is a
measure of fine motor coordination, than control subjects. The scores got worse with age,
which was not unexpected as fine motor coordination declines with age. However, Mn
exposure appears to exacerbate this decline (Cowan et al., 2009b).
Gender is another common factor which may influence an individual’s
susceptibility to Mn toxicity. The 2011-2012 NHANES study of U.S. residents reported
significantly higher blood Mn levels in women of all ethnicities than men. The authors
suggest metabolic differences in the regulation of Mn between men and women may
underlie the difference (Oulhote et al., 2014). A recent study among the Chinese general
population also indicates that women’s blood Mn levels are about 29% higher than men’s
(Zhang et al., 2015), consistent with reports in the literature that Korean and Italian
women’s Mn levels are 25% higher (Bocca et al., 2011; Lee et al., 2012) and Canadian
women have about 23% higher levels (Clark et al., 2007) than the respective men’s
population.
Gender may also be a contributing factor to developing cardiovascular toxicity
after Mn exposure. In a study of male and female smelters exposed to Mn, female
smelters had significantly shorter P-R intervals compared to controls and there was no
difference in males. QRS and T waves were also significantly different for female
smelters (Jiang and Zheng, 2005). Ethnicity could potentially be a factor that could
influence susceptibility to Mn toxicity. In NHANES 2011-2012, the Asian population
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tended to accumulate significantly more Mn than either non-Hispanic Caucasians or nonHispanic black individuals (Oulhote et al., 2014).
Persons with iron deficiency are of special concern, because animal evidence
indicates that gastrointestinal absorption of manganese is enhanced by iron deficiency
(Mena et al., 1969).
While pregnancy is not a pre-existing condition, it is a condition during which the
susceptibility to Mn toxicity may be increased. Again, the 2011-2012 NHANES
demonstrates that pregnant women accumulate higher levels of Mn than do other persons
(Oulhote et al., 2014). In a recent study of maternal blood Mn levels and
neurodevelopment of infants at 6 months of age, researchers discovered significant
associations between the mother blood Mn levels and their children’s scores on mental
and psychomotor developmental indexes. Interestingly, both high and low Mn blood
levels were associated with lower scores (Chung et al., 2015). Maternal blood Mn levels
have also been shown to be associated with inhibited enzyme activity of newborn
erythrocyte Ca-pump at both low and high levels of maternal Mn (Yazbeck et al., 2006).
A study conducted among pregnant women from Paris suggests that environmental
exposure to Mn may increase the risk of preeclampsia. Mn cord blood concentrations in
that study were significantly higher in women with preeclampsia (Vigeh et al., 2006).
From a mechanistic point of view, SLC30A10, a solute carrier (family 30 and
member 10), has been suggested to regulate Mn export from the cells. This protein is
highly expressed in the liver with a higher specificity for Mn than Zn. Genetic alterations
in the SLC30A10 enzyme have recently been discovered. An autosomal recessive
mutation in this transport protein leads to an inherited Mn-hypermanganesemia (DeWitt
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et al., 2013; Tuschl et al., 2013) and results in a pleomorphic phenotype, including
dystonia and adult-onset Parkinsonism (Leyva-Illades et al., 2014).

1.6 Diagnosis and Clinical Intervention

1.6.1 Biomarkers of Mn exposure
In Mn occupational exposures, the symptoms often develop quickly because the
exposure levels are relatively high. In comparison, symptoms resulting from
environmental exposures may be much more subtle and thus difficult to detect because
they develop slowly, over a lifetime. Thus, it is crucial to detect these changes with a
reliable biomarker in order to prevent the irreversible damage or the loss of function
resulting from Mn toxicity. The biomarkers associated with monitoring Mn exposure in
animal and human studies are summarized in Table 2.

Table 2. Possible Biomarkers of Mn Exposure. Body tissues and fluids previously used as biomarkers to assess Mn
accumulation are summarized with the method of analysis and predicted utility in epidemiological studies.
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Table 2 continued.
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Blood and urine are the most commonly used biological matrices for
biomonitoring. However, the poor relationships between Mn concentrations in blood and
urine and the external exposure levels make it very difficult to determine the internal
exposure (Smith et al., 2007; Zheng et al., 2011). For example, the half-life of Mn in
blood is less than 2 hours (Zheng et al., 2000). Plasma Mn concentrations measured
during the dosing phase of a chronic Mn exposure study began to decline after two
weeks, although Mn exposure was still ongoing (O’Neal et al., 2014a) Mn can be
detected in human saliva samples. Our human study on Mn-exposed welders found that
changes of saliva Mn concentrations mirrored those of serum Mn levels. But, because of
a fairly large variation in saliva Mn levels, the authors did not recommend to use saliva
Mn to assess Mn exposure (Wang et al., 2008). Because more than 95% of Mn is
eliminated in bile to feces, urine Mn levels are expected to be very low (Schroeder et al.,
1966). For these reasons, we do not recommend using Mn levels in blood, urine or saliva
as the biomarkers of Mn exposure.
Attempts to identify additional non-invasive biomarkers have concluded that
using hair and nail samples may be a possibility. In our own studies (Cowan et al.,
2009a,b), we collected hair and nail samples from smelters and control subjects. The data
showed such vast variation that we believe it would be misleading to report these data. A
thorough, yet rapid process must be developed in order to eliminate external
contamination before hair and nail samples can be used in research. Regardless, studies
of residents living near a ferromanganese refinery in Brazil have shown that significant
correlations exist between hair and fingernail Mn levels and the performance on
neuropsychological tests (Viana et al., 2014). Grashow and colleagues (2014) have
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recently suggested using toenail Mn concentration as a biomarker of occupational
welding fume exposure (Grashow et al., 2014); their study, however, did not relate the
toenail Mn level to any biological outcomes.
In a study of Mn-exposed smelters, Mn concentrations in plasma and erythrocytes
were found to increase with a corresponding decrease of Fe concentrations in plasma and
erythrocytes (Cowan et al., 2009a,b). Since Mn concentrations reflect the environmental
exposure and Fe concentrations reflect a biological response to Mn exposure, combining
both parameters by dividing the Mn concentration by the Fe concentration (i.e.,
MnC/FeC) would enlarge the difference between groups and therefore increase the
sensitivity. This thought process led to the development of a concept of Mn/Fe ratio in
plasma (pMIR) or erythrocytes (eMIR) (Cowan et al., 2009a). Because there is a
significant correlation between pMIR and eMIR to airborne Mn concentration, both
pMIR and eMIR appear to be good candidates as the biomarkers for Mn exposure
assessment. Nonetheless, the same study also showed a better correlation between eMIR
and low- or high- exposure outcomes (Cowan et al., 2009a). The utility of pMIR in
environmental exposure assessment requires more rigorous testing. Additionally, as Mncitrate in blood rapidly enters brain, elevated levels of plasma or serum Mn-citrate may
be a biomarker of elevated risk of Mn-dependent neurological disorders in occupational
health (Michalke and Fernsebner, 2014).
A relatively long half-life (about 8-9 years in human) of Mn in the skeletal system
(see above) renders bone Mn concentration an ideal indicator to assess the body burden
of Mn. The technical challenge has always been the development of equipment with
appropriate sensitivity for such a purpose. The good news is that such a technology has
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now become a reality. In recently published manuscripts, Nie and colleagues have
optimized and verified a neutron activation-based analysis (NAA) technique for
noninvasive, real-time quantification of Mn concentrations in bone. The equipment, at
this writing, is compact enough to be transportable to the sites for testing human workers
and subjects. The method is sensitive and can quantify Mn concentrations as low as 0.5
ppm of Mn in bone (Liu et al., 2014; Liu et al., 2013) and recently even lower to 0.3 ppm
(personal communication).
Another non-invasive technique that can be used to analyze Mn exposure in vivo
is MRI. Mn accumulation in the brain can be visualized as an increased T1-weighted
“hyper-intense” MRI signal. By dividing the signal observed in the globus pallidus by the
signal observed in the white matter in the frontal cortex and multiplying by 100, a pallidal
index (PI) can be calculated to quantify Mn intensity. The PI has been proven to be a
reliable marker for Mn exposure (Dydak et al., 2011; Jiang et al., 2007). Workers with
more than 5 years’ experience showed nearly 100% occurrence of enhanced PI,
suggesting that the PI is specific for Mn exposure even when no clinical symptoms are
evident (Jiang et al., 2007). One downside for using MRI is that it is only good for recent
exposures. In human studies of smelters or intravenous ephedrone users, the signal in the
globus pallidus almost completely disappears 5-6 months after cessation of exposure
(Jiang et al., 2007; Sikk et al., 2011).
Magnetic resonance spectroscopy (MRS) is another useful technique to quantify
neurochemical markers associated with Mn exposure (Jiang et al., 2007). Quantitation of
GABA, glutamate, total creatine (tCr), and N-acetyl-aspartate (NAA)/tCr values, along
with other macromolecules, has been made available by MRS. In the thalamus and basal

29
ganglia of Mn-exposed smelters, levels of GABA were nearly doubled, whereas the mean
airborne Mn level was only 0.18 mg/m3, which is below the previous occupational
standard (OSHA, 2013). This may indicate an early metabolic or pathological change
associated with low-level Mn exposure and MRS appears capable of detecting these
biochemical changes before the full-blown symptoms become evident (Dydak et al.,
2011).
For animal researchers, recent advancement in the synchrotron XRF imaging
technique allows to visualize the concentration and distribution pattern of multiple metals
in brain. The technique can now reach the resolution to the single cell level (Robison et
al., 2013).

1.6.2 Clinical Intervention
The foremost therapeutic strategy in treatment of Mn toxicity is to remove the
patient from the source of the Mn exposure. If the intoxication is life threatening, the
procedures to relieve the critical signs and symptoms should first be employed. For a
thorough treatment, chelation therapies can help reduce the body burden of Mn; but such
treatments may not be able to improve symptoms. Another possible therapy includes Fe
supplementation.
Chelation of free Mn with intravenous EDTA has been shown to increase Mn
excretion in urine and decrease Mn concentrations in blood; but chelation does not
significantly improve patients’ clinical symptoms (Crossgrove and Zheng, 2004; Jiang et
al., 2006). A recent report by Tuschl et al., (2013) demonstrates that two patients with
inherited hyper-manganesemia who received EDTA chelation had a significantly
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increased urinary excretion of Mn. Whole blood Mn levels and the MRI signals in the
globus pallidus were also reduced (Tuschl et al., 2013). In vitro studies have documented
that EDTA can effectively block toxic effects of Mn on mitochondrial oxygen
consumption when added either before or after Mn exposure (Liu et al., 2013). Thus, for
the purpose of reducing Mn in the blood compartment in the initial emergency phase,
EDTA has a therapeutic benefit. However, EDTA molecules are highly water soluble and
poorly pass across the blood brain barrier. The low brain bioavailability of EDTA limits
its effectiveness in treatment of Mn intoxication (Jiang et al., 2006).
Para-aminosalicylic acid (PAS) is an FDA approved drug used for the treatment
of tuberculosis. Studies mainly in Chinese patients show the promising effectiveness in
treating severe Mn intoxication with promising prognosis (Jiang et al., 2006). Animal
studies further verify its chelating effect in removing Mn from the body (Zheng et al.,
2009). As a hard Lewis acid, Mn3+ can form a stable complex with hard donor atoms
such as oxygen donors in PAS structure, while the Mn2+ cation prefers relatively softer
donors such as nitrogen, which is also present in PAS structure. Thus, it is possible that
PAS may form stable complexes with both Mn2+ and Mn3 species and remove them from
where they are stored. Moreover, the salicylate structure in PAS, which has a proven antiinflammatory effect, may contribute to the therapeutic prognosis of PAS in treatment of
manganism (Jiang et al., 2006; Yoon et al., 2009). Our recent studies also demonstrated
that the parent PAS was found predominantly in blood and in choroid plexus tissues,
whereas its metabolite AcPAS was found in brain parenchyma, CSF, choroid plexus and
capillary fractions (Hong et al., 2011). Both PAS and AcPAS were transported in the
brain by the multidrug resistance-associated protein 1 (MRP1), a member of the
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superfamily of ATP-binding cassette (ABC) transporters. However, the removal or efflux
of PAS from brain parenchyma into blood was mediated by the multidrug resistance
protein 1 (MDR1), also called P-glycoprotein (Hong et al., 2014).
One additional therapy includes Fe supplementation. In a pilot study with a
sample size of one, Tuschl et al. (2013) showed that Fe supplementation, in addition to
chelation therapy, led to a marked improvement of neurological symptoms, whereas the
chelation therapy alone did little to improve symptoms. The authors proposed that
supplementing with Fe may help reduce blood Mn levels and lower Mn body burden
(Tuschl et al., 2013).

1.7 Discussion
The past decade is a thriving period in the history of Mn research. The total
volume of publications related to “manganese toxicity” by a PubMed search in the last 11
years is 1,619 (from our last published review on 1 April 2004 to this writing on 5 April
2015), which far exceeds the cumulative numbers of 1,199 published papers on Mn
toxicity for the past 167 years ever since Couper (Couper, 1837) reported on the first case
of manganism in 1837 (~ to 31 March 2004). On a more fundamental level, the essence
of what we consider to be a Mn exposure has undergone a significant change, from
traditionally recognized occupational manganism to low-level Mn exposures in a variety
of environmental settings, nutritional sources, contaminated foods, infant formulas, and
water, soil and air with natural or man-made contaminations. Cumulative evidence on Mn
toxicities and the vast public interest in this metal speak volumes of its public health
importance, calling for a thorough understanding of its risk, the mechanism of its harm,
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some forms of effective clinical interventions, and any applicable strategy for prevention.
Thus, we predict that the research on Mn toxicity is far from finished and will become
even more productive in the coming decade.

1.8 Research Challenges
The research challenges addressed by this dissertation are as follows: i) the lack
of knowledge in toxicokinetic behavior of Mn in bone and the association between bone
Mn levels and brain Mn levels, ii) the lack of understanding in changes in common
neurotransmitters associated with Parkinsonian disorders following subchronic exposure
to Mn, iii) the lack of evidence as to whether Mn affects adult neurogenesis, and iv) the
lack of research to understand whether and how Cu dyshomeostasis impacts adult
neurogenesis.

1.9 Central Hypothesis
The central hypothesis under investigation in this doctoral dissertation is that Mn
exposure leads to substantial accumulation of Mn in the body, particularly in bone tissues
and produces subclinical effects in the CNS, including alteration of levels of critical
neurotransmitters in brain. Mn accumulation may result in diminished neuronal repair
capacity, and in this way, may ultimately contribute to neurodegenerative damage.
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1.10 Specific Aims to Test Central Hypothesis
To test the central hypothesis in this doctoral dissertation, we have designed and
accomplished the following specific aims:
1. Determine the toxicokinetic parameters (absorption, distribution, and
elimination) of Mn in bone tissue. The toxicokinetics of Mn in bone were determined
by measuring Mn content in bone using atomic absorption spectroscopy (AAS) at various
times during the accumulation and elimination phases after oral dosing. The rates with
which Mn accumulates and eliminates from bone tissues were also investigated. Several
bones with different composition were analyzed to determine if bone-specific differences
existed. Lastly, correlations between brain and bone Mn levels were evaluated to identify
if bone Mn concentrations accurately represent brain Mn concentrations. Rationale:
Approximately 40% of the body burden of Mn is stored in bone. This is an important first
step to determining if and how Mn stored in bone may be released over time, serving as
an endogenous source of continued Mn exposure, particularly with regard to the central
nervous system.
2. Characterize Mn accumulation in rat brain after exposure and investigate the
effects on regional neurochemistry. In this aim, we quantified Mn concentrations and
neurotransmitter levels in the central nervous system using AAS and high performance
liquid chromatography (HPLC). We further investigated the resulting changes in
monoamines using immunohistochemistry to determine if the enzyme responsible for the
metabolism of dopamine, tyrosine hydroxylase was altered. Levels of DARPP-32, a
marker of striatal medium spiny neurons, were also investigated. Lastly, we determined if
cell death occurred as a result of Mn exposure using histology probes for Fluorojade C in
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rat brain slices. Rationale: Studies in literature have investigated changes in
neurochemistry; yet, the results remain inconclusive. Depending on the dose level of Mn
used or the duration of exposure, the results, particularly with regard to dopamine, vary
considerably. This research utilized several dose levels and examined multiple brain
regions to determine if a dose response relationship existed and whether effects were
limited to a particular region.
3. Identify how Mn exposure affects the processes of neurogenesis and gliogenesis in
the adult subventricular zone. In this aim, we investigated differential changes in
expression of BrdU, DCX, and GFAP in the SVZ following intranasal instillation of Mn
using immunohistochemistry (IHC) techniques and confocal quantification. The cells that
reside in this region may migrate to the olfactory bulb where they undergo further
changes. Expression of BrdU, DCX, and GFAP were also evaluated in the various cell
layers of the olfactory bulb. A sub-aim of this hypothesis was to characterize the
intranasal instillation technique for future use in studies of Mn neurotoxicity and adult
neurogenesis by investigating changes in neurochemistry using HPLC and expression of
mRNA and protein levels of selected metal transporters. Physiological measurements
were also made to determine if overt toxicity or immune response occurs following
intranasal Mn exposure. Rationale: Recent work from our lab has shown that Mn
exposure by intranasal instillation alters adult neurogenesis in the SVZ. This is the first
application of the intranasal instillation technique to studies of adult neurogenesis
following Mn exposure. These studies are of critical importance given that the primary
exposure route following Mn toxicity in humans is direct olfactory transport.
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Investigating changes in the SVZ and OB could provide new evidence for the association
between Mn exposure and Parkinson’s disease.

1.11 Significance of the Research
The interaction between Mn neurotoxicity and Parkinson’s disease is complex and
not completely understood. Many associations between Mn-induced Parkinsonism and
Parkinson’s disease have been found in humans but the results have often been
contradictory. Additionally, recent evidence from our lab has suggested that Mn exposure
alters processes of neuronal repair and adult neurogenesis in the SVZ known to be active
in Parkinson’s disease. It is well-warranted to further investigate changes in this region as
well as changes in neurochemistry following Mn exposure because alterations in these
processes could lead to dysregulation of a variety of other processes in the body. An
understanding of how Mn exposure influences adult neurogenesis and how Cu levels are
regulated in the SVZ are critical for the development of effective therapeutic strategies in
neurodegenerative diseases which implicate Cu dysregulation in their pathologies.
The contribution of our research is expected to be a detailed understanding of how
Mn exposure affects neurochemistry and adult neurogenesis. Specifically, we expect to 1)
elucidate toxicokinetic parameters of Mn in bone which will help in the search for a
suitable biomarker of Mn exposure and determine if Mn stored in bone can serve as an
internal depot of Mn for extended durations, 2) determine how Mn exposure regionally
affects brain neurochemistry and potentially uncover dose-response relationships, 3)
demonstrate that the intranasal route of Mn exposure is a suitable method for studies of
adult neurogenesis and Mn toxicity in general, and 4) discover how Mn interacts with
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brain repair mechanisms, specifically the proliferation and differentiation of neural
progenitor stem cells.
The experimental methodologies to be used are rigorous and diverse, including
atomic absorption spectroscopy, high performance liquid chromatography,
immunohistochemistry, Western blotting, quantitative polymerase chain reaction (qPCR),
and behavioral assays to pursue important new information about Mn toxicity in the
mammalian system. Understanding how brain and bone Mn levels correlate after Mn
exposure will help discover a novel biomarker suitable for the assessment of Mn
exposure in humans. Importantly, the primary route of Mn exposure in the human
population is inhalation; so utilizing an intranasal route of exposure could more closely
mirror what occurs in the human population. No other researchers have used this
technique to investigate metal toxicity and neurogenesis. By this pathway, environmental
contaminants, including Mn, directly interact with the central nervous system and
therefore further investigation of this exposure route is well warranted.
Completion of this work will provide evidence of Mn interaction with neuronal
repair mechanisms and lead to a new area of toxicology research, specifically metals
toxicology. A better understanding of these processes may present novel pathways and
target strategies for regulating the processes of adult neurogenesis in the SVZ and SGZ
by guiding and encouraging the existing processes. This work will assist future
researchers investigating Parkinson’s disease, Alzheimer’s disease, Amyotrophic Lateral
Sclerosis, Wilson’s and Menke’s diseases as well as stroke, and traumatic brain injury,
among many other applications, making our work in the field of adult neurogenesis
highly significant and of great interest. Additionally, these findings in the SVZ can be
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applied to the analysis of other regions with more limited neurogenic capabilities,
including the hypothalamus, further extending the scope of the research.

1.12 Structure of the Dissertation
This dissertation is organized in the following sequence: the introduction and
background are presented in Chapter 1, which provides an in-depth analysis of the new
findings from the last 10 years. Chapter 2 is devoted to the toxicokinetic understanding of
Mn in bone and its relationship to Mn accumulation in brain. This is followed by a
thorough analysis of neurotransmitter concentrations in brain as a result of Mn exposure
in Chapter 3. Chapter 4 details the changes to neurogenic function that occur in the
subventricular zone and olfactory bulb following intranasal Mn exposure. Finally,
Chapter 5 summarizes the findings and discusses the future directions of this work.
Notably, most of the research data have been published (i.e., data in Chapters 2 and 3) or
are prepared for publication (i.e., data in Chapter 4). Thus, the presentation in these
chapters follows the structure of published papers. To maintain the flow of each
individual chapter, some repetitive background information is expected in the
introduction sections.
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CHAPTER 2: MANGANESE ACCUMULATION IN BONE FOLLOWING CHRONIC
EXPOSURE IN RATS: RELATIONSHIP TO MANGANESE LEVELS IN BRAIN

2.1 Abstract
Literature data indicate that bone is a major storage organ for manganese (Mn),
accounting for 43% of total body Mn. However, the kinetic nature of Mn in bone,
especially the half-life (t 1/2 ), remained unknown. The study presented in this chapter was
designed to understand the time-dependence of Mn distribution in rat bone after chronic
oral exposure. Adult male rats received 50 mg Mn/kg (as MnCl 2 ) by oral gavage, 5 days
per week, for up to 10 weeks. Animals were euthanized every two weeks during Mn
administration for the uptake study, and on day 1, week 2, 4, 8, or 12 after the cessation
at 6-week Mn exposure for the t 1/2 study. Mn concentrations in bone (MnBn) were
determined by AAS analysis. By the end of 6-week’s treatment, MnBn appeared to reach
the steady state (T ss ) level, about 2-3.2 fold higher than MnBn at day 0. Kinetic
calculation revealed t 1/2 s of Mn in femur, tibia, and humerus bone of 77 (r=0.978), 263
(r=0.988), and 429 (r=0.994) days, respectively; the average t 1/2 in rat skeleton was about
143 days, equivalent to 8.5 years in human bone. Moreover, MnBn were correlated with
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Mn levels in striatum, hippocampus, and CSF. These data support MnBn as a useful
biomarker of Mn exposure.

2.2 Introduction
Occupational exposure to manganese (Mn), such as in mining, smelting, welding
or dry-cell battery production, has been associated with a neurodegenerative parkinsonian
disorder clinically called manganism (Barbeau et al., 1976; Chandra et al., 1981;
Crossgrove and Zheng, 2004; Jiang et al., 2006). Environmental exposure to this toxic
metal has also been linked to the consumption of Mn-containing pesticides and
contamination in drinking water and food (Bouchard et al., 2011). Addition of Mn to
gasoline as the anti-knocking reagent, methylcyclopentadienyl Mn tricarbonyl (MMT)
further raises concerns about health risks associated with a potential increase in
environmental levels of Mn (Butcher et al., 1999; Sierra et al., 1995). Recently,
increasing numbers of cases of Mn-induced Parkinsonism have been observed among
drug addicts using ephedrone (Sikk et al., 2011). It is because of rising public health
concerns that a thorough understanding of Mn neurotoxicity, including its distribution in
the body and mechanism of action, is well justified.
Patients suffering from manganism have signs and symptoms closely resembling,
but not identical to, Parkinson’s disease (PD) (Aschner et al., 2007; Jiang et al., 2006;
Racette et al., 2012). Recent data also show that Mn may play a role in PD etiology
(DeWitt et al., 2013; Lucchini et al., 2007). Since clinically manifested Mn neurotoxicity
is usually progressive and irreversible, early diagnosis becomes critical to treatment and
prevention of Mn intoxication. Historically, searches for biomarker(s) of Mn exposure
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and health risk have focused on Mn concentrations in blood, urine, and/or nail. These
biomarkers, however, are of limited use for exposure assessment in that primarily
intracellular accumulation of Mn renders blood, urine, or nail Mn levels inaccurate in
reflecting the true body burden of Mn (Apostoli et al., 2000; Zheng and Monnot, 2012).
For example, in group comparisons among active workers, blood Mn has some utility for
distinguishing exposed from unexposed subjects; yet a large variability in mean values
renders it insensitive for discriminating one individual from the rest of the study
population. Human studies using magnetic resonance imaging (MRI), in combination
with non-invasive assessment of γ-aminobutyric acid (GABA) by magnetic resonance
spectroscopy (MRS), have provided evidence of Mn exposure in patients devoid of
clinical symptoms of Mn intoxication (Dydak et al., 2011; Jiang et al., 2007). These
methods, however, do not provide an adequate estimation of Mn body burden in a longterm, low-dose Mn exposure scenario (Zheng and Monnot, 2012). Thus, to date, a
reliable biomarker to accurately reflect Mn exposure or body burden remains unavailable.
Data in literature suggest that, at normal physiological conditions, Mn
accumulates extensively in human bone tissues (Pejovic-Milic et al., 2009; Schroeder et
al., 1966; Zaichick et al., 2011). Schroeder et al. (1966) observed an average
concentration of 2 mg/kg of Mn in bone ash, which gives rise to about 32.5% of body Mn
in bone, according to our recent calculation (Liu et al., 2013). The International
Commission on Radiological Protection (ICRP) has reported approximately 40% of body
Mn accumulates in bone (ICRP, 1972). Information from animal studies of Mn
accumulation in bone can be found in literature, albeit is very limited (Dorman et al.,
2005; Seaborn and Nielsen, 2002). Using a physiologically-based pharmacokinetic
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modeling approach, Andersen et al. (1999) reported that Mn stored in bone tissues
contributed to over 40% of body Mn; the estimate is closer to the aforementioned human
data. Studies by Furchner et al. (1966) using radioactive 54Mn administered orally to rats
at a normal physiological dose have found that the radioisotope in bone had a half-life of
more than 50 days, which was much longer than the 54Mn half-life in other rat tissues.
Another study by Newland et al. (1987) in primates using 54Mn reported that Mn had a
relatively long half-life of about 220 days in the whole head after inhalation exposure. In
the same study, the researchers found that the half-life of 54Mn in brain tissues from the
same animals was much shorter; hence they ascribed a long half-life of 54Mn in the head
to 54Mn present in the skull or to replenishment from other depots (Newland et al., 1987).
These data have clearly established that bone is one of the major organs for long-term
storage of Mn in the body. Thus, a reliable assessment of Mn health benefits or risks
should take into account the extensive Mn deposition in bone. However, knowledge on
the rate of Mn accumulation in human or animal bone, and the pertinent biological halflife of Mn in bone was incomplete.
Recent advances in neutron activation-based detection technology has made it
possible to develop a portable neutron activation analysis (NAA) system for quantifying
MnBn (Aslam et al., 2008; Liu et al., 2013; Pejovic-Milic et al., 2009). This highly
innovative technique uses a portable deuterium–deuterium neutron generator (as the
neutron source) to detect Mn in bone, non-invasively and in real time, in human subjects.
To support this technical innovation, there was a need to understand the toxicokinetics of
Mn in bone under a long-term, low-dose exposure condition.
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The purposes of the current study were to (1) characterize the time-dependent
accumulation of Mn in rat bone following chronic oral administration of Mn to animals;
(2) determine the elimination t 1/2 of Mn in bone tissues; (3) investigate if bone samples
collected from different body parts had similar or different kinetic characteristics; and (4)
seek the correlations between MnBn and Mn concentrations in select brain regions
known to be targets of Mn neurotoxicity. Understanding the time-dependent changes of
tissue distribution of Mn within bone, central nervous system (CNS), and other tissues
will help understand Mn neurotoxicity described in the following chapters.

2.3 Materials and Methods

2.3.1 Chemicals
Chemical reagents were purchased from the following sources: Mn chloride
tetrahydrate (MnCl 2 •4H 2 O) from Fisher Scientific (Pittsburgh, PA); Mn and Cu standard
solutions were from SCP Science (Champlain, NY); ketamine from Fort Dodge (Fort
Dodge, IA ); xylazine from Vedco (St. Joseph, MO). All reagents were analytical grade,
HPLC grade, or the best available pharmaceutical grade.
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2.3.2 Experimental design
The overall experimental design is illustrated below (Figure 1):

Figure 1. Chapter 2 Experimental Design. Bones were collected and analyzed at each
time point shown. The top row indicates ongoing dose administration. The bottom row
collection days begin once dosing has ceased.
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Phase 1 studies were designed to determine the time course of Mn accumulation
in bone. Rats received daily administration of 50 mg Mn/kg as MnCl 2 by oral gavage, 5
days per week for the period of time specified in the above illustration. In this phase, dose
administration lasted up to 10 weeks with cohorts of animals euthanized every two weeks
to determine the steady state Mn concentrations (T ss ) in bone following oral exposure.
Phase 2 studies were designed to determine the elimination t 1/2 of Mn from bone
tissues. The results from phase 1 suggest a T ss was reached by 6 weeks of continuous Mn
exposure. After the last dose of the week-6 dose administration, animals were euthanized
at 24 hours, 2 weeks, 1, 2 and 3 months to determine t 1/2 of MnBn.

2.3.3 Animals and Mn Administration
Male Sprague Dawley rats were purchased from Harlan Laboratories, Inc.
(Indianapolis, IN). Upon arrival, animals were housed in a temperature-controlled, 12-h
light/dark cycle room and allowed to acclimate for one week prior to experimentation. At
the time of use, rats were 8 weeks old and weighed 220-250 g. Animals had ad libitum
access to filtered tap water and pelleted rat chow (Harlan Teklad 2018 Diet, Harlan
Laboratories). The studies were approved by the Institutional Animal Care and Use
Committee at Purdue University.
MnCl 2 •4H 2 O dissolved in sterile saline was administrated to rats by oral gavage
of 50 mg Mn/kg, once per day, 5 days per week, for up to 10 weeks. This dose regimen
was selected based on our preliminary study showing plasma Mn concentration of ~25
µg/L after 2-week oral doses, which is comparable to blood Mn levels in Mn-exposed
human subjects. Earlier human studies indicate that Mn-poisoned workers usually have
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blood Mn concentrations between 4-15 µg/L (Inoue and Makita, 1996; Vezér et al.,
2007). Our own human study among 39 Mn-poisoned welders in Beijing reveals that the
welders with a distinct manganism have a blood Mn level in the range of 8.2-36 µg/L
(Crossgrove and Zheng, 2004). Thus, a continuous daily oral gavage at 50 mg/kg would
likely result in a steady-state blood concentration similar to chronic occupational
exposure in humans. The daily equivalent volume (4 ml/kg) of sterile saline was given to
control animals. Twenty-four hours after the last injection, rats were anesthetized with
ketamine/xylazine (75:10 mg/kg; 1 mg/kg, ip). Cerebrospinal fluid (CSF) samples, free of
blood, were collected using a 26G butterfly needle inserted between the protuberance and
the spine of the atlas, and blood samples were obtained from the descending aorta and
processed for plasma. Rat brains were dissected to harvest choroid plexus from lateral
and third ventricles, hippocampus, striatum, and frontal cortex. Samples were stored at 80°C for later analysis.

2.3.4 Determination of Mn, Fe, Cu and Zn Concentrations by AAS
All brain and bone samples were digested with concentrated ultrapure nitric acid
in a MARSXpress microwave-accelerated reaction system. Plasma and CSF samples
were digested overnight with nitric acid in a drying oven at 55°C. An Agilent
Technologies 200 Series SpectrAA with a GTA 120 graphite tube atomizer was used to
quantify Mn, Fe, Cu and Zn concentrations. Digested samples were diluted 50, 500, or
1000 times with 1.0% (v/v) HNO 3 in order to keep the readings within the concentration
range of the standard curves. Ranges of calibration standards were 0-5 μg/l for Mn, 0-10
μg/l for Fe, and 0-25 μg/l for Cu and Zn. Detection limits for Mn, Fe, Cu and Zn were
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0.09 ng/ml, 0.18 ng/ml, 0.9 ng/ml, and 0.28 ng/ml, respectively, of the final assay
solution (Zheng et al., 1998, 1999, 2009).

2.3.5 Toxicokinetic and Statistics Analysis
Values of MnBn from various body parts were plotted as a function of time.
Calculation of the terminal-phase elimination rate constant (K e ) was based on the
assumption of first-order elimination kinetics (Gibaldi and Perrier, 1982; Zheng et al.,
2001). A linear regression analysis was used to estimate the K e of individual curves
obtained from different body bones, from which the t 1/2 was obtained using the following
equation:
t1/2 =

0.693
𝐾𝐾𝑒𝑒

All data are expressed as mean ± S.D.; statistical analyses of the differences
between groups were carried out by one-way ANOVA with post hoc comparisons by
Dunnett’s test or Student’s t-test using SPSS for Windows (version 20.0). The differences
between the two means were considered significant if p values were equal to or less than
0.05.

2.4 Results

2.4.1 Increased Mn concentrations in body fluids after Mn exposure
Following oral chronic Mn exposure, the plasma concentrations of Mn were
significantly increased compared to baseline (week 0) after only two weeks of Mn
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exposure (Fig. 2). After 4 weeks of Mn dosing, plasma Mn concentration remained
significantly higher compared to the baseline, but it declined from the 2 week value (Fig.
2). Plasma Mn concentrations were not significantly different after 6, 8, or 10 weeks of
Mn exposure as compared to the baseline. Similarly, Mn concentration in CSF was
significantly increased compared to baseline after 2 weeks of Mn exposure (p < 0.05; Fig.
2). Interestingly, Mn concentrations in CSF samples remained significantly higher at 4, 6,
8, and 10 weeks of dosing in comparison to the baseline value (p < 0.01; Fig. 2). Between
the sixth and eighth weeks of Mn exposure, Mn levels in the CSF appeared to plateau.
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Figure 2. Time Course of Mn Concentrations in Plasma and Cerebrospinal Fluid.
Rats received 50 mg Mn/kg as MnCl 2 by oral gavage once daily, five days per week for
the time indicated. Mn concentrations in plasma and CSF were determined by AAS. Data
represent mean ± S.D., n = 5-6; *p < 0.05, ** p < 0.01.
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2.4.2 Increased Mn Concentrations in Bones after Mn Exposure
Mn accumulation in bone was investigated in bone samples including femur,
tibia, humerus, and parietal bones. While chronic Mn oral exposure did not significantly
affect animals’ body weights after 6 weeks exposure, the weight of femur bones was
significantly reduced compared to controls (-8.5%, p < 0.01; Table 3). Concentrations of
Mn in bone appeared to be elevated after only two-weeks of exposure, although the
values were not statistically significant (Fig. 3). After 4-weeks of exposure, a significant
accumulation of Mn in bone was observed in all bone samples (p < 0.05; Fig. 3). This
increase in Mn accumulation in all bone samples continued until the 8th week of Mn
exposure. Since there were no statistically significant differences between the data points
from the 6th-, 8th- or 10th-week bone samples, MnBn appeared to reach the steady state
(T ss ) concentration after 6-weeks of Mn exposure (Fig. 3).
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Table 3. Changes of Total Body Weight and Femur Bone Weight s after Chronic
Oral Mn Exposure in Rats. Rats received 50 mg Mn/kg as MnCl2 by oral gavage once
daily, five days per week, for 6 weeks. Mn concentrations were determined by AAS. Data
represent mean ± S.D., n = 5-6; * p < 0.05.

Control
Mn-treated

Body Weight
Day 0
18 Weeks
261.6 ± 5.22 354.9 ± 16.24
268.4 ± 8.65 352.13 ± 9.96

Bone Weight
Day 0
18 Weeks
1.07 ± 0.13 1.30 ± 0.02
1.21 ± 0.38 1.19 ± 0.01*
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Figure 3. Time-Dependent Accumulation of Mn in Rat Bones. The animal treatment
regimen is described in the legend to Fig. 1. Mn concentrations in various bone samples
were determined by AAS. Data represent mean ± S.D., n = 5-6; * p < 0.05, ** p < 0.01
indicating group comparisons made between samples collected at times after Mn
exposure and samples at time 0.

52
2.4.3 Mn t 1/2 in Rat Bones
To determine the elimination t 1/2 , animals were exposed to Mn for 6 weeks until
the T ss was reached. Bone tissues were then dissected at 24 hours, 2 weeks, 1, 2 and 3
months following exposure cessation for AAS quantification of Mn concentrations in
femur, tibia, humerus, and parietal bone. Average values for each type of bone were
plotted on a semi-log scale over time to yield four separate regression lines. The slopes of
these regression lines were taken as the individual elimination rate constant K e and used
to calculate the MnBn t 1/2 for each bone type. Our calculations result in t 1/2 s of 77, 263,
429, and 690 days for femur, tibia, humerus, and parietal bones, respectively. To estimate
the Mn t 1/2 in the whole rat skeleton, the values for all bones at each time point were
averaged. Following the same procedure used to calculate the t 1/2 in individual bones, the
average MnBn t 1/2 was estimated to be approximately 143 days (Fig. 4).
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Figure 4. Terminal Phase Elimination Half-Life (t 1/2 ) of Mn in bones. Rats received
50 mg Mn/kg as MnCl 2 by oral gavage once daily, five days per week for 6 weeks.
Groups of animals were euthanized at the times indicated. The values of MnBn were
plotted as a function of time; the elimination rate constants were estimated by linear
regression analysis, and used to calculate the elimination t 1/2 . To estimate average t 1/2 in
rat skeleton, all values at each time point were averaged and the linear regression method
was then used.
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2.4.4 Correlations between Mn Concentrations in Bone and Mn Concentrations in
Selected Brain Regions
To test the hypothesis that Mn stored in bone tissues may serve as the internal
source of Mn in brain, a linear regression method was used to correlate Mn
concentrations in the striatum and hippocampus with MnBn from the same animals.
Since the choroid plexus in brain ventricles transports metals and secretes the CSF, which
provides the internal milieu of the CNS (Zheng et al., 2003), correlations between MnBn
and Mn concentration in choroid plexus and CSF collected from the same animals were
also investigated. The results showed that there were strong correlations between MnBn
and Mn levels in striatum (correlation coefficient r=0.7549, p < 0.001) and hippocampus
(r=0.7823, p < 0.001). Interestingly, the Mn concentration in the choroid plexus was also
strongly associated with MnBn (r=0.6519, p < 0.001), so was the correlation between
MnBn and CSF (r=0.7204, p < 0.001), suggesting that bone could potentially serve as an
endogenous source of Mn to the body and CNS (Fig. 5).
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Figure 5. Changes of Mn Concentrations in Brain, Choroid Plexus and CSF as a
Function of Mn Concentration in Bone. Mn concentrations in all tissues were
determined by AAS. Liner regression was used to estimate the correlation coefficients.
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2.4.5 Correlation of Mn in Bone with Concentrations of Fe, Cu, and Zn in Rat Skeleton
To understand how Mn accumulation in bone affects accumulation of other
metals, such as Fe, Cu, and Zn in the rat skeleton, the linear regression method was again
used to correlate MnBn with concentrations of Fe, Cu, and Zn in femur, tibia, and
humerus bones from the same animals. The results showed there were strong positive
correlations between MnBn and Fe levels in the rat bones (r=0.8509; p < 0.001), and
MnBn and Zn (r=0.7510; p < 0.001), but an inverse correlation between MnBn and Cu
(r=-0.7259; p < 0.001; Fig. 6). The results suggested that Mn accumulation in bone likely
affected other essential metals in bone.
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Figure 6. Changes of Fe, Cu and Zn Concentrations in Bone as a Function of Mn
Concentration in Bone. Concentrations of Mn, Fe, Cu and Zn were determined by AAS.
Liner regression was used to estimate the correlation coefficients.
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2.4.6 MnBn in Rats with Other Mn Exposure Paradigm
A rapid time-dependent Mn accumulation in bone observed in Phase 1 of this
study raised the question as to whether alternative Mn dose regimens and routes of
exposure may lead to similar Mn accumulation in bone. In our previous studies, we have
used a subchronic Mn exposure model by administering rats 6 mg Mn/kg (low dose) or
15 mg Mn/kg (high dose) as MnCl 2 , 5 days per week for 4 weeks by intraperitoneal
injection, and found significant alterations in neurochemical profiles (O’Neal et al.,
2014b). To investigate bone Mn accumulation in this animal model, rats received ip
injections of Mn with the same dose regimen. Following 4-weeks ip dose administration,
MnBn was significantly increased in both exposure groups as compared to controls (49.3
± 9.3 for low dose, 172.9 ± 35.3 for high dose vs. 13.0 ± 7.8 for control; mean ± S.D.
µg/g; p < 0.01; Fig. 7). It was apparent that Mn accumulated in bone tissues was in a
dose-dependent manner after ip Mn exposure.
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Figure 7. Mn Concentration in Rat Bone after Chronic IP Injection Exposure. Rats
received 6 mg Mn/kg as MnCl 2 by ip. injections once daily, five days per week, for 4
weeks. Data represent mean ± S.D., n = 5-6; *p < 0.05, ** p < 0.01
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2.4.7 Mn Concentration in Muscle
In vivo noninvasive measurements of MnBn (Liu et al., 2013) will likely include
some contribution of Mn present in skeletal muscle. We determined Mn concentrations in
muscle in animals receiving oral doses of Mn. The soleus muscle was selected because of
its proximity to the tibia, one of the bones commonly measured in vivo. This proximity
makes soleus muscle the ideal candidate for examination because it will directly impact
measurements of MnBn in humans. The results showed an initial increase of Mn in the
soleus muscle, which reached a statistical significance after only 4 weeks of dose
administration (p < 0.05; Fig. 8). However, similar to the Mn concentrations in plasma
and CSF, the levels of Mn began to decrease despite continued administration of Mn, and
stayed relatively unchanged in comparison to controls at time 0 (~0.35-0.40 µg/L). Thus,
it seems likely that under long-term, chronic exposure conditions, the Mn concentration
in muscle tissues would remain at a relatively constant level.
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Figure 8. Mn Concentration in Muscle after Chronic Oral Mn Exposure. Mn
concentrations in soleus muscle were determined by AAS. Data represent mean ± S.D.,
n = 5-6; * p < 0.05. Figure 17. Time-dependent accumulation of Mn in selected brain
regions following chronic oral Mn exposure. Rats received 50 mg Mn/kg as MnCl 2
by oral gavage once daily, five days per week for the time indicated. Mn concentrations
in brain were determined by AAS. Data represent mean ± S.D., n = 5-6; *p < 0.05, ** p <
0.01.
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2.5 Discussion
This study is the first to report estimations of the t 1/2 of Mn in bone after a chronic
oral Mn exposure. Other reports in literature have described extensive Mn accumulation
in bone (Pejovic-Milic et al., 2009; Schroeder et al., 1966; Zaichick et al., 2011); yet
none has calculated the half-life of Mn in the rat skeleton.
Occupational exposure to Mn in the air at concentrations from 0.1-1.27 mg/m3
shows levels of Mn in the blood to be 10.3-12.5 μg/l (Vezér et al., 2007). Among patients
with clinical signs and symptoms of manganism, the blood Mn concentration varies
between 4-40 µg/L (Crossgrove and Zheng, 2004; Inoue and Makita, 1996; Jiang, et al.,
2007). Interestingly, the plasma Mn concentration in rats at day 30 following this oral
dose regimen is ~20 µg/L; the level is highly comparable to human Mn blood level at
poisoning. Interestingly, the steady-state concentrations of Mn in rat striatum under this
dose regimen are about 1-1.2 µg/g between four and six weeks of dose administration;
under this brain concentration range, a significant striatal neurodegenerative injury has
been observed (Fujioka et al., 2003). Noticeably, environmental exposure to Mn has been
known to occur through eating foods and drinking water contaminated with Mn (ATSDR,
2012). Studies of humans drinking contaminated water in Bangladesh and Greece show
that levels of Mn between 50 μg/l and 8.61 mg/l can cause adverse health effects
(Hafeman et al., 2007; Kondakis et al., 1989). The LD 50 of oral MnCl 2 exposure in rats is
338 mg/kg (McMillian, 1999). Our dose of 50 mg/kg is approximately 15% of this value.
Although rats were exposed orally in the current study, the ATSDR (2012) reports that
health effects observed after an oral exposure are similar to those observed after an
inhalation exposure. Thus, the current oral Mn administration appears to be an
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appropriate animal model for chronic Mn intoxication study including Mn accumulation
and elimination from bone tissues.
It is interesting to know that in the first 4 weeks of Mn dose administration MnBn
continued to increase, while the blood Mn concentration started to decline by the end of
the 4th week of dosing. Although the blood Mn concentration returned to nearly baseline
level after 10 weeks of exposure, MnBn remained significantly higher than in controls.
This observation supports the view that a short blood t 1/2 of Mn is due primarily to its
intracellular distribution (Zheng et al., 2000) and thus, Mn blood concentration is deemed
insufficient for assessment of Mn exposure or health risk (Zheng et al., 2011). Data from
the current study clearly demonstrate that the bone tissue serves as a storage site upon Mn
chronic exposure. Indeed, the average t 1/2 of MnBn was estimated to be about 143 days.
In a comparative study of human and rat developmental time points and associated body
weights, Sengupta (2011) proposes that every 16.7 days throughout the life of the rat is
equivalent to one human year. Using this analogy, we estimate the half-life of Mn in the
rat femur to be 4.61 years, tibia 15.75 years, humerus 25.69 years, and parietal bone
would be an astounding 41.32 years. To estimate the value for the entire skeleton, it is
more appropriate to take the half-lives of bone sampled from different body parts. Thus,
by using the average half-life in in the current study, we estimate that the average halflife of Mn in the rat skeleton corresponds to 8.6 years for humans.
The current study also reveals an interesting observation, i.e., the shortest halflives of Mn are observed in the weight-bearing bones. Specifically, we observed the
shortest half-lives in femur and tibia bones and the longest in parietal bone. Regarding
animal locomotor behavior, rats are a generalist species, with skeletal structures
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developed for burrowing, running, jumping, and walking. Although not bipedal, rats do
spend time standing on their hind limbs while exploring or searching for food. This
potentially puts more pressure on the femur and tibia bones when compared with their
humerus or parietal bones. This leads to another interesting question as to why the
weight-bearing bones have a shorter storage time for Mn.
In both adult humans and rats, the main function of the skeleton is remodeling.
Bone remodeling consists of both bone formation and resorption. Between the different
types of bones, there are anatomical and functional differences. For example, the
perfusion rate within tubular long bones differs between areas of cortical bone such as the
diaphysis, and areas of trabecular bone, including the femoral head and neck. Tøndevold
and Eliasen (1982) have found that the perfusion rate is highest in areas with more
trabecular bone and lowest in the diaphysis with more cortical bone. They also show that
the perfusion rate is similar between the femur and tibia (Tøndevold and Eliasen, 1982),
although the differences between these and other bone types, such as parietal bone,
remain unknown. Serrat et al. (2007) indicate that some bones, such as the humerus, have
different ossification patterns than does the femur. Bancroft et al. (2002) also suggest that
the differences in fluid perfusion rates among bone tissues could alter the levels of
nutrients including intracellular calcium and other biochemical factors, such as
prostaglandin E2 and cyclooxygenase-2 in bone in vitro. Further, they observe that the
fluid flow in these tissues mechanically stimulates pressure gradients so to move fluid
outward into the cortical bone (Bancroft et al., 2002). Taking into account these literature
data, we postulate that differences in anatomical structure, perfusion rate of bone tissues,
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and hydrostatic pressure or compression may explain the observed differences in Mn
half-lives in different bones.
In the present study, we do not see significant changes in animals’ body weights
after chronic Mn oral exposure. However, we did observe the weight of femur bone to be
significantly reduced after 18 weeks of Mn exposure. This observation suggests that in
addition to simple storage, Mn ions accumulated in bone may have a direct detrimental
effect on bone’s normal structure and function. In addition, we found that MnBn was
positively associated with Fe and Zn in bone but inversely related to Cu. The implications
of these relationships are currently unknown. Thus, Mn-induced osteotoxicity as a result
of chronic Mn exposure in humans as well as animals deserves further in-depth
investigation.
To understand whether MnBn could be used as a potential biomarker for Mninduced neurotoxicity, we correlated MnBn with Mn levels in selected brain regions,
including striatum, hippocampus, and choroid plexus from the same animals. It was
evident that the values of MnBn were well correlated with each of these brain regions.
These relationships are important for studies of Mn neurotoxicity in humans, for striatum
is known to accumulate Mn to a great extent in humans (Dydak et al., 2011; Jiang et al.,
2007), hippocampus is a potential target of Mn toxicity (Wang et al., 2012), and Mn
accumulation in the choroid plexus is known to cause the dysregulation of the
homeostasis of iron and copper in the central milieu (Zheng et al., 2003; 2012).
One of the purposes of this study was to build a theoretical foundation for human
noninvasive quantitation of MnBn by using a novel deuterium-deuterium (DD) neutron
generator–based neutron activated analysis (NAA) system (Liu et al., 2013). A
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transportable version of this system, which has been developed recently at Purdue
University, has a detection limit of 0.7 ppm (µg/g). Schroeder et al. (1966) report that
normal human subjects have a MnBn of 2 µg/g, which was determined using postmortem
human bone tissues. Based on our current data, MnBn at the steady-state exceeds 1 µg/g.
Thus, this transportable AAS device shall be of practical value in human study. The
concentration of Mn in muscle was also determined in order to understand the kinetic
changes of Mn levels in this tissue. Our results demonstrated that the Mn concentration in
muscle remained constant after chronic exposure. Taken together, we feel that because
MnBn has a long half-life, is well correlated with levels of Mn in brain and is not
interfered by Mn in muscle, the MnBn measured in vivo by the transportable NAA
system would serve as an excellent biomarker of Mn exposure in occupational and
environmental research.
This study has limitations. First, the study as designed does not allow us to
investigate the regional distribution and deposition of Mn within bone. Current studies in
the lab are investigating the differences in distribution of Mn between cortical and
trabecular bone. At the time of writing, our preliminary data from animals exposed to 6
mg Mn/kg as MnCl 2 via ip injection five days per week for four weeks suggests that Mn
accumulates in the trabecular bone of control animals, but in the cortical bone of Mnexposed animals. Further work by synchrotron XR technique to depict regional
distribution of Mn in bone is desirable. Second, our current study does not address how
Mn ions gain access to bone tissues, what subcellular ligands in bone tissues Mn ions are
bound with, and whether Mn transporters, such as divalent metal transporter-1 (DMT1)
and transferrin receptor (TfR), play any roles in Mn deposition and its toxicity to other
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metals. Finally, due to the limited budget, the current study was not able to investigate the
percentage of Mn in bone with regards to the total body burden, although such
percentages have been reported in literature (see Introduction).
In summary, the data presented in this report suggest that a 4-week Mn oral
exposure can lead to a significant accumulation of Mn in bone tissues. The half-lives of
Mn in rat bone are in the range of 77-690 days with an average of 143 days. Moreover,
the weight-bearing bones such as femur appear to have a shorter t 1/2 than non-weight
bearing bones. Since brain Mn levels change as a function of MnBn, we propose that the
MnBn may be an effective biomarker for assessment of Mn exposure and health risk.
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CHAPTER 3: SUBCHRONIC MANGANESE EXPOSURE ALTERS
NEUROCHEMISTRY IN A RAT MODEL

3.1 Abstract
High levels of manganese (Mn) in the brain are neurotoxic and result in a
progressive, irreversible disorder known as manganism which includes both
psychological and motor disturbances. Evidence suggests that Mn exposure impacts
neurotransmitter levels in the brain. However, it remained unclear if subchronic, lowlevel Mn exposure resulted in alterations in neurotransmitter systems with concomitant
behavioral deficits. The study in this chapter used high performance liquid
chromatography (HPLC) to quantify neurotransmitter levels in rat striatum, substantia
nigra, and hippocampus. Subchronic Mn exposure via i.p. injection of 15 mg Mn/kg as
MnCl 2 caused significantly increased dopamine levels in the striatum. The enhancement
was accompanied by significantly elevated levels of the dopamine metabolites, DOPAC
and HVA, in the striatum. In addition, levels of HVA were significantly increased in the
substantia nigra and hippocampus. Mn toxicity on neurochemical concentrations in brain
could be the consequences of Mn accumulation in bones (Chapter 2). These data indicate
that subchronic, low-level Mn exposure disrupts multiple neurotransmitter
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systems in the rat brain which may be responsible, in part, for observed locomotor
deficits. The data presented in this chapter may provide clues to understanding the effects
of Mn exposure on adult neurogenesis (investigated in Chapter 4).

3.2 Introduction
Manganese (Mn) is an essential trace element required for normal function and
development of many physiological processes. In the central nervous system, Mn
functions as a cofactor for enzymes necessary for neuronal function and neurotransmitter
biosynthesis, such as superoxide dismutase 2, pyruvate decarboxylase, and glutamine
synthetase (Aschner et al., 2009; Bowman et al., 2011; Schneider et al., 2009). Normally,
regulatory mechanisms carefully maintain homeostatic levels of Mn in the body by
controlling absorption and elimination of excess metal via hepatobiliary excretion
(Klaassen, 1976). However, excess Mn exposure can overload these mechanisms
(Schneider et al., 2009), leading to Mn accumulation in body tissues, including bone
(Chapter 2), liver, kidney, and pancreas (Dobson et al., 2004). Mn in the 2+ and 3+ states
readily crosses the blood-brain barrier (BBB) (Aschner et al., 1999) and preferentially
accumulates in specific brain regions, such as striatum (STR), globus pallidus,
cerebellum, and hippocampus (HP) (Andersen et al., 2010; Fitsanakis et al., 2008; O'Neal
and Zheng, 2015).
Adequate levels of Mn are obtained from food, such as nuts, tea, and legumes,
and water intake (Bowman et al., 2011). Mn dusts in the air, Mn-containing pesticides in
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soil, contaminated water, and occupational exposure during mining and agricultural
processes, are potential sources of toxic exposure (Mergler, 1999). The highest levels of
exposure are observed in the workplace, where workers chronically exposed to levels < 5
mg/m3 have reported symptoms of Mn toxicity (Crossgrove & Zheng, 2004). These
symptoms result from toxic Mn accumulation in the caudate putamen, globus pallidus,
STR, and substantia nigra (SN) (Aschner et al., 1999) and are clinically diagnosed as
manganese intoxication or manganism. Manganism is a severe, progressive and largely
irreversible disorder that resembles, but is distinguishable from idiopathic Parkinson’s
disease (PD) and other extrapyramidal motor disorders (Racette et al., 2012a).
The prevailing symptoms of manganism include poor hand-eye coordination,
bradykinesia, changes in mood and memory deficits, abnormal gait, muscle and joint pain
or weakness, bent posture, and a kinetic tremor (Mergler, 1999; Racette et al., 2012a).
These symptoms exist as a slowly progressing biphasic continuum, with psychiatric
symptoms appearing first in the “prodromal period” or early phase of the disease, while
motor symptoms dominate the later, “established” phase (Racette et al., 2012a; Rodier,
1955) and persist even after the person is no longer exposed to Mn (Aschner et al., 2009;
McMillian, 1999).
Mn accumulation in the basal ganglia may alter levels of neurotransmitters, such
as dopamine (DA) and GABA, in the striatum and in pathways postsynaptic to the
nigrostriatal system (McMillian, 1999; Racette et al., 2012a) which produce the observed
motor symptoms. Data from rodent studies generally offer conflicting reports on how
Mn exposure affects neurochemistry and motor function. A general consensus regarding
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the effects of Mn on motor function is that hyperactivity is observed early in Mn toxicity,
in both human and animal studies, and as the disease progresses, patients and animals
both tend to become hypoactive.
There is evidence that Mn exposure results in a Parkinson’s phenotype, with
decreased dopamine in the striatum. However, dopaminergic neurons in the substantia
nigra and their terminals in the striatum, which are selectively lesioned in Parkinson’s
disease, remain intact after Mn intoxication (Guilarte, 2010). Thus, changes in
neurotransmission, as opposed to frank cell-loss, likely underlie behavioral observations.
Most studies to date have focused on striatal dopamine levels and not regional differences
in other monoamines and their metabolites, or GABA. Additionally, few studies have
aimed to investigate changes in motor function in animals, particularly rodents, despite
many of the prominent symptoms of manganism being motor deficits, including
abnormal gait and postural impairment. Therefore, the present study was undertaken to
identify alterations in multiple neurotransmitter systems resulting from subchronic, lowlevel Mn exposure in rats. We have previously used a Mn exposure dose regimen, i.e., 6
mg/kg i.p. injection for 4-6 weeks to study Mn toxicity on iron (Fe) and copper (Cu)
transport properties in brain barrier systems (Zheng et al., 1999; Zheng et al., 2009). To
ensure a dose-related response, the current study used two dose levels, 6 mg/kg and 15
mg/kg, which bracket the commonly used doses to investigate changes in Mn levels with
concomitant changes in regional neurochemistry, motor function, and changes at the
cellular level. Neurotransmitter levels were assessed in the striatum, substantia nigra, and
hippocampus, an area implicated in learning and memory. It was necessary to study the
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hippocampus because many of the earliest symptoms of manganism are due to impaired
memory. Thus, examination of changes in 4 neurotransmitter (dopamine,
norepinephrine, serotonin, and GABA) systems in multiple brain regions was expected to
provide significant data on the complex neurochemical changes that result from Mn
intoxication.

3.3 Materials & Methods
3.3.1 Chemicals
All chemicals were of analytical grade, HPLC grade or the highest available
pharmaceutical grade. HPLC grade water was obtained from a NANOpure Diamond
Ultrapure Water System (Barnstead International, Dubuque, IA); Mn chloride
tetrahydrate (MnCl 2 ·4H 2 O) from Fisher Chemical (Fair Lawn, NJ); nitric acid,
tripotassium phosphate (K 3 PO 4 ) and DPX mountant from VWR International (Radnor or
West Chester, PA); Mn, Cu, Zn, and Fe stock solutions from SCP Science (Champlain,
NY); perchloric acid from RICCA (Arlington, TX); dopamine, 3,4dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine
(5-HT), 5-hydroxyindolacetic acid (5-HIAA), noradrenaline (NE), γ-aminobutyric acid
(GABA) standards, disodium hydrogen phosphate, anhydrous (Na 2 HPO 4 ) triethylamine
(TEA), octanesulfonicacid (OSA), acetonitrile, paraformaldehyde (PFA), sodium
phosphate monobasic (NaH 2 PO 4 ), Triton X-100, and porcine skin gelatin from Sigma
(St. Louis, MO). Bovine serum albumin (BSA) was purchased from Thermo Scientific
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(Rockford, IL); methanol, ethylenediaminetetraacetic acid (EDTA), and sucrose from
Macron Fine Chemicals (Center Valley, PA); o-phthalaldehyde (OPA) from Pickering
Laboratories (Mountain View, CA); and BCA protein assay kit from BioRad (Hercules,
CA). Normal donkey serum was purchased from Jackson ImmunoResearch (West
Grove, PA); mouse monoclonal anti-TH and rabbit polyclonal anti-DARPP-32 antibodies
from Millipore (Temecula, CA); secondary donkey anti-mouse IR800 and donkey antirabbit IR800 antibodies from LICOR (Lincoln, NE); histoclear from National
Diagnostics (Atlanta, GA); potassium permanganate from Amresco (Solon, OH);
Fluorojade C from Histochem (Jefferson, AR); and glacial acetic acid from Mallinckrodt
Chemicals (Phillipsburg, NJ).

3.3.2 Animals
Male Sprague Dawley rats were obtained from Harlan Laboratories, Inc.
(Indianapolis, IN) and allowed to acclimate to the holding room for 7 days after arrival.
Rats at time of experimentation were 8 weeks of age, weighing approximately 240-260g
at study initiation. Animals were randomized by drawing numbers for treatment
designation. Rats were group housed in a temperature- (72 ± 4 °C) and humidity- (3070%) controlled room on a 12 hour light/dark cycle (lights on at 0600). Rats had ad
libitum access to food (Harlan 2018 rodent diet) and reverse osmosis water.
All animal studies were approved by the Institutional Animal Care and Use
Committee at Purdue University.
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3.3.3 Mn Administration and Experimental Design
According to Cooper (1984), doses of 5-20 mg/kg/d have not been shown to be
very toxic in animal studies and therefore, our selected doses should not cause acute
toxicity. The dose of 6 mg/kg was selected because it has been administered previously in
our lab by multiple dose routes, including intravenous, oral, and intraperitoneal. With this
dose, our lab has shown a significant reduction in both succinate dehydrogenase and
aconitase (Zheng et al., 1999).
Stock solutions of 6 mg Mn/ml (low dose) and 15 mg Mn/kg (high dose) were
prepared by dissolving MnCl 2 ·4H 2 O in saline and passing through a 0.2 µm syringe
filter. Mn-exposed rats received ip injections of either 6 mg Mn/kg or 15 mg Mn/kg in a
volume of 1 ml/kg once per day, 5 days per week, for 4 consecutive weeks. Control
animals were administered the same volume of sterile saline.

3.3.4 Sample Collection
Animals were euthanized by decapitation 24 h after the last dose. Brains were
quickly removed from the skull and bisected midsagittally. The left hemispheres were
stored in 4% paraformaldehyde for histological evaluation. The right hemispheres
reserved for neurochemistry were placed in a coronal rat brain matrix and 2 mm slices
containing the desired brain regions were obtained. The samples were then further
dissected on ice to obtain striatum, substantia nigra, and hippocampal samples, which
were then flash-frozen in liquid nitrogen. Liver and femur tissues were collected for
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determination of metal concentrations using atomic absorption spectroscopy (AAS).
Samples were stored at -80°C until processing.

3.3.5 Behavioral Testing
On days 8, 11, and 18 of dosing, animal’s locomotor activity was evaluated using
an open field behavioral test. Animals were transferred to the behavioral testing room
and placed inside an open field chamber. The chambers were constructed of solid opaque
Plexiglas measuring 40 cm × 40 cm. Top Scan Lite computer software (version 2.0;
Clever Sys Inc. Copyright 2000-2011) was used to generate a model of the open field
chamber with accurate perimeter measurements and a center field comprising 60% of the
total area. Animals were placed in the open field chambers for 5 min and their positions
were recorded by a camera mounted on the ceiling. Behavioral testing conditions were
simulated on two separate occasions during the first week of dosing to acclimate the
animals to the testing environment. Animals’ average velocities and distances traveled
during the experiment were quantified using the Top Scan Lite software.

3.3.6 Atomic Absorption Spectroscopy
Liver and femur samples collected at necropsy were weighed on an analytical
balance (AB204-S; Mettler Toledo, Columbus, OH) and transferred to a digestion vial. A
total volume of 2 ml nitric acid (HNO 3 ) was added to each sample. Tissues were
digested in a high pressure MarsXpress microwave (CEM Corporation, Matthews, NC)
for 15 min at 200°C. Each digestion was transferred to a volumetric flask and diluted
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with ddiH 2 O to 5 ml. Each digestion solution was mixed thoroughly, transferred to a 15
ml conical tube, sealed with parafilm, and stored at 4°C until analysis. Hepatic and
femur Mn, copper (Cu), zinc (Zn), and iron (Fe) concentrations were quantified using an
Agilent Technologies 200 Series SpectraAA with GTA 120 graphite furnace (Santa
Clara, CA). Concentration ranges of standard solutions were between 1-10 ppb for Mn,
1-50 ppb for Cu, 1-1.05 ppb for Zn, and 1-20 ppb for Fe. A 0.1% HNO 3 blank was
prepared and used to dilute metal standards at 1000 mg /l to appropriate working
standards. Samples were further diluted with ddiH 2 O to keep the readings within the
concentration range of the standard curves. The detection limit for Mn was 0.038 µg/l of
the assay solution. Metal content was expressed as µg/g of tissue.

3.3.7 Neurochemical Analysis
Neurotransmitter analysis was conducted similarly as previously described (Wang
et al., 2013). Briefly, STR, SN, and HP samples were frozen in liquid nitrogen at
necropsy and stored at -80°C until processing. Samples were sonicated in 0.5 ml 0.4N
perchloric acid (HClO 4 ) on ice, at 40% power, pulsing for 45 s to precipitate proteins.
Samples were then centrifuged at 16,400 g for 35 min at 4°C. Supernatant was
transferred to 0.22 µm Spin-X tube with nylon filter (Corning, Corning, NY) and
centrifuged at 1000 g for 15 min at 4°C. Samples were then stored at -80°C until HPLC
analysis. A Dionex UltiMate 3000 (ThermoScientific; Germering, Germany) system
with a built in autosampler and a Coulochem III (Thermo Scientific) electrochemical
detector were used for HPLC analysis of DA, its metabolites DOPAC and HVA, as well

77
as 5-HT and its metabolite 5-HIAA, NE, and GABA. The optimized method used an
isocratic monoamine mobile phase (consisting of 0.08 M NaH 2 PO 4 , 10% methanol, 2%
acetonitrile, 2.0 mM OSA, 0.025 mM EDTA, and 0.2 mM TEA, in 13 mΩ purified
water, pH 2.4). Samples were injected and monoamines separated on a reverse phase
C18 column (150 x 3.2mm, 3.0 μm particle size, MD-150, Thermo Scientific,
Bannockburn, IL) protected by a guard column. Separation occurred at 32 °C at a flow
rate of 0.6 ml/min. For GABA detection, samples were derivatized with OPA (ophthalaldehyde, methanol, and 2-mercaptoethanol) before injection onto the column. The
isocratic mobile phase (pH 6.75) consisted of Na 2 HPO 4 in 13 mΩ purified water with
22% methanol and 3.5% acetonitrile. Separation occurred at 35°C with a flow rate of 0.5
ml/min. For monoamine neurotransmitter and metabolite detection, the electrochemical
potential of the detector was set at 250 mV, with a conditioning cell at -150 mV. For
GABA detection, the electrochemical potential of the detector was set at 550 mV, with a
conditioning cell at -150 mV. Neurotransmitter and metabolite levels in each sample
were quantified by comparing sample values to a reference curve prepared by adding
standards of a known concentration to perchloric acid. Chromeleon 7.0 software was
used for data acquisition and analysis. Neurotransmitter concentrations were expressed
as ng/mg of protein as assessed by BCA protein assay (Smith et al., 1985) using BSA as
the standard (Bradford, 1976).
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3.3.8 Immunohistochemistry
At necropsy, the left hemisphere was immersed in 4% paraformaldehyde (PFA,
catalog # P6148-500G; Sigma, St. Louis, MO) and post-fixed for 7 days at 4°C. Then,
hemispheres were stored in a 30% (w/v) sucrose (catalog # 8360-06; Macron Fine
Chemicals, Center Valley, PA) solution until sinking. The hemispheres were coronally
sectioned in 30µm increments on a microtome (Microm HM450, Thermo Scientific;
Walldorf, Germany) and sections were placed in cryoprotectant solution and stored at 20°C until labeling. Free-floating slices were rinsed 6 times with phosphate buffered
saline (PBS), 10 min per rinse. Sections were blocked in 10% normal donkey serum in
PBST containing 0.3% Triton X-100 for 1 h. Sections were incubated in primary
antibody, either mouse monoclonal anti-TH (1:2000; cat. #MAB318; Millipore;
Temecula, CA) or rabbit polyclonal anti-DARPP32 (1:500; cat.#AB10518; Millipore;
Temecula, CA) diluted in PBST with 1% donkey serum for 72 h at 4°C. Sections were
rinsed 3 times with PBS and incubated with either donkey anti-mouse IR800 (1:500;
cat.#926-32212; Li-Cor; Lincoln, NE) or donkey anti-rabbit IR800 (1:500; cat.#92632213; Li-Cor; Lincoln, NE) diluted in PBST with 1% donkey serum for 2 h at room
temperature. After 3 washes with PBS, sections were mounted on slides and air-dried
overnight at room temperature. After immersion in Histoclear for 10 min, slides were
blotted dry and coverslipped with DPX mountant. Immunofluorescence quantification
was performed similar to previously described (Cannon et al., 2013; Tapias et al., 2014).
Briefly, immunofluorescence was detected with the Odyssey infrared imaging system
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(Li-Cor; Lincoln, NE) at 21µm resolution. Regions of interest were selected and
intensity of each region determined using Image Studio software (version 3.1).
Another set of slices was processed for Fluorojade C staining to identify
degenerating neurons. Slices were removed from cryoprotectant and rinsed 6 times in
PBS for 10 min per rinse. Slices were mounted on slides coated with 0.5% porcine skin
gelatin and dried overnight at room temperature. Slides were then immersed for 5 min in
0.03M tripotassium phosphate (K 3 PO 4 ,) in 70% ethanol, diluted from 200% ethanol in
water, and then rinsed in 70% ethanol and water for 2 min each. Followed by immersion
in a 0.06% potassium permanganate solution for 10 min and rinsed in water for 2 min.
Slides were immersed in a 0.0001% Fluorojade C solution, diluted in 0.1% glacial acetic
acid for 10 min followed by 3 rinses in water for 2 min each. Slides were dried on a
50°C heating block (Lab Line Instruments, Inc.; Melrose Park, IL) for 5 min and cleared
in Histoclear for 1 min. At this point, slides were blotted dry and coverslipped with DPX
mountant. All Fluorojade C staining steps were performed at room temperature.
Negative control slices were treated in the same manner as all other slices, but primary
antibody was omitted. Slices from animals treated with kainic acid were used as a
positive control (Sarkar & Schmued, 2011). Fluorescence was assessed on an Olympus
(BX53F; Tokyo, Japan) microscope using a FITC filter and 50 ms pixel dwell time. The
microscope was equipped with an Olympus (U-HGLGPS; Tokyo, Japan) light source.
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3.3.9 Statistical Analysis
All data are expressed as mean ± S.D. Statistical analyses of the differences
between groups were carried out by one-way ANOVA. Where ANOVA analysis
indicated that significant differences between groups occurred, specific differences were
identified by post hoc analysis using Tukey’s test. Statistical analysis of the behavioral
data was done by one-way ANOVA with repeated measures. A p-value less than 0.05
was considered statistically significant. All analyses were conducted using Graph Pad
Prism (Version 3.0, Graph Pad Prism; San Diego, CA).

3.4 Results
3.4.1 Mn Exposure Reduces Body Weight
Animals were weighed daily prior to dose administration and weights recorded to
the nearest 0.1 g (Fig. 9). At the beginning of the study, there was no significant
difference in body weights between groups (n=5 in all groups). All animals weighed 252
± 8 g. Mn treatment reduced animal’s body weight in a dose dependent manner. Animals
in the group receiving 6 mg Mn/kg lost an average of 10 g during the first three days of
dosing and began to regain weight by the fourth day. Animals in the group receiving 15
mg Mn/kg lost an average of 40 g during the first five days of dosing and began to regain
weight by the sixth day. Although Mn-treated animals regained weight to some extent,
average body weights were significantly lower than control beginning on the second day
of dosing, an effect that persisted for the duration of the study.
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Noticeably, Mn dose administration by oral gavage at 50 mg/kg once daily, five
days per week, for 6 weeks did not significantly reduce the body weight of Mn-treated
animals compared with control animals; group averages at the end of the study were
within 3g of one another (Table 3).
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Figure 9. Daily Intraperitoneal Injections of MnCl 2 Resulted in Reduced Weight
Gain among Mn-Exposed Animals. Rats were weighed prior to daily dose
administration and weights were averaged for each group. Mn exposure resulted in
significant changes in body weights in a dose-dependent manner. Control rats (square)
consistently gained weight over the course of the study while animals in the low (6
mg/kg; triangle) and high (15 mg/kg; inverted triangle) dose groups showed an initial
decrease in body weight but began to gain weight after 3 and 5 days, respectively. Rats in
the Mn-exposed groups continued to gain weight, but at significantly reduced rate
compared with controls for the duration of the study. Error bars indicate S.D.
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3.4.2 Mn Accumulates in the STR and HP
AAS analysis was completed to determine if and to what extent Mn accumulated
in brain tissue following Mn exposure. The levels of Mn in the STR and HP from both
Mn-exposed groups were significantly higher than in controls (p < 0.001; Table 4).
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Table 4. Concentration of Metal in Select Rat Brain Regions Following Subacute
Mn Exposure. Atomic absorption spectroscopic analysis of Mn content in rat brain
samples. Animals received i.p. injection of 6 or 15 mg/kg Mn once daily for 5 days per
week for 4 weeks. Metal concentrations were quantified and are expressed as ug/g wet
weight. Mn concentrations were significantly increased in the STR and HP of both Mntreated groups compared with controls. Data represent mean ± S.D., n-7-10; #p < 0.001.

6 mg Mn/kg as MnCl 2
STR
HP
Control 0.785 ± 0.229
0.642 ± 0.082
#
Treated 2.904 ± 0.483
1.924 ± 0.313#

15 mg Mn/kg as MnCl 2
STR
HP
0.426 ± 0.164
0.337 ± 0.048
#
2.636 ± 0.745
1.505 ± 0.458#
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3.4.3 Mn Exposure Resulted in Hypoactivity
The average distance traveled decreased for animals in all groups between the
first and the last training sessions (Fig. 10A). The average velocities correspondingly
decreased for each group (Fig. 10B). However, these changes did not reach statistical
significance. During the later training sessions, some animals exhibited long periods of
inactivity in the testing chambers. Examination of these two related behavioral
parameters at each time point revealed significant decreases in distance traveled during
the second and third behavioral testing sessions for the high dose group as compared with
the control group (10.4 ± 2.42 vs. 19.4 ± 6.71, 7.6 ± 2.70 vs. 16.2 ± 1.30 m, respectively;
mean ± S.D.; high dose vs. control; p < 0.05). Additionally, the average velocity of the
high dose group was significantly decreased compared to that of the control group during
the third behavioral testing session (0.027 ± 0.011vs. 0.058 ± 0.002 m/s; mean ± S.D.;
high dose vs. control; p < 0.05). No significant differences were observed during the first
behavioral training session, which occurred during the second week of dose
administration.
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Figure 10. Open Field Analysis of Locomotor Activity. Distance traveled (A) and
average velocity (B) were measured in an open field test on study days 8, 11, and 18.
Animals were placed in the testing apparatus and behaviors measured for five minutes on
each testing day. Values for each group were averaged and are shown. Distance traveled
and average velocity were significantly reduced in both treatment groups compared with
controls 8 days after Mn exposure began. These effects disappeared when animals were
evaluated on study days 11 and 18. ANOVA with Tukey’s post hoc test. Error bars
represent S.D. (n = 3-5). *: p < 0.05 for 6 mg/kg group compared with control; #: p <
0.05 for 15 mg/kg group compared with control.
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3.4.4 Levels of Biogenic Amines and Metabolites in Brain Tissue Following Mn
Exposure
The DA level in the STR was significantly higher in the high-dose group than the
control group (157.0 ± 15.73 vs. 99.8 ± 42.10 ng/mg protein; mean ± S.D.; high vs.
control; p < 0.05; Fig. 11A). DA levels in the SN and HP displayed a non-monotonic
curve, with no statistical significances, where levels were decreased following 4 weeks of
low-dose Mn treatment and were slightly higher in the high dose group, but not quite
reaching the same levels as the control group (Fig. 11E,I).
Levels of the DA metabolite, DOPAC, in the STR of the high-dose group was
significantly higher than those of the low-dose and control groups (10.7 ± 2.16, 16.9 ±
1.68 vs. 10.6 ± 4.87 ng/mg protein; mean ± S.D.; low, high vs. control; p < 0.05 for both;
Fig. 11B). Levels of DA and DOPAC were similarly elevated in both the SN and HP,
but these changes did not reach statistical significance (Fig. 11F,J).
Following 4 weeks of high-dose Mn exposure, levels of the secondary DA
metabolite, HVA, were significantly higher in the STR compared with the low-dose and
control groups (5.4 ± 1.58, 10.5 ± 1.79 vs. 2.7 ± 3.63 ng/mg protein; mean ± S.D.; low
dose, high dose vs. control; p < 0.05 and < 0.001, respectively; Fig. 11C). HVA levels
in the SN and HP were also significantly higher in the high-dose group than in the control
group (in SN, 0.6 ± 0.29 vs. 0.3 ± 0.06 ng/mg protein; in HP, 0.2 ± 0.04 vs. 0.1 ± 0.02
ng/mg protein; high dose vs. control; p < 0.05 and 0.01 respectively; Fig. 11G,K).
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The DA turnover ratio was defined as the sum of the DA metabolites, DOPAC
and HVA, divided by DA in each brain region. While DA turnover in the STR appeared
to be increased, differences were not significant (Fig. 11D). In the SN, DA turnover was
significantly increased for both Mn-treatment groups when compared with the control
(1.5 ± 0.37, 1.6 ± 0.27 vs. 0.9 ± 0.22; mean ± S.D.; low, high vs. control; p < 0.05 for
both; Fig. 11H). There was no difference between the turnover ratios of the low- and
high-dose groups.

In the HP, differences in DA turnover did not reach statistical

significance (Fig. 11L).
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Figure 11. HPLC Analysis of Dopamine, its Metabolites, and Turnover. DA
(A,E,I), and its metabolites 3,4-dihydrophenylacetic acid (DOPAC; B,F,J), and
homovanillic acid (HVA; C,G,K) were quantified in STR (A-C), SN (E-G), and HP (IK) by HPLC with electrochemical detection. DA turnover in each region was calculated
as the sum of the metabolites divided by DA concentration (D,H,L). ANOVA with
Tukey’s post hoc test. Data represent mean ± S.D. (ng/mg protein; n = 3-5). *: p < 0.05,
**: p < 0.01.
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5-HT levels in the STR and SN were not significantly changed following either
Mn-treatment as compared with the control (Fig. 12A,D). In the HP, levels of 5-HT
revealed a non-monotonic curve, decreasing in the low-dose but increasing in the highdose group, in comparison with the control group. The level of 5-HT in the HP was
significantly higher in the high-dose treatment group than in the low-dose group (3.2 ±
0.80 vs. 1.9 ± 0.20 ng/mg protein; mean ± S.D.; high dose vs. low dose; p < 0.01; Fig.
12G).
Significantly elevated levels of the 5-HT metabolite, 5-HIAA, were observed in
the STR of the high-dose group, when compared with the low-dose group (4.7 ± 0.58 vs.
3.3 ± 0.47 ng/mg protein; mean ± S.D.; high dose vs. low dose; p < 0.05; Fig. 12B). Mn
exposure did not affect the level of 5-HIAA in the SN or HP (Fig. 12E,H).
The 5-HT turnover ratio is defined as the amount of 5-HIAA divided by 5-HT in
each brain region. 5-HT turnover was not statistically changed in the three brain regions
studied. (Fig. 12C,F,I).
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Figure 12. HPLC Analysis of Serotonin, its Metabolite, and Turnover. 5-HT
(A,D,G) and its metabolite 5-HIAA (B,E,H) were quantified using HPLC with
electrochemical detection. 5-HT turnover was calculated by dividing the concentration of
5-HIAA by 5-HT (C,F,I). ANOVA with Tukey’s post hoc test. Data represent mean ±
S.D. (ng/mg protein; n = 3-5). *: p < 0.05.
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NE levels in the STR and SN were not significantly different between Mn
exposed and control animals (Fig. 13A-B). In the HP, significantly higher NE levels
were observed in the high-dose exposure group compared with the low-dose group (6.4 ±
1.29 vs. 4.1 ± 0.81 ng/mg protein; mean ± S.D.; high dose vs. low dose; p < 0.05; Fig.
13C).
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Figure 13. HPLC Analysis of Norepinephrine Levels. NE levels in striatum (STR)
(A), substantia nigra (SN) (B), and hippocampus (HP) (C) were quantified using HPLC
with electrochemical detection. ANOVA with Tukey’s post hoc test for multiple
comparisons. Data represent mean ± S.D. (ng/mg protein; n = 3-5). *: p < 0.05.
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Levels of GABA, the main inhibitory neurotransmitter, were not statistically
different in the STR or SN (Fig. 14A-B). A significant increase in the HP GABA level
was observed in high-dose Mn exposed animals compared with controls (2,221 ± 310.4
vs. 1,441 ± 524.5 ng/mg protein; mean ± S.D.; high dose vs. control; p < 0.05; Fig. 14C).
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Figure 14. HPLC Analysis of GABA Levels. GABA levels in striatum (STR) (A),
substantia nigra (SN) (B), and hippocampus (HP) (C) were quantified using HPLC with
electrochemical detection. ANOVA with Tukey’s post hoc test for multiple comparisons.
Data represent mean ± S.D. (ng/mg protein; n = 3-5). *: p < 0.05.
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3.4.5 Immunohistochemistry of Striatum Following Mn Exposure
Fluorescence intensities of TH and DARPP-32 were not statistically different in
the STR of Mn-exposed animals in comparison with those of control animals (Fig. 15C
and 16C). Fluorojade C staining did not identify degenerating neurons in any group (data
not shown).
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Figure 15. Quantitative Infrared Immunofluorescence Analysis of Striatal TH.
Coronal slices from rat striatum (STR) were probed for antibodies against TH.
Secondary antibodies were tagged with an infrared fluorescent marker. Depicted are
representative scans showing fluorescence intensity in STR slices from control animals
(A) and Mn treated animals (B). Manually selected ROIs are shown as dashed lines. A
minimum of three slices were quantified from each animal and the resulting values were
averaged. Group values were averaged and are shown (C). No difference was observed
between control and either low or high dose groups. Mn treatment did not affect STR TH
signal intensity. ANOVA with Tukey’s post hoc test for multiple comparisons. Data
represent mean ± S.D. (n = 4-5).
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Figure 16. Quantitative Infrared Immunofluorescence Analysis of Striatal
DARPP32. Coronal slices from rat striatum (STR) were probed for antibodies against
DARPP32. Secondary antibodies were tagged with an infrared fluorescent marker.
Depicted are representative scans showing fluorescence intensity in striatal slices from
control animals (A) and Mn treated animals (B). A minimum of three slices were
quantified from each animal and the resulting values were averaged. Group values were
averaged and are shown (C). No difference was observed between control and either low
or high dose groups. Mn treatment did not affect striatal DARPP32 signal intensity.
ANOVA with Tukey’s post hoc test for multiple comparisons. Data represent mean ±
S.D. (n = 4-5).
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3.5 Discussion
The data presented in the current study have established that subchronic, lowdoses of MnCl 2 significantly altered levels of neurotransmitters in rats and produces a
dose-dependent decrease in locomotor behaviors.
The low dose Mn treatment used in this study has been detailed in a previous
report from our laboratory and others (Lebda et al., 2012; Zheng et al., 2009). The high
dose level of Mn used in this paper has been used by several other laboratories (Ou et al.,
2011; Hong et al., 1984; Husain et al., 2001). Under these dose regimens, Mn exposure
significantly reduced animals’ body weights. Additionally, Mn treatment at the high dose
markedly reduced motor activity.
In a review of Mn exposed animal models, McMillian (1999) noted that
behavioral results from many studies show a “slowly developing biphasic response to Mn
exposure,” with an initial increase in the observed behavior followed by a subsequent
decline in behavior. This is true for multiple species, including rats and monkeys
(Nachtman et al., 1986; Vezér et al., 2007). However, in the current study, we did not
observe the initial increase in motor activity. This could be due to a late first time point
that may miss the early behavioral changes. An alternative hypothesis is that our animals
were at the tail end of the early, prodromal phase. As such, the observed hypoactivity
may have resulted from altered neurochemistry and progression of the treatments’ effects.
Our HPLC results clearly demonstrated that DA levels in STR, but not in SN,
were significantly increased after Mn treatment. The elevated level of DA in the STR
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observed in our study is consistent with reports in the literature that at lower internal
cumulative doses of Mn exposure, there is a trend towards increasing DA levels in the
STR (reviewed by Gwiazda et al., 2007). Our dose levels were within the range they
reviewed and our findings were in agreement with their conclusions.
We have also observed significantly increased levels of HVA in the STR; but
increases in NE were limited to the HP. Increased levels of HVA and NE in the STR have
been observed in studies with dose duration from 90-120 days (Chandra et al., 1979).
Species differences between the two studies (i.e. mice vs. rats) may account for the
discrepancy noted. While there is a report to suggest increased GABA in the STR for a
wide range of Mn doses (Gwiazda et al., 2007), we did not observe significant changes in
striatal GABA, but did find significantly increased levels of GABA in the HP of Mntreated rats. In the SN, GABA levels were unchanged.
Several reports have demonstrated that Mn treatment initially causes an increase
in DA, HVA, and NE, but as the exposure increases, the neurotransmitter levels are
decreased (Chandra et al., 1979; Chandra & Shukla, 1981; Cotzias et al., 1974). It was
proposed that DA and NE are increased due to increased synthesis of biogenic amines
early in manganism (Chandra et al., 1979). Our data are in close agreement with this
hypothesis. Several mechanisms may potentially explain the findings in this study. First,
the increased levels of the enzyme MAO-B may metabolize DA to DOPAC. Gwizada et
al. (2007) noted increased MAO-B levels after low doses of Mn and they also showed
increased striatal DA, in agreement with our results. Our DA turnover results further
support this possible mechanism. Second, Guilarte et al. (2006) proposed that DA
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neurons may have an impaired ability release DA into the synapse after Mn exposure,
which could cause intracellular DA levels to increase. Calabresi et al. (2001) postulated
that altered release characteristics may alter the life-time of DA within the STR. Finally,
it is plausible that Mn may stimulate TH activity to increase DA production (Chandra et
al., 1979). In this study, we have assessed levels of TH in the STR of all groups of rats
by immunofluorescence; however, the striatal TH expression was not affected by Mn
exposure. Thus, it is unlikely that the increases in DA levels were attributable to Mn
action on TH. In future studies, it may be prudent to investigate changes of TH levels in
SN, because DA is primarily synthesized in the SN and axons project to the STR (Kunar
et al., 1999).
It must be noted that differences in Mn species, dose routes, durations and
frequencies used may yield different results due to the complex effects of Mn (OrdoñezLibrado et al., 2008). For example, a similar study by Blecharz-Klin, et al. (2012) used
an intranasal dose route for two weeks instead of four in slightly older animals; they did
not observe a difference in either striatal DA or DOPAC, but noted a decreased level of
striatal HVA. Additionally, they observed decreased DA turnover. It is possible that
different dose regimens may exert marked differences in neurochemical changes.
Our recent X-ray fluorescence imaging data show that Mn accumulates in the SN
(Robison et al., 2012). However, the current neurochemistry study showed that the SN
appears to be largely unaffected by Mn treatment. We noted altered levels of HVA in the
SN, but the region was unaffected for all other neurotransmitters investigated. These SN
neurons are spared, at least in the early stages of the disease (Roth, 2009).
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It is worth noting that there has been significant effort devoted to examining a
potential role that Mn exposure may play in PD. The observation of increased DA is in
contrast to a key feature of PD, which is striatal DA depletion due to loss of nigrostriatal
DA neurons. Chronic Mn-induced increases in DA could be deleterious as DA itself is a
reactive molecule contributing to oxidative stress (Hastings & Zigmond, 1994). Finally,
PD is characterized by complex neurochemical changes, beyond striatal DA depletion
alone. Even in a straightforward animal model involving chemical ablation of
nigrostriatal DA neurons, complex changes occur in other neurotransmitter systems
(Schwarting & Huston, 1996). Thus, elucidating similarities and differences between Mn
treatment and prominent PD models will require additional studies.
In summary, our neurochemistry data are in agreement with existing data in the
literature, suggesting that this dose regimen produces a model of early manganism.
Because the symptoms of manganism are slowly progressive and exist along a
continuum, perhaps this model is nearer the end of the first phase. Use of this model of
early manganism may allow the study of mechanisms that progress to clinical
manganism. Cotzias (1958) noted that the early phase may lack motor disturbances and
the disease primarily consists of psychological symptoms. These psychological
symptoms are harder to detect and therefore, more sophisticated behavioral analyses to
assess the symptoms such as disturbance of sleep, eating and sexual disturbances may be
needed.
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CHAPTER 4: MANGANESE INTERACTION WITH BRAIN REPAIR
MECHANISMS IN THE ADULT SUBVENTRICULAR ZONE FOLLOWING
INTRANASAL EXPOSURE

4.1 Abstract
Manganese (Mn) is necessary for normal biological processes; however,
overexposure to this metal can lead to toxic accumulation in the body, particularly in the
brain. Mn accumulation in the brain can result in altered copper (Cu) homeostasis.
Altered Cu levels are implicated in a variety of neurodegenerative disease pathologies.
The goal of this study was to test the hypothesis that Mn accumulation in the rat
subventricular zone (SVZ) led to altered neurogenesis as a result of altered Cu
homeostasis in this region. Adult male rats were intranasally exposed to Mn daily for two
weeks. During the last four days of Mn administration, rats also received twice daily
injections of BrdU to label actively proliferating cells in the SVZ. Brain slices from these
animals were used for immunohistochemistry studies and triple labeled for BrdU and
DCX (neuroblasts), and GFAP (stem cells) to distinguish between newly differentiated
cell types. Following Mn exposure, Mn concentrations were significantly increased and
Cu concentrations were significantly decreased in the SVZ. Following Mn exposure,
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BrdU and DCX expression were significantly increased in the SVZ as well as the
olfactory bulb while GFAP was only significantly increased in the SVZ. The results of
this study demonstrate that Mn exposure affects adult neurogenesis by altering Cu
homeostasis in the SVZ. This suggests that Mn exposure may negatively impact those
neurodegenerative diseases which implicate Cu in their pathology.

4.2 Introduction
Exposure to high levels of the essential metal manganese (Mn) is neurotoxic,
resulting in manganism, an irreversible neurological disease with symptoms similar to,
but distinguishable from idiopathic Parkinson’s disease. Excess exposure predominantly
occurs via inhalation in occupational settings, which is not surprising because Mn is one
of the most commonly used metals in industrial processes. It is used both as a pure metal
and an alloy to produce a variety of products including dry-cell batteries, glass and
ceramics (Nadaska, Lesny, and Michalik, 2012). The median onset of disease is 1 year
after exposures begin and includes both motor and behavioral symptoms (Racette et al.,
2012a). Motor symptoms are exclusively attributed to accumulation of Mn in the basal
ganglia (Newland, 1999).
In our lab, we have confirmed that Mn accumulates in the rodent basal ganglia
and other brain regions, with considerable accumulation in the subventricular zone (SVZ)
and the hippocampus (HP); the latter has the structure called the subgranular zone (SGZ)
in the dentate gyrus. The SVZ and SGZ are important in adult neurogenesis because these
are the only two recognized neurogenic niches in the adult mammalian brain. These
niches house microenvironments capable of maintaining a population of actively
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dividing, undifferentiated neural stem progenitor cells (Garzon-Muvdi and QuinonesHinojosa, 2010). The neurogenic capability of the SVZ is due in part to its proximity to
nutrients and growth factors in the cerebrospinal fluid (CSF) filling the lateral ventricles
where the SVZ is located (Curtis, Faull and Eriksson, 2007). In the SVZ, there are four
cell types: the ependymal cells “type E” cells, “type B” cells which are astrocytic stem
cells (ASCs; GFAP+ astrocytes) and give rise to “type C” (nestin+ transit-amplifying)
cells, which finally differentiate into “type A” neuroblasts (DCX+) (Doetsch et al., 1999;
Zaverucha-do-Valle et al., 2013). The neuroblasts migrate anteriorly along the rostral
migratory stream (RMS) to the olfactory bulb (OB) where they may mature into local
interneurons. Surviving cells are able to functionally integrate, replacing dead cells of the
same phenotype. It has been suggested that functionally integrated new neurons
participate in neural plasticity, learning and memory, as well as sexual behaviors in
mammals, and song production in birds (Alvarez-Buylla and Garcia Verdugo, 2002).
The cells in the SVZ can be stimulated by neurodegenerative diseases, such as
Huntington’s disease, and also epilepsy and stroke (Curtis, Faull and Eriksson, 2007) or
Mn exposure (Fu et al., 2015; Wang et al., 2012). In our lab, we have shown that Mn
exposure by subchronic intraperitoneal injection induces cell proliferation in the SVZ.
Further, we have investigated changes in cell differentiation after Mn exposure and
showed increased production of glial cells.
Mn accumulates in the striatum (STR), hippocampus (HP), and substantia nigra
(SN), brain regions implicated in clinical manganism, as well as the SVZ. In the SVZ, we
also observed a significant reduction in copper (Cu) levels after Mn treatment (Fu et al.,
2015). This is interesting because synchrotron analysis reveals Cu levels in this brain
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region are about 20-30 times higher than in other brain structures (Pushkar et al., 2013), a
finding our lab has confirmed using atomic absorption spectroscopy (AAS). These
findings suggest that high Cu levels in the SVZ are required to maintain the normal status
of neurogenesis in adult brains, and that Mn exposure alters Cu homeostasis in the SVZ.
Cu dyshomeostasis in the brain is implicated in the pathology of a number of
neurodegenerative diseases, including idiopathic Parkinson’s disease, Alzheimer’s
disease, familial amyotrophic lateral sclerosis, prion disease, Wilson’s disease and
Menkes’ disease (Barnham and Bush, 2008, Gaggelli et al., 2006, Mates et al., 2010,
Zheng and Monnot, 2012).
Previous in vivo studies of adult neurogenesis have investigated the effects of Mn
exposure via intraperitoneal, intravenous, or oral gavage administration of Mn-containing
solutions (Fu et al., 2015; Kikuchihara et al., 2015). However, the primary route of toxic
Mn exposure in the human population is inhalation, which permits a direct pathway from
the environment into the central nervous system (CNS). This route is of particular
relevance to adult neurogenesis studies because direct transport along the olfactory
pathway would ensure the highest concentration of Mn reached the OB. Retrograde
transport of Mn from the OB along the RMS would potentially deliver higher
concentrations of Mn to the SVZ than any other route of exposure.
The present studies used an intranasal instillation (IN) technique to study the
effects of Mn exposure on adult neurogenesis. The goals of this study were: (1) to
identify the changes in adult neurogenesis resulting from Mn exposure, (2) to determine
the extent of metal dysregulation after Mn exposure, and (3) to establish IN as a valuable
route of administration for modeling Mn neurotoxicity and studying neurogenesis in adult
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rats. The results of these studies are expected to provide direct evidence of Mn interaction
with neuronal repair mechanisms by altering Cu homeostasis. These results are likely to
create a new area of toxicology research, specifically metals and neurotoxicological
research.

4.3 Materials and Methods

4.3.1 Experimental Design and Animals
Male Sprague Dawley rats were obtained from Harlan Laboratories, Inc.
(Indianapolis, IN) and allowed to acclimate to the test facility for 7 days. When the study
commenced, animals were 8 weeks old and weighed approximately 180-200 g. Rats were
group housed in a temperature- (72 ± 4 °C) and humidity- (30-70%) controlled room on a
12 hour light/dark cycle (lights on at 0600). Rats had ad libitum access to food (Harlan
2018 rodent diet) and reverse osmosis water.
Rats were weighed each day prior to dose administration. At the time of
experimentation, rats received an IN of saline (as control), 0.2, or 0.8 mg Mn/kg as
MnCl 2 daily for 14 days. These doses were chosen based on the work by Blecharz-Klin
et al., (2012) who showed altered neurochemistry and behavior following this regimen.
During the last 4 days of Mn administration, rats also received twice daily intraperitoneal
injections of 50 mg BrdU/kg. BrdU is a thymidine analog that is incorporated into the
DNA of actively dividing cells during the S phase of the cell cycle. Animals’ final body
weights were recorded and rats were euthanized 24 hr after the last Mn administration.
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See Figure 17 for a diagram of the overall experimental design. All animal studies were
approved by the Institutional Animal Care and Use Committee at Purdue University.
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Figure 17: Chapter 4 Experimental Design. Shows daily Mn instillations, BrdU
injections, and necropsy schedule.
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4.3.2 Intranasal Instillation Technique
Prior to Mn administration, rats were anesthetized using 2% isoflurane gas. A
Hamilton syringe coupled to a length of flexible polyethylene tubing (0.18 mm inner
diameter) was filled with the dose solution to be instilled. The tubing was inserted
approximately 2 cm into the rat’s nostril and 10 µL of solution was instilled at the
olfactory mucosa (see Figure 18). The tubing was removed and the procedure repeated in
the other nostril; the starting side alternated each day (Genter et al., 2012). The intranasal
instillation method has previously been used to study Mn exposure by many researchers,
including Tjälve et al. (1996) and Gianutsos et al. (1997).
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Figure 18: Diagram of Intranasal Instillation Procedure. Blue line indicates path of
flexible tubing into rodent nasal passage. Dose solutions are instilled at the olfactory
mucosa (OM) and Mn passes primary neurons by retrograde transport directly into the
olfactory bulb (OB) within the CNS. Over time, Mn is transported into deeper brain
structures.
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4.3.3 Euthanasia and Necropsy
Rats were deeply anesthetized by intraperitoneal injection with a
ketamine/xylazine cocktail (75/10 mg/kg) and exsanguinated. Rats used for
immunohistochemistry studies were perfused with phosphate buffered saline, pH 7.4
(PBS) followed by 4% paraformaldehyde to fix the tissues. The whole brain was removed
and postfixed in 4% paraformaldehyde at 4°C. Rats used for all other studies were not
perfused. From these animals, blood samples were collected from the descending aorta
into heparinized vials. Brains were removed and the SVZ, STR, HP, OB, choroid plexus,
pituitary, thalamus and frontal cortex tissues were dissected on ice. Lung tissue and
femurs were also collected. All tissues were stored at -80°C until processed. Blood was
not stored; it was processed for plasma 20 min after collection.

4.3.4 Atomic Absorption Spectroscopy
Tissue samples collected at necropsy were weighed then digested in enough
concentrated nitric acid (HNO 3 ) to completely cover the tissues. Digestion was facilitated
by using a high pressure MarsXpress microwave (CEM Corporation, Matthews, NC) for
15 min at 200°C. SVZ, CP, and pituitary tissues were digested in acid overnight in an
oven at 55°C. Each digestion was diluted with ddiH 2 O to keep the readings within the
ranges of the standard curves: 1-10 ppb for Mn and 1-50 ppb for Cu. Tissue metal
concentrations were quantified using an Agilent Technologies 200 Series SpectrAA with
GTA 120 graphite furnace and expressed as µg/g of tissue.
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4.3.5 Western Blotting
Total protein was isolated from each brain region. Tissues were lysed in RIPA
homogenization buffer, minced with spring scissors, and then sonicated. Tissues were
incubated on ice for 10 min and centrifuged at 12,000 x g for 15 min at 4°C. Supernatant
was collected and protein was denatured by boiling for 5 min at 95°C. Pierce BCA
Protein Assay (ThermoFisher) was used to quantify protein. Approximately 50 µg of total
protein was loaded per lane and separated on a 10-15% SDS-polyacrylamide gel then
blotted onto a polyvinylidene membrane using a semi-dry transfer (BioRad).
The membrane was blocked in 5% non-fat dry milk diluted in a solution of Trisbuffered saline solution with 0.01% Tween 20 pH 7.4 (TBST) for 2 hr at room
temperature. The membrane was incubated overnight at 4°C with primary rabbit anti-Ctr1
antibody (43 kDa; 1:2,000) in blocking solution diluted 1:5 in TBST. To detect the
primary antibodies, membranes were incubated for 2 hr at room temperature in a solution
containing horseradish peroxidase-conjugated secondary anti-rabbit antibody (1:3,000).
The signals were visualized using enzyme chemiluminescent solutions. Membranes were
rinsed in TBST and stripped in stripping buffer for 20 min then rinsed again. The
blocking procedure was repeated. The primary antibody solution contained mouse anti-βactin (42 kDa; 1:5,000) and the secondary antibody solution contained horseradish
peroxidase-conjugated anti-mouse antibody (1:10,000). Each blot was performed in
triplicate.
For α-synuclein and Iba1 blotting, the membrane was blocked in Li-Cor blocking
solution (Li-Cor). The membrane was incubated overnight at 4°C in a primary antibody
solution containing mouse anti-α-synuclein (14 kDa; 1:1,500) or rabbit anti-Iba1 (17
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kDa; 1:1,000) and chicken anti-β-actin (42 kDa; 1:3,000) in TBST. To detect the primary
antibodies, membranes were incubated for 2 hr at room temperature in TBST containing
infrared-linked secondary antibodies donkey anti-mouse (Li-Cor, IR800; 1:20,000),
donkey anti-rabbit (Li-Cor, IR800; 1:20,000) or donkey anti-chicken (Li-Cor, IR680;
1:20,000). The blots were imaged with the Odyssey infrared imaging system (Li-Cor) at
84 µm resolution with medium intensity and quantified with Image Studio software
(version 3.1). Each blot was performed in triplicate.

4.3.6 qPCR Analysis of Dmt1 and Ctr1 mRNA
Total RNA was isolated from tissues using TRIzol reagent following the
manufacturer’s instructions. RNA samples were reverse-transcribed using the BioRad
iScript cDNA synthesis kit (Hercules, CA). The iTaq Universal SYBR Green Supermix
was used for qPCR analyses following the manufacturer’s instructions.
Dmt1 cDNA was amplified using the following nucleotide sequences:
Forward primer: 5’-GAT TCC AGA CGA TGG TGC TT-3’
Reverse primer: 5’- GTG AAG GCC CAG AGT TTA CG -3’
Ctr1 cDNA was amplified using the following nucleotide sequences:
Forward primer: 5’-ACC TTT GCG CTG ACT CTC AT-3’
Reverse primer: 5’- TGA TCG ATC TCC ATG TGG TT -3’
β-actin was used as an internal control with the following sequences:
Forward primer: 5’- AGC CAT GTA CGT AGC CAT CC -3’
Reverse primer: 5’- CTC TCA GCT GTG GTG GTG AA -3’
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Primers were designed using the Primer Express 3.0 software. All primers were
obtained from Integrated DNA Technologies. Experimental conditions were optimized
for annealing temperature, primer specificity, and amplification efficiency. The
amplification was performed in the CFX ConnectTM quantitative Real-Time PCR
Detection (qPCR) system (BioRad, Hercules, CA) with an initial 3 min denaturation at
95oC followed by 40 cycles of 30 sec denaturation at 95oC, 10 sec gradient from 55.0 to
65.0oC and a 30 sec extension at 72oC. A dissociation curve was used to verify that the
majority of fluorescence detected could be correlated to the labeling of specific PCR
products, and to verify the absence of primer dimers and sample contamination. Each
qPCR reaction was run in triplicate. Relative mRNA expression ratios between groups
were calculated using the delta-delta cycle time (ΔΔCt) formulation; Ct is the threshold
cycle time value. Ct values of Dmt1 and Ctr1 were normalized to the reference gene in
the same sample. The relative ratio between control and treatment groups was then
calculated and expressed as relative increases, setting the control as 100% following the
method of Livak and Schmittgen (2001).
4.3.7 Biogenic Amine Quantification
Neurotransmitter analysis was conducted as previously described (O’Neal et al.,
2014b; Wang et al., 2013). Briefly, OB and thalamus samples were sonicated in 0.5 ml
0.1N perchloric acid (HClO 4 ) on ice, at 50% power, pulsing for 45 s to precipitate
proteins. Samples were then centrifuged at 16,400 x g for 35 min at 4°C. Supernatant
was transferred to 0.22 µm Spin-X tube with nylon filter (Corning) and centrifuged at
1000 x g for 15 min at 4°C. Prepared samples were then stored at -80°C until HPLC
analysis. A Dionex UltiMate 3000 (ThermoScientific; Germering, Germany) system
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with a built in autosampler and a Coulochem III (Thermo Scientific) electrochemical
detector were used for HPLC analysis of DA, its metabolites DOPAC and HVA, as well
as 5-HT and its metabolite 5-HIAA, NE, GABA, glutamate, and taurine. The optimized
monoamine method used an isocratic mobile phase (consisting of 0.08 M NaH 2 PO 4 , 10%
methanol, 2.0 mM OSA, 0.025 mM EDTA, and 0.2 mM TEA, in 13 mΩ purified water,
pH 2.4). Samples were injected and monoamines separated on a reverse phase C18
column (150 x 3.2mm, 3.0 μm particle size, MD-150, Thermo Scientific, Bannockburn,
IL) protected by a guard column. Separation occurred at 32 °C at a flow rate of 0.6
ml/min. For GABA, glutamate, and taurine detection, samples were first derivatized with
OPA (o-phthalaldehyde, methanol, and 2-mercaptoethanol) before injection onto the
column. The isocratic mobile phase (pH 6.75) consisted of Na 2 HPO 4 in 13 mΩ purified
water with 22% methanol and 4% acetonitrile. Separation occurred at 35°C with a flow
rate of 0.5 ml/min. For monoamine neurotransmitter and metabolite detection, the
electrochemical potential of the detector was set at 250 mV, with a conditioning cell at 150 mV. For GABA, glutamate, and taurine detection, the electrochemical potential of
the detector was set at 550 mV, with a conditioning cell at -150 mV. Neurotransmitter
and metabolite levels in each sample were quantified by comparing sample values to a
reference curve prepared by adding standards of a known concentration to perchloric
acid. A sample chromatogram displaying the results for GABA, glutamate, and taurine is
shown in Figure 19. Chromeleon 7.0 software was used for data acquisition and analysis.
Neurotransmitter concentrations were expressed as ng/mg of protein as assessed by BCA
protein assay (Smith et al., 1985) using bovine serum albumin as the standard (Bradford,
1976).
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Figure 19. Sample HPLC Chromatogram. Analysis of olfactory bulb tissue from a
control animal showing separated peaks identified as GABA, glutamate, and taurine.
Electrochemical detector used for analysis of neurotransmitters.
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4.3.8 BrdU/DCX/GFAP Triple Imaging in Brain Sections
Brains were transferred from 4% paraformaldehyde after 7 days to a 30% sucrose
solution for 7 days to equilibrate tissue, preventing the formation of ice crystals during
freezing. Frozen brains were cut (30 µm thickness) on a microtome and stored in
cryoprotectant at -20°C. Every 6th section (180 µm interval) throughout the SVZ and
SGZ was used for IHC. During processing, sections were removed from cryoprotectant
and floating slices were triple-rinsed in PBS x 10 min (rinsed). Sections were incubated
in 2M HCl for 2 hr to denature DNA then rinsed. Denatured slices were blocked in PBS
containing 0.5% Triton X-100 (v/v), 5% BSA, and 10% normal goat serum for 1.5 hr at
room temperature and then rinsed. Rinsed sections were incubated overnight at 4°C with
mouse anti-BrdU (1:400), rabbit anti-DCX (1:1,000), chicken anti-GFAP (1:1,000)
primary antibody in blocking solution diluted 1:10 with PBS. The sections were rinsed
and incubated for 2 hr at room temperature with goat anti-mouse (488 nm; 1:1,000), goat
anti-rabbit (555 nm; 1:1,000), and goat anti-chicken (638 nm; 1:1,000) secondary
antibody in dilute blocking solution. Labeled sections were rinsed for 15 min and
mounted on charged slides then coverslipped in ProLong Gold antifade solution
(Molecular Probes). Slides were protected from light and allowed to dry overnight at
room temperature. BrdU, DCX and GFAP immunofluorescence were visualized in the
same sections using a Nikon inverted confocal laser scanning microscope. Images of the
SVZ and OB were taken from each slice at 40X (Nikon; Plan Apo, 4X/0.20 ∞ 0.17) and
x100 (Nikon; Plan Apo, 10X/0.45 ∞ 0.17) magnifications. Images of the SVZ were also
taken from each slice at x400 (Nikon; Plan Apo, 40X/0.95 ∞ 0.17) magnification. Images
were scanned with the Nikon EZ-C1 (version 3.90) confocal imaging program. For each
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image, the frame average of 16 images was obtained to improve the signal to noise ratio.
Signal intensities were quantified using the NIS-Elements BR (Version 3.10) program.
The software automatically detected regions of interest (ROIs) and calculated mean
intensity values. A minimum of four to six slices per animal were imaged and the values
averaged to produce one value per animal. The group averages were used for statistical
analysis.

4.3.9 Statistical Analysis
All data are expressed as mean ± S.D. Statistical analyses of the differences
between three treatment groups were carried out by one-way ANOVA. Where ANOVA
analysis indicated significant differences between groups, specific differences were
identified by post hoc analysis using Tukey’s test. Analyses of differences between two
treatment groups were carried out by Student’s t test. Group differences were considered
statistically significant for p-values less than 0.05. All analyses were conducted using
SPSS (Version 21.0).

4.4 Results
4.4.1 Body and Relative Organ Weights Following Mn Exposure
Animals’ body weights were recorded daily throughout the 15-day study. Control
animals showed steady weight gain over the course of the study; final body weights were
272.6 ± 9.2 (mean ± S.D.) as compared to 188.8 ± 6.7 on study day 1. Comparatively,
animals instilled with 0.2 mg/kg and 0.8 mg/kg (cumulative Mn dose ranged from 2.811.2 mg/kg) showed a 7.6% or 12.8% reduction, respectively, in final body weight
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compared with control animals’ final body weights. In previous experiments utilizing
different Mn exposure routes, animals receiving intraperitoneal exposure showed 3.112.0% reduction in body weight gain (cumulative dose range 120-300 mg/kg) compared
with controls (Chapter 3) and animals orally exposed (cumulative dose 1,500 mg/kg)
showed a 5.3% reduction in body weight gain compared with controls (Chapter 2).
For animals instilled with Mn, relative organ weights of the spleen and pituitary
gland were also calculated as:

Relative organ weights were calculated as a crude estimate to determine if
systemic toxicity or immune responses occurred as a result of intranasal Mn exposure.
The spleen and pituitary glands were selected for examination because they play a role in
immune function and their sizes may vary during an immune response. Additionally, the
spleen and pituitary gland have readily distinguishable boundaries which facilitated
collection at necropsy. Comparing the whole organ weights to the animals’ final body
weights revealed that relative organ weights of neither spleen, nor pituitary was
significantly altered following Mn exposure (p=0.74 and p=0.63, respectively). Finally,
whole brain weight was unchanged following intranasal Mn exposure (p=0.08).

4.4.2 Metal Concentrations in Brain and Body Tissues
AAS analysis of select tissues in the brain revealed that Mn concentrations were
significantly increased following Mn instillation of either 0.2 or 0.8 mg/kg in all regions
analyzed, except cerebellum (p=0.44; Table 5). As expected, following an intranasal
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instillation, Mn concentrations in the brain were highest in the olfactory bulb (2.33 ± 1.86
µg/g). Interestingly, the SVZ had the second highest Mn concentration, which was
significantly increased by 95.5% following Mn exposure (1.29 ± 0.45 µg/g for the 0.8
mg/kg dose group compared with the control group (0.66 ± 0.31 µg/g; p < 0.01).
Cu concentrations were differentially affected in brain regions following Mn
exposure (Table 6). In the STR, Cu concentrations were significantly increased following
Mn exposure (4.98 ± 0.56 µg/g compared with 2.57 ± 0.35 µg/g for controls; p < 0.01).
In the SVZ, Cu concentrations were significantly reduced between 46.4%-86.7%
following Mn exposure (5.17 ± 0.78 µg/g and 1.28 ± 0.04 µg/g for 0.2 mg/kg and 0.8
mg/kg, respectively, compared with 9.64 ± 2.81 µg/g in controls; p < 0.01). The SVZ was
the only tissue examined in which Cu concentration was significantly reduced following
Mn exposure. In the majority of tissues analyzed, including the olfactory bulb,
hippocampus, frontal cortex, and cerebellum, Cu concentrations remained unchanged. It
is also interesting to note that basal Cu concentration is highest in the SVZ, about 3.75fold higher than in the STR or 3.4-fold higher than HP Cu concentrations. This confirmed
the previous findings from synchrotron analysis of SVZ that the basal Cu concentration
in the SVZ is 20-30 times higher than those in other brain regions (Pushkar et al., 2013).
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Table 5. Tissue Mn Concentrations Were Analyzed by Atomic Absorption
Spectroscopy Following Intranasal Mn Exposure. Data represent mean ± S.D. µg/g;
n=4-10; *p < 0.05, **p < 0.01, ***p < 0.001 when compared with controls.

Mn Levels
Tissue

control

0.2 mg/kg

0.8 mg/kg

SVZ
Striatum
Hippocampus
Olfactory Bulb
Frontal Cortex
Choroid Plexus
Pituitary
Cerebellum
Other Tissue
Lung
Femur
Plasma

0.66 ± 0.31
0.35 ± 0.05
0.43 ± 0.06
0.64 ± 0.2
0.42 ± 0.15
0.57 ± 0.24
0.93 ± 0.12
0.68 ± 0.16
0.33 ± 0.05
0.37 ± 0.13
0.69 ± 0.10
0.004 ± 0.001

1.31 ± 0.10**
1.07 ± 0.06**
--1.79 ± 0.26**
1.31 ± 0.23*
----1.68 ± 0.25**
--

1.29 ± 0.45**
1.10 ± 0.15**
0.77 ± 0.01***
2.33 ± 1.86*
1.13 ± 0.33**
1.28 ± 0.44*
4.15 ± 0.72***
1.09 ± 0.97
0.75 ± 0.10**
0.50 ± 0.01
2.40 ± 0.38**
0.010 ± 0.002**

Table 6. Tissue Cu Concentrations Were Analyzed by Atomic Absorption
Spectroscopy Following Intranasal Mn Exposure. Data represent mean ± S.D. µg/g;
n=4-10; *p < 0.05, **p < 0.01when compared with controls.

Cu Levels
Tissue
SVZ
Striatum
Hippocampus
Olfactory Bulb
Frontal Cortex
Choroid Plexus
Pituitary
Cerebellum
Other Tissue
Lung
Femur
Plasma

control
9.64 ± 2.81
2.57 ± 0.35
2.81 ± 0.56
2.34 ± 0.28
2.68 ± 0.31
3.34 ± 2.95
0.54 ± 0.14
0.56 ± 0.4
0.21 ± 0.05
0.50 ± 0.02
0.59 ± 0.19
0.19 ± 0.01

0.2 mg/kg
5.17 ± 0.78**
2.51 ± 0.59
--2.39 ± 0.19
3.06 ± 0.75
----0.64 ± 0.09
--

0.8 mg/kg
1.28 ± 0.04**
4.98 ± 0.56**
2.33 ± 0.19
2.64 ± 0.44
2.53 ± 0.22
2.54 ± 0.44
0.45 ± 0.03
0.56 ± 0.06
0.24 ± 0.01
0.51 ± 0.02
0.67 ± 0.11
0.21 ± 0.002**
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4.4.3 Immunohistological Findings from Triple Labeled Brain Slices
In control animals, low magnification (x40) confocal images of sagittal brain
sections revealed the fluorescent BrdU signal was localized to the lateral walls in the
lateral ventricles where the SVZ is located (Figure 20). The BrdU signal can also be
observed in the delta SVZ (ΔSVZ) region, located at the superior aspect of the SVZ
where the RMS begins, and anteriorly into the RMS as well. At this low magnification,
labeling for DCX and GFAP was also visible. This region shows high levels of DCX
expression.
As intranasal instillation of Mn significantly alters Mn and Cu levels in the SVZ,
we hypothesized that Mn exposure would inhibit neurogenesis in the SVZ and ΔSVZ, the
superior aspect of the SVZ leading directly to the RMS. To test this hypothesis, animals
received twice daily injections of 50 mg/kg BrdU during the last four days of Mn
exposure to pulse-label actively dividing cells in the SVZ. In contradiction to our original
hypothesis, BrdU signals were clearly increased following Mn exposure (Figure 20 top
row). Quantification of the average fluorescence intensity confirms the signal was
significantly increased by 25.1% after 0.2 mg/kg Mn exposure (p < 0.05; Figure 21).
An increase in BrdU signal indicates an increase in the proliferation of new cells
in this neurogenic niche. These cells are capable of differentiating to neuroblasts or
producing new glial cells to maintain the pool of astrocytic stem cells (ASCs), the true
neural stem cells in the region. For a complete understanding of Mn-induced
neurotoxicity, it is necessary to understand how Mn exposure affects these differentiation
processes, potentially resulting in altered neuronal and glial populations. To test the
effects of Mn exposure on cell differentiation in the SVZ, brain slices from each exposure
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group were triple-labeled for BrdU, DCX (to identify neuroblasts), and GFAP (to identify
ASCs). Triple-labeling revealed that BrdU expressing cells in the SVZ also expressed
DCX or GFAP, indicating that both neuroblasts and ASCs were actively proliferating in
the SVZ. Quantification of the dual-fluorescence signals in sagittal slices revealed
significant 27.0% increases in expression of both DCX and GFAP (p < 0.01) following
0.2 mg/kg Mn exposure (Figure 21). These same changes were not observed following
0.8 mg/kg Mn exposure. This indicated that Mn exposure not only increased the
proliferation of cells, but also differentiation of the cells to either neuroblasts (DCX+) or
ASCs (GFAP+).
In the ΔSVZ region, DCX was significantly increased following 0.8 mg/kg Mn
exposure (58.8%; p < 0.01). GFAP remained unchanged in the ΔSVZ region (p = 0.334).
Combining the fluorescence intensities for the SVZ and ΔSVZ at low
magnification (x40) revealed significant increases of 28.9%, 29.2%, and 8.9% for BrdU,
DCX, and GFAP respectively (p < 0.01) following 0.2 mg/kg Mn exposure.

125

Figure 20. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the
SVZ at low magnification. Rats received twice daily injections of 50 mg/kg BrdU
during the last four days of the study to pulse-label actively dividing cells in the SVZ.
Representative images from each treatment group show labeling of BrdU (red), DCX
(green), GFAP (blue), BrdU/DCX, BrdU/GFAP, and merge at low magnification (x40).
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Figure 21. Quantification of IHC triple labeling in the SVZ for BrdU, DCX, and
GFAP at low magnification (x40). Bar graph shows the fluorescence intensity for each
label in the SVZ. Data represent mean ± S.D., n = 4; * p < 0.05, ** p < 0.01 as compared
with controls.
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The trend in increasing expression of BrdU and DCX after Mn exposure observed
at low magnification (x40) continued for the high magnification images (x100 and x400,
Figure 22). At x100 magnification, BrdU label was significantly increased by 83.1%, and
DCX label was significantly increased by 78.4% (p < 0.01) following 0.2 mg/kg Mn
exposure. At x400 magnification, BrdU expression was significantly increased following
both 0.2 and 0.8 mg/kg Mn exposure, 54.4% and 37.7%, respectively as compared with
control (p < 0.01; Figure 23). Thus, Mn-exposure appeared to disturb the processes of
both cell proliferation and differentiation critical for normal adult neurogenesis.
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Figure 22. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the
SVZ at high magnification. Representative images from each treatment group are
shown. The circle in the x100 magnification (top row) indicates the approximate area of
the SVZ enlarged in the x400 magnification images below of BrdU (red), DCX (green),
GFAP (blue), BrdU/DCX, BrdU/GFAP, and merge.
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Figure 23. Quantification of IHC staining in the SVZ for BrdU, DCX, and GFAP at
high magnification (x400). Bar graph showing fluorescence intensity for each label in
the SVZ. Data represent mean ± S.D., n = 4; ** p < 0.01 compared with controls.
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At higher magnification of the ΔSVZ region, we observed BrdU signal colocalized with both the DCX and GFAP signals; this was particularly evident when
comparing the BrdU/DCX and BrdU/GFAP combined images (Figure 24).
Quantification of ΔSVZ images at high magnification (x100) similarly revealed a 53.5%
significant increase in BrdU expression following 0.8 mg/kg Mn exposure (p < 0.05)
(Figure 25). DCX and GFAP expression were non-significantly increased following Mn
exposure (p = 0.08 and 0.06, respectively). Increasing magnification to x400 in the ΔSVZ
showed significantly increased BrdU expression following both 0.2 and 0.8 mg/kg Mn
exposure (71.7% and 74.6%, respectively) compared with controls (p < 0.05).
Additionally, DCX expression significantly increased by 91.8% in the ΔSVZ following
0.8 mg/kg Mn exposure (p < 0.05).
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Figure 24. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the
ΔSVZ at high magnification. Representative images from each treatment group are
shown. The square in the x100 magnification (top row) indicates the approximate area of
the ΔSVZ enlarged in the x400 magnification images below of BrdU (red), DCX (green),
GFAP (blue), BrdU/DCX, BrdU/GFAP, and merge.
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Δ

Figure 25. Quantification of IHC staining in the ΔSVZ region for BrdU, DCX, and
GFAP at high magnification (x400). Bar graph showing fluorescence intensity for each
label in the ΔSVZ. Data represent mean ± S.D., n = 4; * p < 0.05 compared with controls.
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Newly proliferated BrdU+ cells may begin to migrate along the RMS to their final
destination in the olfactory bulb. Cells that survive in the olfactory bulb are capable of
migrating further to the glomerular layer or the granule layer. Therefore, we assessed the
changes within these two layers of the olfactory bulb with or without Mn exposure. This
examination is of particular importance in that intranasal manganese exposure resulted in
the highest concentration of Mn in the olfactory bulb. High magnification images (x100)
of the olfactory bulb (Figure 26) showed BrdU expression in the glomerular layer was
significantly increased by 58.9% following 0.2 mg/kg intranasal Mn exposure (p < 0.01;
Figure 27). Additionally within the glomerular layer, DCX expression was significantly
increased by 51.9% following 0.2 mg/kg Mn exposure (p < 0.01).
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Figure 26. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the
olfactory bulb at high magnification (x100). Representative images from each
treatment group are shown. The square indicates the glomerular cell layer of the olfactory
bulb and the circle indicates the granule cell layer of the olfactory bulb labeled for BrdU
(red), DCX (green), GFAP (blue), BrdU/DCX, BrdU/GFAP, and merge.
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Figure 27. Quantification of IHC staining in the olfactory bulb for BrdU, DCX, and
GFAP at high magnification (x100). Bar graph showing the fluorescence intensity for
each label in the granule and glomerular cell layers. Data represent mean ± S.D., n = 4;
** p < 0.01 compared with controls.
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4.4.4 Dmt1 and Ctr1 mRNA and Protein Expression Following Intranasal Mn Exposure
Altered metal levels in the brain have differential effects on brain function in
neurodegenerative disease, and specifically in the SVZ, altered metal levels affect the
processes of cell proliferation and differentiation critical for normal adult neurogenesis. A
complete understanding of the factors affecting neurogenesis could potentially lead to
improved therapies for neurodegenerative disease, stroke, and brain injury. Therefore, it
is of utmost importance that we begin to explain the mechanisms responsible for altered
metal homeostasis in the SVZ. Altered metal levels could be due to the changes in
proteins participating in regulation of cellular metal homeostasis. Two metal transporters
known to be involved in Mn and Cu homeostasis, i.e., divalent metal transporter-1
(Dmt1) and Cu transporter 1 (Ctr1), were selected as candidates for further investigation.
In previous studies, we have shown that Mn accumulation in the SVZ induces a 13%
increase in Dmt1 following intraperitoneal exposure (Fu et al., 2015). However,
following IN Mn exposure, qPCR results in this study revealed that neither Dmt1 nor
Ctr1mRNA expression was significantly altered in SVZ, OB, STR, or HP (p values
ranging from 0.28-0.67). Of note, increasing expression of Dmt1 in the STR was close to,
but did not reach statistical significance (p = 0.07).
By using Western blotting techniques, the total protein expression was also
analyzed in these same tissues. Although it appeared that CTR1 protein expression was
increased in the SVZ, but decreased in the STR following Mn exposure, quantification of
Western blots did not reveal significant differences between groups in all tissues
examined. The most striking result from these studies was the discovery that there was
limited expression of CTR1 protein in both the OB and HP (Figure 28).
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After intranasal Mn exposure, the highest levels of Mn in the brain were found in
the OB. We investigated potential changes in α-synuclein and Iba1 in the OB following
Mn exposure because some of the earliest symptoms of Parkinson’s disease are observed
in this brain region. According to the Braak hypothesis of Parkinson’s disease pathology,
olfactory structures are among the first to display pathological changes, and olfactory
deficits are a common early symptom of Parkinson’s disease (Braak et al., 2003;
Berendse et al., 2011). Additionally, increased α-synuclein aggregation is a hallmark
Parkinson’s disease. Mn exposure is known to induce oxidative stress and inflammation
which are important pathways in Mn-induced neurotoxicity; therefore, expression of
Iba1, a marker of activated microglia, was analyzed in the olfactory bulb. Through these
studies, it was revealed that olfactory α-synuclein was not significantly altered following
IN Mn exposure (p = 0.22). Although it appeared Iba1 expression was significantly
increased following Mn exposure, the increase did not reach statistical significance (p =
0.06). Noticeably, the proteins in these blots were poorly resolved and the signals
overlapped, particularly for the β-actin signal, which made them unsuitable for
quantification. Although the quality of the Western Blot results leaves much to be
desired, the trend towards increasing expression of olfactory Iba1 was consistent for 6
blots.
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Figure 28. Western blots showing CTR1, α-synuclein, and Iba1 protein expression
following intranasal Mn exposure. CTR1 protein levels detected in SVZ (A), STR (B),
HP (C), and OB (D) using horseradish peroxidase-linked secondary antibodies. α –
synuclein detected in OB (E), and Iba1 detected in OB (F) using Odyssey infrared
imaging system. Each well contains approximately, 50 µg protein, n=3 per group. Each
blot analyzed in triplicate (at a minimum).

139
4.4.5 HPLC Evaluation of Biogenic Amines in Olfactory Bulb and Thalamus
These studies followed the dose regimen detailed by Blecharz-Klin et al. (2013) who
investigated neurochemical alterations following the IN Mn exposure. These authors
showed only modest changes in any neurotransmitter system with the most striking result
being a significant decrease in DA concentrations in the hippocampus. They also showed
a significant increase in norepinephrine in the cortex and a significant decrease in
serotonin in the cortex, hippocampus and striatum. Magnetic resonance spectroscopy
studies of the human population exposed to Mn consistently reveal group differences in
GABA expression in the thalamus (Dydak et al, 2011). Blecharz-Klin et al. (2013) did
not investigate changes in GABA, nor did they investigate changes in the thalamus.
Therefore, in the present study, GABA concentrations in the thalamus and olfactory bulb
were investigated using HPLC. Changes in monoamine levels, including dopamine and
serotonin and their metabolites were also evaluated in these brain regions.
Although the concentrations of GABA in the thalamus and OB were not significantly
altered, it was interesting to note that thalamic GABA levels appeared to be reduced
following Mn exposure (p = 0.32). Glutamate was not significantly altered in either the
thalamus or olfactory bulb (p = 0.1-0.32). Lastly, monoamine data was not significantly
altered following intranasal Mn exposure in either the OB or thalamus. DA
concentrations in the thalamus appeared to be reduced following Mn exposure, but the
variability was too large to provide conclusive results (n=3-4; p = 0.095).
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4.5 Discussion
Previous work from our lab has shown that Mn exposure following intraperitoneal
injection leads to significant accumulation in the SVZ and significantly altered Cu levels
in this region. Cu levels are normally high in the SVZ, an area with known neurogenic
function, even in adulthood. We hypothesized that the high basal Cu concentrations in the
SVZ were necessary for normal adult neurogenesis in this niche. The effects on adult
neurogenesis resulting from altered metal homeostasis following intranasal Mn exposure
were unknown in this area. The AAS data presented here demonstrated that intranasal
instillation of Mn led to significant accumulation of Mn in the SVZ and correspondingly,
a significant decrease in SVZ Cu concentrations was observed. The IHC data revealed a
significant increase in the expression of BrdU in the SVZ, ΔSVZ, and glomerular cell
layer of the olfactory bulb following intranasal Mn exposure. Additionally, expression of
DCX in these regions was also significantly increased following Mn exposure. GFAP
expression was significantly increased only in the SVZ, the finding was not surprising
because GFAP labels astrocytic stem cells, the true stem cells of the SVZ niche. These
cells do not migrate, but proliferate in the SVZ niche, maintaining a pool of
undifferentiated progenitor cells. GFAP expression did not change in the ΔSVZ which
could indicate that the superior aspect of the SVZ does not maintain a pool of neural stem
cells. Recently, we showed BrdU+ cells mainly expressed DCX, with fewer BrdU+ cells
expressing GFAP following intraperitoneal Mn exposure (Fu et al., 2015). Our similar
findings here suggest that Mn exposure mainly affected proliferating neuroblasts
originating in the SVZ.
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The application of the intranasal instillation route of Mn exposure is novel to the
study of adult neurogenesis. There are several advantages of intranasal instillation over
other traditional exposure routes, including, but not limited to: a more biologically
relevant dose route with greater bioavailability (Tjälve et al., 1996) following direct
transport into the CNS (Dorman et al., 2004), smaller cumulative doses, and shorter study
durations because Mn can bypass the blood-brain barrier (Thompson et al., 2007).
Although neurochemistry was unaffected in the current study, modest changes in
dopamine and serotonin and their metabolites have been observed following this dose
administration (Blecharz-Klin et al., 2012). Additionally, we observed highly significant
changes in both Mn and Cu concentrations in the brain following this route of exposure
that are similar in magnitude to changes observed after intraperitoneal exposure. This is
striking because the cumulative doses used in this study are less than 10% those used in
intraperitoneal studies to achieve the same results. This finding suggests that Mn
exposure by inhalation may be more harmful than other routes of exposure. Interestingly,
changes in animals’ body weights and relative organ weights which are indicators of
general toxicity (Oszlanczi et al., 2010) were not significantly different between
intranasal and intraperitoneal exposures, suggesting that the intranasal route is no more
toxic than is intraperitoneal exposure, with regard to systemic toxicity.
After intranasal instillation, Mn levels were highest in the OB, suggesting Mn first
entered the brain at the OB and followed retrograde transport to more posteriorly located
brain structures, such as the SVZ and STR. Mn levels were unchanged at the cerebellum,
which was anticipated given the expected rate of Mn transport. It is estimated to take 6
weeks for Mn to reach the cerebellum by this exposure route (Dorman et al., 2002),
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whereas our study lasted for only two weeks. The same group of researchers has also
shown that Mn concentrations in the OB remain elevated for up to 45 days following
exposure (Dorman et al., 2004), suggesting there is great potential for Mn exposure to
continue following dose cessation after this route of exposure.
Because of the SVZ’s close proximity to the STR, it was important to confirm
two discreet tissues were collected correctly at necropsy. Previous research from our lab
has shown that tissue collected as SVZ shows amplification of nestin, a marker of
proliferating cells following qPCR analysis. If this tissue was not the SVZ, there would
be no amplification of this gene. Likewise, in the current study, Mn concentrations at
each dose level were significantly different between the SVZ and the STR (control p <
0.01, 0.2 mg/kg p < 0.001, and 0.8 mg/kg p < 0.05). Additionally, differences in the Cu
concentrations following Mn exposure also verified that the SVZ and striatal tissues were
distinct; Cu concentrations were significantly reduced in the SVZ, while they were
significantly increased in the STR.
Our observations raise several interesting questions: 1) what is the significance of the
high Cu concentrations in the neurogenic niche; what is the function with regard to adult
neurogenesis? 2) Are high Cu concentrations required for normal adult neurogenesis? 3)
Is the mechanism responsible for accumulating high Cu levels in the SVZ altered
following Mn exposure?
We have shown that basal Cu levels are extraordinarily high in the SVZ and they
significantly decreased following Mn exposure. Kikuchihara et al. (2015) also showed a
significant reduction of Cu concentration in the subventricular zone (SGZ) following Mn
exposure. It is unknown if the basal Cu levels in the SGZ are significantly higher than
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those in surrounding tissues because we cannot dissect out the SGZ at this time. It is also
unknown if Mn exposure affects the Cu level in the SGZ. It would be possible in future
studies to dissect out the entire dentate gyrus from the HP to check metal concentrations
using AAS or use synchrotron analysis to detect Cu levels within the SGZ specifically.
The results of the current study and the results from work in the SGZ by Kikuchihara’s
group suggest that Cu homeostasis is important in adult neurogenesis (Kikuchihara et al.,
2015). Since a Cu imbalance is implicated in a variety of neurodegenerative diseases, it is
possible that Cu dyshomeostasis is the beginning of a decline in proper brain repair
mechanisms following Mn exposure. This deserves immediate investigation. Our results
provide direct evidence that adult neurogenesis and gliogenesis are stimulated following
intranasal Mn exposure.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS

5.1 Summary
The transition metal Mn is the 12th most abundant element on earth (Nadaska et
al., 2012). It is found in every cell in the body and is required for normal development
and function of every cell in the body (Aschner et al., 2007; Crossgrove and Zheng, 2004;
Guilarte, 2010). However, overexposure to this metal is toxic to various organ systems.
The central nervous system is the primary target of Mn toxicity, with Mn accumulation in
the globus pallidus producing signs and symptoms similar but not identical to idiopathic
Parkinson’s disease, including bradykinesia, memory deficits, and kinetic tremor
(Bowman et al., 2011; Jiang et al., 2006; Racette et al., 2005). Overexposure to Mn
primarily results from inhalation of high concentrations of Mn in the air in occupational
settings such as welding, smelting, and dry-battery production (Cowan et al., 2009a,b;
Keen and Lönnerdal, 1995; Racette et al., 2012). Regulatory standards are designed to
protect workers from toxic exposures; however, researchers studying these populations
have routinely shown Mn exposures above regulatory standards occur. More alarming
still is the fact that low-level occupational exposure, with air Mn concentrations at or
below occupational standards can also be detrimental. Neurochemical, neurobehavioral,
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and neuroendocrine changes may occur before structural damage occurs, and are
linked to pathogenic conditions (Alessio et al., 1989; Cowan et al., 2009a,b; Dydak et al.,
2011; Lucchini and Zimmerman, 2009; Mutti et al., 1996).
Research on Mn neurotoxicity has often investigated changes in neurotransmitter
expression and function, and studies suggest that dopaminergic neurons and their
terminals are lesioned similar to Parkinson’s disease following Mn exposure, but the
results from other studies is often contradictory and the effect of Mn exposure on
neurotransmitters remains uncertain.
It is known that symptoms of Mn-induced toxicity continue to progress even
though further exposure has stopped, but it is unknown whether release of Mn from
storage organs including bone could account for continual disease progression.
Lastly, it is unknown what the effect of Mn exposure is on the SVZ, a region with
rich neurogenic potential; the SVZ in the lateral ventricles houses actively proliferating
neural stem cells. These cells can differentiate and migrate anteriorly to the olfactory
bulb. The olfactory bulb is the first brain region metals and other contaminants come into
contact with following direct transport into the brain by way of olfactory neurons. The
effect of olfactory Mn transport on either the olfactory bulb or the SVZ also remains
unknown.
The studies in this doctoral dissertation were designed to address several of these
research challenges in the field of Mn neurotoxicological research.
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5.1.1 Chapter 2 Summary
Bone is a major storage organ for Mn, sequestering more than 40% of the total
Mn in the body. The toxicokinetics of Mn in bone tissue, particularly the rate of
accumulation, time to steady-state concentration, and half-life of Mn in bone remained
unknown. Mn and Cu concentrations in bone tissues from rats orally exposed to Mn were
evaluated at various times both during ongoing administration of Mn and following
cessation of Mn exposure. We showed a rapid accumulation of Mn in bone followed by a
much slower elimination from bone. We calculated the half-life of Mn in rat bone and for
the first time were able to estimate the half-life of Mn in human bone to be approximately
8.6 years. We showed that Mn reaches steady-state concentrations after only 6 weeks.
Lastly, the results of our work showed that Mn concentrations in bone were well
correlated with concentrations in brain, indicating that bone is an accurate biomarker of
Mn exposure and Mn accumulation in brain. The significance of this work was
immediately apparent—it has helped provide support for use of bone as a biomarker of
Mn exposure in the human population.

5.1.2 Chapter 3 Summary
Motor symptoms resulting from Mn toxicity resemble idiopathic Parkinson’s
disease. However, animal studies suggest that dopaminergic neurons selectively lesioned
in Parkinson’s disease remain intact after Mn intoxication (Guilarte, 2010). Therefore,
some other change must be responsible for behavioral observations and motor function.
Reports of Mn exposure altering neurotransmitter and metabolite levels have been
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published (Gwiazda et al., 2007; Racette et al., 2012a), but the findings are often
contradictory and widely debated. We investigated regional changes in dopamine and
other neurotransmitters, including serotonin, norepinephrine, and GABA in rats
subchronically exposed to Mn by intraperitoneal injection to attempt to explain
differences in brain regions implicated in Parkinson’s disease. We also used three dose
levels to uncover a possible dose-response relationship. We showed significantly
increased levels of DA and its metabolites in the striatum, as well as increased dopamine
turnover in other brain regions affected by Parkinson’s disease. Additionally, GABA
levels were significantly higher in the hippocampus. No structural abnormalities were
identifiable in any region evaluated. In conclusion, the results from this study showed
that Mn exposure had more pronounced effects on neurotransmitter expression in the
striatum rather than the substantia nigra following Mn exposure. We also showed that Mn
exposure did have a dose-dependent effect on locomotor behavior in rats.

5.1.3 Chapter 4 Summary
Excess exposure to Mn in the human population predominantly occurs following
inhalation. Mn accumulates in the olfactory bulb and can be transported to deeper brain
structures, possibly including the subventricular zone, an area with known neurogenic
capacity. The effect of Mn exposure in this region was unknown. Following a two-week
intranasal Mn exposure in rats and pulse-labeling of BrdU at the end of the study, brain
sections were evaluated for changes in cell proliferation and differentiation in the SVZ.
The results of our work showed significant accumulation of Mn and a significant
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reduction in Cu concentrations in the SVZ following Mn exposure. This altered metal
homeostasis was found to be coupled with altered cell proliferation and differentiation.
Following Mn exposure, there were significantly more BrdU+ cells in the SVZ compared
with controls. Additionally, there were more cells expressing markers for neuroblasts
(DCX+) and astrocytic stem cells (GFAP+). Interestingly, we noted significantly
increased expression of both BrdU and DCX, but not GFAP in the glomerular layer of the
olfactory bulb. This is important because it shows for the first time that intranasal Mn
exposure directly interacts with neurogenesis, potentially affecting neuronal repair
mechanisms.
5.2 Limitations
The studies in this dissertation have several limitations. First, the dose, exposure
route and duration are different for each study. The method selected for each study design
was appropriate, but the differences between studies limited the ability to directly
compare the results. Therefore, it is difficult to draw conclusions between studies (i.e.
between the studies of bone accumulation and neurogenesis). Second, the sample sizes
for neurochemistry and immunohistochemistry were limited. While the statistical power
was sufficient to detect group differences, any important individual differences (for
example cell death) may not have been captured. Lastly, changes in neurochemistry and
neurogenesis due to Mn exposure are expected to be dynamic. The studies in this
dissertation were designed to assess changes in these specific endpoints following Mn
exposure. Because samples were collected at one point in time, in both cases 24 hr after
dose cessation, it is possible that important differences were not captured. For instance,
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perhaps neurochemistry is most significantly affected after the initial Mn exposure as
opposed to 24 hr after cessation. It would have been beneficial to have collected samples
at more than one point in time. Similarly, in studies of adult neurogenesis, without
collecting samples over time, it is impossible to draw conclusions about how Mn
exposure affects cell survival or migration.
5.3 Future Directions
The research in this dissertation has established that toxic Mn exposure can alter
neurochemistry in regions important in neurodegenerative disease but there was no
significant effect on dopaminergic cell loss. While our neurochemistry data from these
studies did not result in any definitive dose-response relationship in neurotransmitter
expression, we did show dose-dependent decrease in locomotor behaviors. The open field
test may not be sensitive enough to detect the extent of behavioral changes resulting from
Mn toxicity, nor does it allow for detecting changes in learning and memory following
Mn exposure. Changes we observed in the hippocampus neurotransmission suggest
changes in learning and memory following Mn exposure are possible and should be
investigated. The Morris water maze is the common test used to determine differences in
learning and memory and may be suitable here. To detect differences in motor function,
the rotarod test coupled with a stride analysis test may be more suitable than the open
field test.
We have also showed that Mn exposure had significant effects on toxicokinetics
of Mn storage in and elimination from bone. The levels of Mn in bone were significantly
correlated with levels in brain, making bone a highly useful biomarker of Mn exposure.
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To facilitate development of bone as a suitable biomarker and development of a
technique for measuring Mn in bone, it would be helpful to know the contribution of
other tissues, including skin, muscle, and bone marrow, that could potentially interfere
with collecting accurate measurements of a patient’s bone Mn concentrations. We have
preliminary data suggesting neither muscle nor bone marrow contain substantial amounts
of Mn, but this should be verified, and skin (including fur from animals) should be
evaluated as well.
Lastly, intranasal Mn exposure has been demonstrated to be an effective route of
exposure for the study of Mn neurotoxicity and adult neurogenesis. The primary route of
exposure in humans is by inhalation. By this route, a large percentage of Mn is taken into
the CNS directly at the olfactory mucosa while a smaller fraction is inhaled or swallowed
and passes into the blood. Circulation permits additional uptake of Mn into the CNS from
the blood through the brain barrier systems. The method of intranasally instilling Mn
directly at the olfactory mucosa maximizes the amount of Mn directly entering the CNS
and minimizes the amount of Mn available to enter into systemic circulation.
Mn accumulation in other brain regions leads to altered neurochemistry. Changes in
neurochemistry may cause subtle neuronal injuries. It is worthwhile to investigate
changes in neurochemistry in the SVZ and see if these subtle changes may trigger adult
neurogenesis processes in the SVZ, leading to increased proliferation and migration of
DCX+ cells to the OB for the purpose of neuronal repair. Additionally, it would be
interesting to investigate levels of glutamate in the frontal cortex of intranasally instilled
animals as changes in frontal cortex glutamate have been seen in MRS experiments with
Mn exposed workers.
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The answers to the following questions are currently unknown: 1) why are basal Cu
levels are so high in the SVZ, 2) how does Mn accumulate in this region, and 3) how
does Mn accumulation subsequently disrupt Cu homeostasis in the SVZ. It is important
for a complete understanding of Mn neurotoxicity in relationship to neurodegenerative
disease pathology that each of these questions be addressed. The present studies began to
address how Mn accumulates and how Cu levels are altered following Mn exposure, but
the results were inconclusive and the methods did not consider all possible transporters
which could be participating in altered metal homeostasis. An analysis of the repertoire of
metal transporters involved in Mn and Cu homeostasis should be undertaken to fully
explain these changes.
Overall, it can be concluded from the data presented in these studies that neurotoxic
Mn exposure causes subclinical alterations in neurochemistry, metal concentrations and
homeostasis, and animal behavior. These changes have not led to any detectable
structural damage within the time frame investigated in these studies and the results of
this work do not suggest that structural damage is imminent. However, some of the
changes observed are themselves toxic (i.e., increased levels of DA), and are capable of
affecting other biological processes. Therefore, it seems likely that Mn exposure may
ultimately lead to structural damage. This deserves further investigation.

LIST OF REFERENCES

152

LIST OF REFERENCES

Alessio L, Apostoli P, Ferioli A, Lombardi S (1989). Interference of manganese on
neuroendocrinal system in exposed workers. Preliminary report. Biol Trace Elem
Res. 21:249-253.
Alvarez-Buylla A, Garcia-Verdugo JM (2002). Neurogenesis in adult subventricular
zone. The Journal of Neuroscience 22(3):629-634.
Andersen ME, Dorman DC, Clewell HJ, Taylor MD, Nong A (2010). Multi-dose-route,
multi-species pharmacokinetic models for manganese and their use in risk
assessment. Journal Of Toxicology And Environmental Health Part A 73(2):217–
234. doi:10.1080/15287390903340849
Andersen ME, Gearhart JM, Clewell HJ, 3rd. (1999). Pharmacokinetic data needs to
support risk assessments for inhaled and ingested manganese. NeuroToxicology
20:161-171.
Apostoli P, Lucchini R, Alessio L (2000). Are current biomarkers suitable for the
assessment of manganese exposure in individual workers? Am J Ind Med 37:283290.
Arora M, Bradman A, Austin C, Vedar M, Holland N, Eskenazi B, Smith DR (2012).
Determining fetal manganese exposure from mantle dentine of deciduous teeth.
Environ Sci Technol. 46(9):5118–25.

153
Aschner JL, Aschner M (2005). Nutritional aspects of manganese homeostasis. Mol
Aspects Med. 26:353-362.
Aschner, M., Erikson, K. M., Herrero Hernández, E., Hernández, E. H., & Tjalkens, R.
(2009). Manganese and its role in Parkinson’s disease: from transport to
neuropathology. Neuromolecular medicine, 11(4), 252–266. doi:10.1007/s12017009-8083-0
Aschner M, Gannon M (1994). Manganese (Mn) transport across the rat blood-brain
barrier: saturable and transferrin-dependent transport mechanisms. Brain Research
Bulletin 33(3):345-349.
Aschner M, Guilarte TR, Schneider JS, Zheng W (2007). Manganese: recent advances in
understanding its transport and neurotoxicity. Toxicology and Applied
Pharmacology 221:131-147.
Aschner M, Vrana KE, Zheng W (1999). Manganese uptake and distribution in the
central nervous system (CNS). Neurotoxicology 20:173–180.
Aslam, Pejovic-Milic A, Chettle DR, McNeill FE (2008). Quantification of manganese
in human hand bones: a feasibility study. Phys. Med. Biol. 53 4081–4092.
ATSDR (2012). Toxicological Profile for Manganese. Atlanta, GA: U.S. Department of
Health and Human Services, Public Health Service
Au C, Benedetto A, Aschner M (2008). Manganese transport in eukaryotes: the role of
DMT1. Neurotoxicology 29:569-576.

154
Baker MG, Simpson CD, Sheppard L, Stover B, Morton J, Cocker J, Seixas N (2015).
Variance components of short-term biomarkers of manganese exposure in an
inception cohort of welding trainees. Journal of Trace Elements in Medicine and
Biology 29:123-129.
Bancroft GN, Sikavitsas VI, van den Dolder J, Sheffield TL, Ambrose CG, Jansen JA,
Mikos AG (2002). Fluid flow increases mineralized matrix deposition in 3D
perfusion culture of marrow stromal osteoblasts in a dose-dependent manner.
PNAS 99(20):12600-12605.
Barbeau A, Inoué N, Cloutier T (1976). Role of manganese in dystonia. Adv Neurol
14:339-352.
Barnham KJ, and Bush AI (2008). Metals in Alzheimer’s and Parkinson’s diseases. Curr.
Opin. Chem. Biol. 12(2):222-228.
Bellusci M, La Barbera A, Padella F, Mancuso M, Pasquo A, Grollino MG, Leter G,
Nardi E, Cremisini C, Giardullo P, Pacchierotti F (2014). Biodistribution and acute
toxicity of a nanofluid containing manganese iron oxide nanoparticles produced by
a mechanochemical process. Int J Nanomedicine 9:1919-1929.
Berendse HW, Roos DS, Raijmakers P, Doty RL (2011). Motor and non-motor correlates
of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 310(1-2):21-24. doi:
10.1016/j.jns.2011.06.020.
Blecharz-Klin, K., Piechal, A., Joniec-Maciejak, I., Pyrzanowska, J., & WidyTyszkiewicz, E. (2012). Effect of intranasal manganese administration on
neurotransmission and spatial learning in rats. Toxicology and applied
pharmacology, 265(1):1–9. doi:10.1016/j.taap.2012.09.015

155
Bocca B, Madeddu R, Asara Y, Tolu P, Marchal JA, Forte G (2011). Assessment of
reference ranges for blood Cu, Mn, Se and Zn in a selected Italian population. J
Trace Elem Med Biol. 25:19-26.
Bouchard MF, Laforest F, Vandelac L, Bellinger D, Mergler D (2007). Hair manganese
and hyperactive behaviors: pilot study of school-age children exposed through tap
water. Environmental Health Perspectives 115:122-127.
Bouchard MF, Sauve S, Barbeau B, Legrand M, Brodeur ME, Bouffard T, Limoges E,
Bellinger DC, Mergler D (2011). Intellectual impairment in school-age children
exposed to manganese from drinking water. Environmental Health Perspectives
119:138-143.
Bowler RM, Gocheva V, Harris M, Ngo L, Abdelouahab N, Wilkinson J, Doty RL, Park
R, Roels HA (2011). Prospective study on neurotoxic effects in manganese-exposed
bridge construction welders. NeuroToxicology 32(5):596-605.
Bowman AB, Kwakye GF, Hernández EH, Aschner M. (2011). Role of manganese in
neurodegenerative diseases. Journal of Trace Elements in Medicine and Biology
25(4):191–203. doi:10.1016/j.jtemb.2011.08.144
Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E (2003). Staging
of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging
24(2):197-211.
Bradford MA (1976). A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Analytical
Biochemistry 72:248-254.

156
Butcher DJ, Zybin A, Bolshov MA, Niemax K (1999). Speciation of
methylcyclopentadienyl manganese tricarbonyl by high-performance liquid
chromatography-diode laser atomic absorption spectrometry. Analytical
Chemistry 71:5379-5385.
Cahill DF, Bercegeay MS, Haggerty RC, Gerding JE, Gray LE (1980). Age-related
retention and distribution of ingested Mn3O4 in the rat. Toxicol Appl Pharmacol.
53:83-91.
Calabresi P, Ammassari-Teule M, Gubellini P, Sancesario G, Morello M, Centonze D,
Marfia GA, et al. (2001). A synaptic mechanism underlying the behavioral
abnormalities induced by manganese intoxication. Neurobiology of disease
8(3):419–32.
Cannon JR, Geghman KD, Tapias V, Sew T, Dail MK, Li C, Greenamyre JT (2013).
Expression of human E46K-mutated a-synuclein in BAC-transgenic rats replicates
early-stage Parkinson's disease features and enhances vulnerability to mitochondrial
impairment. Experimental Neurology 240:44-56.
doi:10.1016/j.expneurol.2012.11.007; PMID: 23153578
Chandra SV, Shukla GS (1981). Concentrations of striatal catecholamines in rats given
manganese chloride through drinking water. Journal of Neurochemistry 36(2):683–
687. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7463083
Chandra SV, Shukla GS, Murthy RC (1979). Effect of stress on the response of rat brain
to manganese. Toxicology and Applied Pharmacology 47(3):603–608.

157
Chandra SV, Shukla GS, Saxena DK (1979). Manganese-induced behavioral dysfunction
and its neurochemical mechanism in growing mice. Journal of Neurochemistry
33(6):1217–21.
Chandra SV, Shukla GS, Srivastawa RS, Singh H, Gupta VP (1981). An exploratory
study of manganese exposure to welders. Clin Toxicol 18:407-418.
Charash B, Placek E, Sos TA, Kligfield P (1982). Dose-related effects of manganese on
the canine electrocardiogram. J. Electrocardiol. 15:149-152.
Chen JY, Tsao G, Zhao Q, Zheng W (2001). Differential cytotoxicity of Mn(II) and
Mn(III): special reference to mitochondrial [Fe-S] containing enzymes. Toxicology
and Applied Pharmacology 175:160-168.
Chua AC, Morgan EH (1997). Manganese metabolism is impaired in the Belgrade
laboratory rat. J Comp Physiol B 167(5):361-369.
Chung SE, Cheong HK, Ha EH, Kim BN, Ha M, Kim Y, Hong YC, Park H, Oh SY
(2015). Maternal blood manganese and early neurodevelopment: the mothers and
children’s environmental health (MOCEH) study. Environmental Health
Perspectives 123(7):717-722.
Clark NA, Teschke K, Rideout K, Copes R (2007). Trace element levels in adults from
the west coast of Canada and associations with age, gender, diet, activities, and
levels of other trace elements. Chemosphere 70:155-164.
Collipp PJ, Chen SY, Maitinsky S (1983). Manganese in infant formulas and learning
disability. Ann Nutr Metab. 27:488-494.

158
Cooper, W. C. (1984) The Health Implications of Increased Manganese in the
Environment Resulting from the Combustion of Fuel Additives: A Review of the
Literature. Journal of Toxicology and Environmental Health 14(1):23-46.
Cotzias GC, Papavasiliou PS, Mena I, Tang LC, Miller ST (1974). Manganese and
Catecholamines. Advances in Neurology 5:235-243.
Couper J (1837). On the effects of black oxide of manganese when inhaled into the lungs.
Brit Ann Med Pharm, Vital Stat Gen Sci. 1:41-42.
Cowan DM, Fan Q, Zou Y, Shi X, Chen J, Aschner M, Rosenthal FS, Zheng W (2009a).
Manganese exposure among smelting workers: blood manganese-iron ratio as a
novel tool for manganese exposure assessment. Biomarkers 14:3-16.
Cowan DM, Zheng W, Zou Y, Shi X, Chen J, Rosenthal FS, Fan Q (2009b). Manganese
exposure among smelting workers: Relationship between blood manganese-iron
ratio and early onset neurobehavioral alterations. NeuroToxicology 30:1214-1222.
Crawford S, Davis K, Saddler C, Joseph J, Catapane EJ, Carroll MA (2011). The ability
of PAS, acetylsalicylic acid and calcium disodium EDTA to protect against the
toxic effects of manganese on mitochondrial respiration in gill of crassostrea
virginica. In Vivo 33:7-14.
Crossgrove JS, Zheng W (2004). Manganese toxicity upon overexposure. NMR
Biomedicine 17:544-553.
Crossgrove JS, Yokel RA (2005). Manganese distribution across the blood-brain barrier
IV. Evidence for brain influx through store-operated calcium channels.
NeuroToxicology 26:297-307.

159
Crossgrove JS, Allen DD, Bukaveckas BL, Rhineheimer SS, Yokel RA (2003).
Manganese distribution across the blood-brain barrier. I. Evidence for carriermediated influx of manganese citrate as well as manganese and manganese
transferrin. NeuroToxicology 24(1):3-13.
Curtis MA, Faull RLM, Eriksson PS (2007). The effect of neurodegenerative diseases on
the subventricular zone. Nat. Rev. Neuroscience 8(9):712-723.
DeSimone LA, Hamilton PA, Gilliom RJ (2009). The quality of our nation’s waters—
Quality of water from domestic wells in principal aquifiers of the United States,
1991-2004—Overview of major findings. U.S. Geological Survey Circular 1332.
p48.
DeWitt MR, Chen P, Aschner M (2013). Manganese efflux in Parkinsonism: insights
from newly characterized SLC30A10 mutations. Biochem Biophys Res Commun.
432(1):1-4.
Dobson AW, Erikson KM, Aschner M. (2004). Manganese neurotoxicity. Annals of the
New York Academy of Sciences 1012:115–128. doi:10.1196/annals.1306.009
Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A (1999).
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.
Cell 97:703-716.
Dorman DC, Brenneman KA, McElveen AM, Lynch SE, Roberts KC, Wong BA (2002).
Olfactory transport: a direct route of delivery of inhaled manganese phosphate to
the rat brain. Journal of Toxicology and Environmental Health, Part A 65:14931511.

160
Dorman DC, McManus BE, Parkinson CU, Manuel CA, McElveen AM, Everitt JI
(2004). Nasal toxicity of manganese sulfate and manganese phosphate in young
male rats following subchronic (13-week) inhalation exposure. Inhalation
Toxicology 16:481-488.
Dorman DC, McElveen AM, Marshall MW, Parkinson CU, Arden James R, Struve MF,
et al. (2005). Maternal-fetal distribution of manganese in the rat following
inhalation exposure to manganese sulfate. NeuroToxicology 26:625-632.
Dydak U, Jiang YM, Long LL, Zhu H, Chen J, Li WM, Edden RA, Hu S, Fu X, Long Z,
Mo XA, Meier D, Harezlak J, Aschner M, Murdoch JB, Zheng W (2011). In vivo
measurement of brain GABA concentrations by magnetic resonance spectroscopy
in smelters occupationally exposed to manganese. Environmental Health
Perspectives 2:219-224.
Eastman RR, Jursa TP, Benedetti C, Lucchini RG, Smith DR (2013). Hair as a biomarker
of environmental manganese exposure. Environ Sci Technol. 47(3):1629-37.
EPA. Mn (CASRN 7439-96-5) Integrated Risk Information System.
Ericson JE, Crinella FM, Clarke-Stewart KA, Allhusen VD, Chan T, Robertson RT
(2007). Prenatal manganese levels linked to childhood behavioral disinhibition.
Neurotoxicol Teratol. 29(2):181-187.
Fitsanakis VA, Zhang N, Anderson JG, Erikson KM, Avison MJ, Gore JC, Aschner M
(2008). Measuring brain manganese and iron accumulation in rats following 14
weeks of low-dose manganese treatment using atomic absorption spectroscopy and
magnetic resonance imaging. Toxicological Sciences 103(1):116–124.
doi:10.1093/toxsci/kfn019

161
Frisbie SH, Ortega R, Maynard DM, Sarkar B (2002). The concentrations of arsenic and
other toxic elements in Bangladesh’s drinking water. Environmental Health
Perspectives 110(11):1147-1153.
Frumkin H, Solomon G (1997). Manganese in the U.S. gasoline supply. American
Journal of Industrial Medicine 31:107-115.
Fu S, O’Neal S, Hong L, Jiang W, Zheng W (2015). Elevated adult neurogenesis in brain
subventricular zone following in vivo manganese exposure: roles of copper and
DMT1. Toxicological Sciences 143(2):482-498.
Fujioka M, Taoka T, Matsuo Y, Mishima K, Ogoshi K, Kondo Y, Tsuda M, Fujiwara M,
Asano T, Sakaki T, Miyasaki A, Park D, and Siesjö BK (2003). Magnetic
resonance imaging shows delayed ischemic striatal neurodegeneration. Ann
Neurol 54(6):732-47.
Fujishiro H, Yano Y, Takada Y, Tanihara M, Himeno S (2012). Roles of ZIP8, ZIP14,
and DMT1 in transport of cadmium and manganese in mouse kidney proximal
tubule cells. Metallomics 4(7):700-708.
Furchner JE, Richmond CR, Drake GA (1966). Comparative metabolism of radionuclides
in mammals. 3. Retention of manganese-54 in the mouse, rat, monkey and dog.
Health Phys 12:1415-1423.
Gao X, Chen J (2013). Moderate traumatic brain injury promotes neural precursor
proliferation without increasing neurogenesis in the adult hippocampus. Exp.
Neurol. 239:38-48.
Garzon-Muvdi T, Quinones-Hinojosa A (2010). Neural stem cell niches and homing:
recruitment and integration into functional tissues. ILAR 51(1):3-23.

162
Genter MB, Newman NC, Shertzer HG, Ali SF, Bolon B (2012). Distribution and
systemic effects of intranasally administered 25nm silver nanoparticles in adult
mice. Toxicologic Pathology 40:1004-1013.
Gianutsos G, Morrow GR, Morris JB (1997). Accumulation of manganese in rat brain
following intranasal administration. Fundamental and Applied Toxicology
37:102-105.
Gibaldi M, Perrier, D (1982). Pharmacokinetics. pp. 84–109, 433–444. Marcel Dekker,
New York.
Gibbons RA, Dixon SN, Hallis K, Russell AM, Sansom BF, Symonds HW (1976).
Manganese metabolism in cows and goats. Biochimica et Biophysica Acta (BBA)General Subjects 444(1):1-10.
Guilarte TR (2010). Manganese and Parkinson’s disease: a critical review and new
findings. Environmental Health Perspectives 118(8):1071–1080.
Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong, DF, Zhou, Y (2006).
Nigrostriatal Dopamine System Dysfunction and Subtle Motor Deficits in
Manganese-Exposed Non-Human Primates. Experimental Neurology 202:381-390.
Guilarte TR, Gonzales KK (2015). Manganese-Induced Parkinsonism Is Not Idiopathic
Parkinson’s Disease: Environmental and Genetic Evidence. Toxicological Sciences
146(2):204-212.
Grashow R, Zhang J, Fang SC, Weisskopf MG, Christiani DC, Cavallari JM (2014).
Toenail metal concentration as a biomarker of occupational welding fume exposure.
J Occup Environ Hyg. 11(6):397-405.

163
Grunecker B, Kltwasser SF, Zappe AC, Bedenk BT, Bicker Y, Spoormaker VI, Wotjak
CT, Czisch M (2013). Regional specificity of manganese accumulation and
clearance in the mouse brain: implications for manganese-enhanced MRI. NMR
Biomed. 26:542-556.
Gwiazda R, Lucchini R, Smith D (2007). Adequacy and consistency of animal studies to
evaluate the neurotoxicity of chronic low-level manganese exposure in humans. J
Toxicol Environ Health A. 70(7):594-605.
Hafeman D, Factor-Litvak P, Cheng Z, van Geen A, Ahsan H (2007). Association
between manganese exposure through drinking water and infant mortality in
Bangladesh. Environ Health Perspect. 115(7):1107-1112.
Harris WR, Chen Y (1994). Electron paramagnetic resonance and difference ultraviolet
studies of Mn2+ binding to serum transferrin. J Inorg Biochem. 54(1):1–19.
Hastings TG, Zigmond MJ (1994). Identification of catechol-protein conjugates in
neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and
glutathione. Journal of Neurochemistry 63:1126-1132. PMID:8051554
He L, Girijashanker K, Dalton TP, Reed J, Li H, Soleimani M, Nebert DW (2006). ZIP8,
member of the solute-carrier-39 (SLC39) metal-transporter family: characterization
of transporter properties. Molecular Pharmacology 70(1):171-180.
Hong L, Jiang W, Zheng W, Zeng S. HPLC analysis of para-aminosalicylic acid and its
metabolite in plasma, cerebrospinal fluid and brain tissues (2011). Journal of
Pharmaceutical and Biomedical Analysis 54:1101-1109.

164
Hong L, Xu C, O’Neal S, Bi HC, Huang M, Zheng W, Zeng S (2014). Roles of Pglycoprotein and multidrug resistance protein in transporting para-aminosalicylic
acid and its N-acetylated metabolite in mice brain. Acta Pharmacol Sin.
35(12):1577-1585.
Hong JS, Hung CR, Seth PK, Mason G, Bondy SC (1984). Effect of Manganese
Treatment on the Levels of Neurotransmitters, Hormones, and Neuropeptides:
Modulation by Stress. Environmental Research 34(2):242-249.
Huang CC, Chu NS, Lu CS, Wang JD, Tsai JL, Tseng JL, Wolters EC, Calne DB (1989).
Chronic manganese intoxication. Arch Neurol 46:1104-1106.
Husain M, Khanna VK, Roy A, Tandon R, Pradeep S, Set PK (2001). Platelet Dopamine
Receptors and Oxidative Stress Parameters as Markers of Manganese Toxicity.
Human & Experimental Toxicology 20(12):631-636.
ICRP. 1972. Report of the task group on reference man. Publication no.23, international
commission on radiological protection, New York.
Inoue N and Makita Y (1996). Neurological aspects in human exposures to manganese.
In: Toxicology of Metals. L. W. Chang, Ed. CRC Press, Boca Raton. pp415421.
Jiang YM, Mo XA, Du FQ, Fu X, Zhu XY, Gao HY, Xie JL, Liao FL, Pira E, and Zheng
W (2006). Effective Treatment of Manganese-Induced Occupational Parkinsonism
with PAS-Na: A Case of 17-Year Follow-Up Study. J. Occup. Env. Med. 48:644649.

165
Jiang YM, Zheng W, Long LL, Zhao WJ, Li XG, Mo XA, Lu JP, Fu X, Li WM, Liu SF,
Long QY, Huang JL, and Pira E (2007). Brain magnetic resonance imaging and
manganese concentrations in red blood cells of smelting workers: Search for
biomarkers of manganese exposure. NeuroToxicology 28:126-135.
Jiang Y, Zheng W (2005). Cardiovascular toxicities upon manganese exposure.
Cardiovascular Toxicology 5:345-354.
Kalia K, Jiang W, Zheng W (2008). Manganese accumulates primarily in nuclei of
cultured brain cells. NeuroToxicology 29:466-470.
Kanayama Y, Tsuji T, Enomoto S, Amano R (2005). Multitracer screening: brain
delivery of trace elements by eight different administration methods. Biometals
18:553-565.
Kannurpatti SS, Joshi PG, Joshi NB (2000). Calcium sequestering ability of mitochondria
modulates influx of calcium through glutamate receptor channel. Neurochem Res.
25(12):1527-1536.
Keen CL, Lönnerdal B (1995). Toxicity of essential and beneficial metal ions.
Manganese. In Handbook of Metal-Ligand Interactions in Biological Fluids,
Berthon G, ed. Marcel Dekker, Inc.: New York, NY. pp683-688.
Khan K, Wasserman GA, Liu X, Ahmed E, Parvez F, Slavkovich V, Levy D, Mey J, van
Geen A, Graziano JH, Factor-Litvak P (2012). Manganese exposure from drinking
water and children’s academic achievement. Neurotoxicology 33:91-97.

166
Khan K, Factor-Litvak P, Wasserman GA, Liu X, Ahmed E, Parvez F, Slavkovich V,
Levy D, Mey J, van Geen A, Graziano JH (2013). Manganese exposure from
drinking water and children’s classroom behavior in Bangladesh. Environmental
Health Perspectives 119:1501-1506.
Kikuchihara Y, Abe H, Tanaka T, Kato M, Wang L, Ikarashi Y, Yoshida T, Shibutani M
(2015). Relationship between brain accumulation of manganese and aberration of
hippocampal adult neurogenesis after oral exposure to manganese chloride in mice.
Toxicology 33(1):24-34.
Klaassen CD (1976). Biliary excretion of metals. Drug Metab Rev. 5(2):165-196.
Kobayashi K, Kuroda J, Shibata N, Hasegawa T, Seko Y, Satoh M, Tohyama C, Takano
H, Imura N, Sakabe K, Fujishiro H, Himeno S (2007). Induction of metallothionein
by manganese is completely dependent on interleukin-6 production. J Pharmacol
Exp Ther. 320(2):721-727.
Kondakis XG, Makris N, Leotsinidis M, Prinou M, Papapetropoulos T (1989). Possible
health effects of high manganese concentration in drinking water. Arch Environ
Health. 44(3):175-178.
Korczynski RE (2000). Occupational health concerns in the welding industry. Appl
Occup Environ Hyg. 5:936-945.
Krebs N, Langkammer C, Goessler W, Ropele S, Fazekas F, Yen K, Scheurer E (2014).
Assessment of trace elements in human brain using inductively coupled plasma
mass spectrometry. J Trace Elem Med Biol. 28(1):1-7.

167
Kunar MJ, Couceyro PR, Lambert PD (1999). Catecholamines. In G.J. Siegel, B.W.
Agranoff, R.W. Albers, S.K. Fisher, & M.D. Uhler (Eds.), Basic Neurochemistry
Molecular, Cellular, and Medical Aspects (pp. 243-261). Philadelphia, PA:
Lippincott-Raven.
Laohaudomchok W, Lin X, Herrick RF, Fang SC, Cavallari JM, Christiani DC,
Weisskopf MG (2011). Toenail, blood and urine as biomarkers of manganese
exposure. J Occup Environ Med. 53(5):506-510.
Leavens TL, Rao D, Anderson ME, Dorman DC (2007). Evaluating transport of
manganese from olfactory mucosa to striatum by pharmacokinetic modeling.
Toxicological Sciences 97:265-278.
Lebda MA, El-Neweshy MS, El-Sayed YS (2012). NeuroToxicology 33(1):98-104.
Lee JW, Lee CK, Moon CS, Choi IJ, Lee KJ, Yi SM, Jang BK, Yoon BJ, Kim DS, Peak
D, Sul D, Oh E, Im H, Kang HS, Kim JH, Lee JT, Kim K, Park KL, Ahn R, Park
SH, Kim SC, Park CH, Lee JH (2012). Korea National Survey for Environmental
Pollutants in the Human Body 2008: Heavy metals in the blood or urine of the
Korean population. Int J Hyg Environ Health. 215:449-457.
Leyva-Illades D, Chen P, Zogzas CE, Hutchens S, Mercado JM, Swaim CD, Morrisett
RA, Bowman AB, Aschner M, Mukhopadhyay S (2014). SLC30A10 is a cell
surface-localized manganese efflux transporter, and parkinsonism-causing
mutations block its intracellular trafficking and efflux activity. J Neurosci.
34(42):14079-95.

168
Liu Y, Koltic D, Byrne P, Wang H, Zheng W, Nie LH (2013). Development of a
transportable neutron activation analysis system to quantify manganese in bone in
vivo: feasibility and methodology. Physiol. Meas. 34:1593-1609.
Liu YZ, Byrne P, Wang HY, Koltick D, Zheng W, Nie L (2014). A compact DD neutron
generator-based NAA system to quantify manganese (Mn) in bone in vivo. Physiol
Meas. 35:1899-1911.
Long Z, Li XR, Xu J, Edden RA, Qin WP, Long LL, Murdoch JB, Zheng W, Jiang YM,
Dydak U (2014). Thalamic GABA predicts fine motor performance in manganeseexposed smelter workers. PLoS ONE 9(2):e88220.
Long LL, Li XR, Huang ZK, Jian YM, Fu SX, Zheng W (2009). Relationship between
changes in brain MRI and 1H-MRS, severity of chronic liver damage, and recovery
after liver transplantation. Exp Biol Med. 234:1075-1085.
Lu L, Zhang LL, Li GJ, Guo W, Liang W, Zheng W (2005). Serum concentrations of
manganese and iron as the potential biomarkers for manganese exposure in welders.
NeuroToxicology 26(2): 257-265.
Lucaciu CM, Dragu C, Copaescu L, Morariu VV (1997). Manganese transport through
human erythrocyte membranes. An EPR study. Biochim Biophys Acta 1328(2):90–
8.
Lucchini RG, Albini E, Benedetti L, Borghesi S, Coccaglio R, Malara EC, et al. (2007).
High prevalence of parkinsonian disorders associated to manganese exposure in
the vicinities of ferroalloy industries. Am J Ind Med 50:788-800.

169
Lucchini R, Zimmerman N (2009). Lifetime cumulative exposure as a threat for
neurodegeneration: need for prevention strategies on a global scale.
NeuroToxicology 30:1144-1148.
Lucchini RG, Dorman DC, Elder A, Veronesi B (2012). Neurological impacts from
inhalation of pollutants and the nose-brain connection. NeuroToxicology 33:838841.
Lucchini RG, Guazzetti S, Zoni S, Donna F, Peter S, Zacco A, Salmistraro M, Bontempi
E, Zimmerman NJ, Smith DR (2012). Tremor, olfactory and motor changes in
Italian adolescents exposed to historical ferromanganese emission.
NeuroToxicology 33:687-696.
Lytle CM, Smith BN, McKinnon CZ (1995). Manganese accumulation along Utah
roadways: a possible indication of motor vehicle exhaust pollution. The Science of
the Total Environment 162:105-109.
Madejczyk MS, Ballatori N (2012). The iron transporter ferroportin can also function as a
manganese exporter. Biochim Biophys Acta 1818(3):651-657.
Marchal G, Ni Y, Zhang X, Yu J, Lodemann KP, Baert AL (1993). Mn-DPDP enhanced
MRI in experimental bile duct obstruction. J Comput Assist Tomogr. 17:290-296.
Mates JM, Segura JA, Alonso FJ, Marquez J (2010). Roles of dioxins and heavy metals
in cancer and neurological diseases using ROS-mediated mechanisms. Free Radical Biol.
Med. 49(9):1328-1341.
McMillian, D.E. (1999). A Brief History of the Neurobehavioral Toxicity of Manganese:
Some Unanswered Questions. NeuroToxicology 20(2-3):499-508.

170
Mena I, Horiuchi K, Burke K, Cotzias GC (1969). Chronic manganese poisoning.
Individual susceptibility and absorption of iron. Neurology 19:1000-1006.
Menezes-Filho JA, Paes CR, Pontes AM, Moreira JC, Sarcinelli PN, Mergler D (2009).
High levels of hair manganese in children living in the vicinity of a ferromanganese alloy production plant. Neurotoxicology 30(6):1207-13.
Mergler D, Baldwin M, Belanger S, Larribe F, Beuter A, Bowler R, Panisset M, Edwards
R, De Geoffroy A, Sassine M-P, Hudnell K (1999). Manganese Neurotoxicity, a
Continuum of Dysfunction: Results from a Community Based Study.
NeuroToxicology 20(2-3):327-342.
Michalke B, Fernsebner K (2014). New insights into manganese toxicity and speciation.
Journal of Trace Elements in Medicine and Biology 28:106-116.
Morello M, Canini A, Mattioli P, Sorge RP, Alimonti A, Bocca B, Forte G, Martorana A,
Bernardi G, Sancesario G (2008). Sub-cellular localization of manganese in the
basal ganglia of normal and manganese-treated rats an electron spectroscopy
imaging and electron energy-loss spectroscopy study. NeuroToxicology 29:60-72.
Mutti A, Bergamaschi E, Alinovi R, Lucchini R, Vettori MV, Franchini I (1996). Serum
prolactin in subjects occupationally exposed to manganese. Ann Clin Lab Sci.
26(1):10-7.
Nachtman JP, Tubben RE, Commissaris RL (1986). Behavioral Effects of Chronic
Manganese Administration in Rats: Locomotor Activity Studies. Neurobehavioral
Toxicology and Teratology 8(6):711-715.
Nadaska G, Lesny J, Michalik I (2012) Environmental Aspect of Manganese Chemistry.
1-16. http://heja.szif.hu/ENV/ENV_100702-A/env100702a.pdf

171
Newland MC, Cox C, Hamada R, Oberdorster G, Weiss B (1987). The clearance of
manganese chloride in the primate. Fundam Appl Toxicol 9:314-328.
Newland C (1999). Animal models of manganese’s neurotoxicity. NeuroToxicology
20(2-3):415-432.
Omokhodion FO, Howard JM (1994). Trace elements in the sweat of acclimatized
persons. Clin Chim Acta. 231(1):23-28.
O’Neal SL, Hong L, Fu S, Jiang W, Jones A, Nie LH, Zheng W (2014a). Manganese
accumulation in bone following chronic exposure in rats: steady-state concentration
and half-life in bone. Toxicology Letters 229(1):90-100.
O’Neal SL, Lee J-W, Zheng W, Cannon JR (2014b). Subacute manganese exposure in
rats is a neurochemical model of early manganese toxicity. NeuroToxicology
44:303-313.
Ono K, Komai K, Yamada M (2002). Myoclonic involuntary movement associated with
chronic manganese poisoning. J Neurol Sci. 199(1-2):93-96.
Ordoñez-Librado JL, Gutierrez-Valdez AL, Colín-Barenque L, Anaya-Martínez V, DíazBech P, Avila-Costa MR (2008). Inhalation of divalent and trivalent manganese
mixture induces a Parkinson’s disease model: immunocytochemical and behavioral
evidences. Neuroscience 155(1):7–16. doi:10.1016/j.neuroscience.2008.05.012
OSHA (2013). Manganese Fume (as Mn). Chemical Sampling Information. United States
Department of Labor, April 2013. Retrieved
from https://www.osha.gov/dts/chemicalsampling/data/CH_250200.html

172
Oszlanczi G, Vezer T, Sarkozi L, Horvath E, Szabo A, Horovath E, Konya Z, Papp A
(2010). Metal deposition and functional neurotoxicity in rats after 3-6 week nasal
exposure by two physicochemical forms of Mn. Enviornmental Toxicology and
Pharmacology 30:121-126.
Ou CY, Huang ML, Jiang YM, Luo HL, Deng XF, Wang C, Wang F, Huang XW (2011).
Effect of Sodium-Paraminosalicylic Acid on Concentrations of Amino Acid
Neurotransmitters in Basal Ganglia of Manganese-Exposed Rats. Zhonghua Yu
Fang Yi Xue Za Zhi 45(5):422-425.
Oulhote Y, Mergler D, Bouchard MF (2014). Sex- and age-differences in blood
manganese levels in the U.S. general population: national health and nutritional
examination survey 2011-2012. Environ health. 13:87. doi: 10.1186/1476-069X-1387.
Pejovic-Milic A, Aslam, Chettle DR, Oudyk J, Pysklywec MW, Haines T (2009). Bone
manganese as a biomarker of manganese exposure: a feasibility study. Am J. Ind.
Med. 52:742-750.
Post JE (1999). Manganese oxide minerals: crystal structures and economic and
environmental significance. Proc Natl Acad Sci USA 96:3447-3454.
Pushkar Y, Robison GA, Sullivan G, Fu SX, Kohne M, Jiang W, Rohr S, Lai B, Marcus
MA, Zakharova T, Zheng W (2013). Aging results in copper accumulations in
subventricular astrocytes. Aging Cell 12:823-832.
Racette BA, Aschner M, Guilarte TR, Dydak U, Criswell SR, Zheng W (2012a).
Pathophysiology of manganese-associated neurotoxicity. NeuroToxicology 33:881886.

173
Racette BA, Criswell SR, Lundin JI, Hobson A, Seixas N, Kotzbauer PT, Evanoff BA,
Perlmutter JS, Zhang J, Sheppard L, Checkoway H (2012). Increased risk of
parkinsonism associated with welding exposure. NeuroToxicology 33(5):13561361.
Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS
(2001). Welding-related Parkinsonism, clinical features, treatment, and
pathophysiology. Neurology 56:8–13.
Racette BA, Tabbal SD, Jennings D, Good L, Perlmutter JS, Evanoff B (2005).
Prevalence of Parkinsonism and relationship to exposure in a large sample of
Alabama welders. Neurology 64:230–235.
Rahil-Khazen R, Bolann BJ, Myking A, Ulvik RJ (2002). Multi-element analysis of trace
element levels in human autopsy tissues by using inductively coupled atomic
emission spectrometry technique (ICP-AES). J. Trace Elem. Med. Biol. 16(1):1525.
Reaney SH, Kwik-Uribe CL, Smith DR (2002). Manganese oxidation state and its
implications for toxicity. Chem. Res. Toxicol. 15(9):1119–1126.
Riojas-Rodriguez H, Solis-Vivanco R, Schilmann A, Montes S, Rodriguez S, Rios C,
Rodriguez-Agudelo Y (2010) Intellectual function in Mexican children living in a
mining area and environmentally exposed to manganese. Environ Health Perspect.
118(10):1465-70.
Robison G, Zakharova T, Fu S, Jiang W, Fulper R, Barrea R, Marcus MA, Zheng W,
Pushkar Y (2012). X-Ray fluorescence imaging: a new tool for studying manganese
neurotoxicity. PloS ONE 7(11):e48899. doi: 10.1371/journal.pone.0048899.

174
Robison G, Zakharova T, Fu S, Jiang W, Fulper R, Barrea R, Zheng W, Pushkar Y
(2013). X-ray fluorescence imaging of the hippocampal formation after manganese
exposure. Metallomics 5:1554-1565.
Rodier J (1955). Manganese poisoning in Moroccan miners. British Journal of Industrial
Medicine 12:21–35.
Roth JA (2009). Are there common biochemical and molecular mechanisms controlling
manganism and parkisonism. Neuromolecular medicine 11(4):281–296.
doi:10.1007/s12017-009-8088-8
Rutchik JS, Zheng W, Jiang YM, Mo XE (2012a). How Does an Occupational
Neurologist Assess Welders and Steelworkers for a Manganese-Induced Movement
Disorder? An International Team’s Experiences in Guangxi, China, Part I. J Occ
Env Med. 54(11):1432-1434.
Rutchik JS, Zheng W, Jiang YM, Mo XE (2012b). How Does an Occupational
Neurologist Assess Welders and Steelworkers for a Manganese-Induced Movement
Disorder? An International Team’s Experiences in Guangxi, China, Part II. J Occ
Env Med. 54(12):1562-1564.
Sarkar S, Schmued L (2011). The Fluoro-Jade Dyes: Novel, Sensitive, and Reliable
Fluorochromes for the Histochemical Localization of Degenerating Neurons. In B.
Bolon & M. T. Butt (Eds.), Fundamental Neuropathology for Pathologists and
Toxicologists Principles and Techniques (pp. 171–179). Hoboken, NJ: Wiley &
Sons, Inc.

175
Schmitt C, Strazielle N, Richaud P, Bouron A, Ghersi-Egea JF (2011). Active transport at
the blood-CSF barrier contributes to manganese influx in the brain. J Neurochem
117:747-756.
Schneider JS, Decamp E, Clark K, Bouquio C, Syversen T, Guilarte TR (2009). Effects
of chronic manganese exposure on working memory in non-human primates. Brain
research 1258:86–95. doi:10.1016/j.brainres.2008.12.035
Schroeder HA, Balassa JJ, Tipton IH (1966). Essential trace metals in man: manganese.
A study in homeostasis. J. Chronic Disease 19:545-571.
Schwarting RK, Huston JP (1996). Unilateral 6-hydroxydopamine lesions of mesostriatal dopamine neurons and their physiological sequelae. Progress in
Neurobiology 49(3):215-266. PMID:8878304
Seaborn CD, Nielsen FH (2002). Dietary silicon and arginine affect mineral element
composition of rat femur and vertebra. Biol Trace Elem Res 89:239-250.
Sengupta P (2011). A scientific review of age determination for a laboratory rat: how old
is it in comparison with human age? Biomed Int. 2:81-89.
Serrat MA, Reno PL, McCollum MA, Meindl RS, Lovejoy CO (2007). Variation in
mammalian proximal femoral development: Comparative analysis of two distinct
ossification patterns. J. Anat. 210:249-258.
Sheng Y, Butler GE, Schumacher M, Cascio D, Cabelli DE, Valentine JS (2012). Sixcoordinate manganese (3+) in catalysis by yeast manganese superoxide dismutase.
Proc Natl Acad Sci USA 109(36):14314-9.

176
Sierra P, Loranger S, Kennedy G, Zayed J (1995). Occupational and environmental
exposure of automobile mechanics and nonautomotive workers to airborne
manganese arising from the combustion of methylcyclopentadienyl manganese
tricarbonyl (MMT). Am Ind Hyg Assoc J. 56:713-716.
Sikk K, Haldre S, Aquilonius S-M, Taba P (2011). Manganese-induced Parkinsonism due
to ephedrone abuse. Parkinson’s Disease 20(6):915-920.
Smith D, Gwiazda R, Bowler R, Roels H, Park R, Taicher C, Lucchini R (2007).
Biomarkers of Mn exposure in humans. Am J Ind Med. 50:801-811.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD,
Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985). Measurement of protein
using bicinchoninic acid. Analytical Biochemistry 150:76-85.
Spangler AH, Spangler JG (2009). Groundwater manganese and infant mortality rate by
county in North Carolina: an ecological analysis. Ecohealth 6:596-600.
Squitti R, Gorgone G, Panetta V, Lucchini R, Bucossi S, Albini E, Alessio L, Alberici A,
Melgari JM, Benussi L, Binetti G, Rossini PM, Draicchio F (2009). Implications of
metal exposure and liver function in Parkinsonian patients resident in the vicinities
of ferroalloy plants. J Neural Transm. 116:1281-1287.
Sriram K, Lin GX, Jefferson AM, Roberts JR, Andrews RN, Kashon ML, Antonini JM
(2012). Manganese accumulation in nail clippings as a biomarker of welding fume
exposure and neurotoxicity. Toxicology 291(1–3):73–82.
Stastny D, Vogel RS, Picciano MF (1984). Manganese intake and serum manganese
intake of human milk-fed and formula-fed infants. Am J Clin Nutr. 39:872-878.

177
Subramanian KS, Meranger JC (1985). Graphite furnace atomic absorption spectrometry
with nitric acid deproteinization for determination of manganese in human plasma.
Science of the Total Environment 57(13):2478-81.
Tapias V, Cannon JR, Greenamyre JT (2014). Pomegranate juic exacerbates oxidative
stress and nigrostriatal degeneration in Parkinson's disease. Neurobiology of Aging
35(5):1162-1176. PMID:24315037
Thompson K, Molina RM, Donaghey T, Schwob JE, Brain JD, Wessling-Resnick M
(2007). Olfactory uptake of manganese requires DMT1 and is enhanced by anemia.
The FASEB Journal 21:223-230.
Tjälve H, Henriksson J, Tallkvist J, Larsson BS, Lindquist NG (1996). Uptake of
manganese and cadmium from the nasal mucosa into the CNS via olfactory
pathways in rats. Pharmacology and Toxicology 79:347-356.
Tøndevold E, Eliasen P (1982). Blood flow rates in canine cortical and cancellous bone
measured with 99Tcm-labeled human albumin microspheres. Acta Orthop. Scand.
53:7-11.
Tran TT, Chowanadisai W, Crinella FM, Chicz-DeMet A, Lönnerdal B (2002). Effect of
high dietary manganese intake of neonatal rats on tissue mineral accumulation,
striatal dopamine levels, and neurodevelopmental status. NeuroToxicology 23:635643.
Tuschl K, Mills PB, Clayton PT (2013). Manganese and the brain. International Review
of Neurobiology 110:277-312.
Vander EL, Colet JM, Muller RN (1997). Spectroscopic and metabolic effects of MnCl2
and MnDPDP on the isolated and perfused rat heart. Invest Radiol. 32:581-588.

178
Vezér T, Kurunczi A, Naray M, Papp A, Nagymajtenyi L. (2007). Behavioral Effects of
Subchronic Inorganic Manganese Exposure in Rats. American Journal of Industrial
Medicine 50:841–852. doi:10.1002/ajim.20485
Viana GF, de Carvalho CF, Nunes LS, Rodrigues JL, Ribeiro NS, de Almeida DA,
Ferreira JR, Abreu N, Menezes-Filho JA (2014). Noninvasive biomarkers of
manganese exposure and neuropsychological effects in environmentally exposed
adults in Brazil. Toxicol Letters 231(2):169-178.
Vigeh M, Yokoyama K, Ramezanzadeh F, Dahaghin M, Sakai T, Morita Y, Kitamura F,
Sato H, Kobayashi Y (2006). Lead and other trace metals in preeclampsia: a casecontrol study in Tehran, Iran. Environ Res. 100:268-275.
Vorhees CV, Graham DL, Amo-Kroohs RM, Braun AA, Grace CE, Schaefer TL, Skelton
MR, Erikson KM, Aschner M, Williams MT (2015). Effects of developmental
manganese, stress, and the combination of both on monoamines, growth, and
corticosterone. Toxicol Rep. 1:1046-1061.
Wang DX, Du XQ, Zheng W (2008). Alteration of saliva and serum concentrations of
manganese, copper, zinc, cadmium and lead among career welders. Toxicol Letters
176:40-47.
Wang X, Li GJ, Zheng W (2006). Upregulation of DMT1 expression in choroidal
epithelia of the blood-CSF barrier following manganese exposure in vitro. Brain
Research 30:1-10.
Wang DX, Zhou WM, Wang SZ, Zheng W (1998). Occupational exposure to manganese
in welders and associated neurodegenerative diseases in China. Toxicol Sci.
42(suppl):24.

179
Wang JD, Huang CC, Hwang YH, Chiang JR, Lin JM, Chen JS (1989). Manganese
induced parkinsonism: an outbreak due to an un-repaired ventilation control system
in a ferromanganese smelter. Br J Ind Med. 46:856-859.
Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM
(2013). Enhanced Synthesis and Release of Dopamine in Transgenic Mice with
Gain-of-Function α6* nAChRs. Journal of Neurochemistry 129(2):315-327.
doi:10.1111/jnc.12616
Wang L, Ohishi T, Shiraki A, Morita R, Akane H, Ikarashi Y, Mitsumori K, Shibutani M
(2012). Developmental exposure to manganese chloride induces sustained
aberration of neurogenesis in the hippocampal dentate gyrus of mice. Toxicol. Sci.
127(2):508–521.
Yazbeck C, Moreau T, Sahuquillo J, Takser L, Huel G (2006). Effect of maternal
manganese blood levels on erythrocyte calcium-pump activity in newborns. Sci
Total Environ 354:28-34.
Yokel RA (2009). Manganese flux across the blood brain barrier. NeuroMolecular
Medicine 11:297-310.
Yoon H, Kim DS, Lee GH, Kim JY, Kim DH, Kim KW, Chae SW, You WH, Lee YC,
Park SJ, Kim HY and Chae HJ (2009). Protective effects of sodium para-amino
salicylate on manganese-induced neuronal death: the involvement of reactive
oxygen species. J Pharm Pharmacol 61:1563-1569.

180
Zaichick S, Zaichick V, Karandashev VK, Moskvina IR( 2011). The effect of age and
gender on 59 trace-element contents in human rib bone investigated by
inductively coupled plasma mass spectrometry. Biological Trace Element
Research 143:41-57.
Zaverucha-do-Valle C, Gubert F, Mesentier-Louro L, Scemes E, Pitossi F, Santiago MF,
Mendez-Otero R. (2013). Resident Neural Stem Cells. In R. Coeli dos Santos
Goldenberg and A.C. Campos de Carvalho (Eds.), Resident Stem Cells and
Regnerative Therapy. (pp. 69-88). Oxford, United Kingdom: Academic Press.
Zhang LL, Lu L, Pan YJ, Ding CG, Xu DY, Huang CF, Pan XF, Zheng W (2015).
Baseline blood levels of manganese, lead, cadmium, copper, and zinc in residents of
Beijing suburb. Environ Res. 140:10-17.
Zheng, W (2001). Neurotoxicology of the brain barrier system: New implications. J
Toxicol-Clin Toxicol. 39(7):711-719.
Zheng W (2005). Blood-CSF barrier in iron regulation and manganese-induced
Parkinsonism. In: The Blood-Cerebrospinal Barrier, Zheng W and Chodobski A,
Ed., CRC Press, New York. pp.413-436.
Zheng W, Ren S, Graziano JH (1998). Manganese inhibits mitochondrial aconitase: A
mechanism of manganese neurotoxicity. Brain Res. 799:334-342.
Zheng W, Fu SX, Dydak U, Cowan DM (2011). Biomarkers of manganese intoxication.
NeuroToxicology 32(1):1-8.
Zheng W, Jiang YM, Zhang YS, Jiang W, Wang X, Cowan DM (2009). Chelation
therapy of manganese intoxication by para-aminosalicylic acid (PAS) in SpragueDawley rats. NeuroToxicology 30:240-248.

181
Zheng W, Kim H, Zhao Q (2000). Comparative toxicokinetics of manganese chloride
and methylcyclopentadienyl manganese tricarbonyl in male Sprague-Dawley rats.
Toxicol Sci. 54:295-301.
Zheng W, Jiang YM, Zhang YS, Jiang W, Wang X, Cowan DM (2009). Chelation
therapy of manganese intoxication by para-aminosalicylic acid (PAS) in SpragueDawley rats. NeuroToxicology 30:240-248.
Zheng W, Aschner M and Ghersi-Egea JF (2003). Brain barrier systems: a new frontier in
metal neurotoxicological research. Invited Review, Toxicol. Appl. Pharmacol.
192:1-11.
Zheng W and Monnot AD (2012).Regulation of brain iron and copper homeostasis by
brain barrier systems: Implication in neurodegenerative diseases. Pharmacol
Ther. 133:177-188.
Zheng W, Zhao Q, Slavkovich V, Aschner M, Graziano JH (1999). Alteration of Iron
Homeostasis Following Chronic Exposure to Manganese in Rats. Brain Research
833:125-132.
Zhu J, Gale EM, Atanasova I, Rietz TA, Caravan P (2014). Hexameric Mn(II) dendrimer
as MRI contrast agent. Chemistry 20:14507-14513.
Zoni S, Bonetti G, Lucchini R (2012). Olfactory functions at the intersection between
environmental exposure to manganese and Parkinsonism. J Trace Elem Med Bio.
26:179-182.

VITA

182

VITA

Stefanie O’Neal
EDUCATION & TRAINING
Graduate:
2011-

Undergraduate:
2002-06

Purdue University, West Lafayette, IN
PhD Candidate

Discipline & Advisor
Toxicology
Wei Zheng, PhD

Indiana University, Bloomington, IN
B.S., Psychology
B.A., Biology

PROFESSIONAL AFFILIATIONS
Academy of Surgical Research, member
American Association for Laboratory Animal Science, ALAT certified
Animal Behavior Management Alliance, junior member
Society of Toxicology, Student Member
RESEARCH EXPERIENCE
School of Health Sciences, Purdue University Toxicology PhD Program
Graduate Research Assistant to Dr. Wei Zheng
May 2012—present
Biomedical Engineering department, Purdue University
Graduate Research Assistant to Dr. Kevin Otto, rotation experience

Mar-May 2012

Biology department, Purdue University
Oct-Jan 2011
Graduate Research Assistant to Dr. Ignacio Camarillo, rotation experience
Medicinal Chemistry and Molecular Pharmacology department, Purdue University
Graduate Research Assistant to Dr. Eric Barker, rotation experience
Aug-Oct 2011
Harlan Laboratories, Inc.
Sr. level surgical technician, group leader
Research technician, study coordinator

2009-2011
2006-2009

183
Biology department, Indiana University
Undergraduate Research Assistant to Gregory Demas

Aug 2005- May 2006

Psychology department, Indiana University & Indianapolis Zoo
Aug 2004- May 2006
Undergraduate Research Assistant to Dr. William Timberlake & Dr. Eduardo Fernande
HONORS & AWARDS
Wayne V. Kessler Graduate Student Award
PULSe Outstanding Graduate Researcher
Society of Toxicology Graduate Student Travel Award
Compton Graduate Travel Award
PULSe Travel Award
Teaching Academy 2013-2014 Graduate Teaching Award
Purdue Engagement Grant to fund Next Generation Scholars
PULSe Travel Award
Committee for Education of Teaching Assistants (CETA) Teaching Award
PULSe & Women in Science Program Travel Award
Certificate of Appreciation for participation in Science in Schools

1.

2.
3.
4.
5.

Spring 2015
Spring 2015
Fall 2014
Fall 2014
Fall 2014
Spring 2014
Spring 2014
Fall 2013
Spring 2013
Fall 2012
2011-2012

SEMINARS
Intranasal Manganese Exposure Activates Adult Neurogenesis in the
Subventricular Zone. Ohio Valley Society of Toxicology, Cincinnati, OH. June
2015.
Environmental Causes of Neurodegenerative Parkinsonian Disorder: Manganese
Exposure and Mode of Action. PULSe Student Seminar, West Lafayette, IN.
April 2015.
Half-Life of Manganese (Mn) in Murine Bone Following Oral Exposure, HSCI
69600 seminar, West Lafayette, IN, March, 2014.
Establishment of a Rodent Model of Manganese-Induced Parkinsonian Disorder,
PULSe Student Seminar, West Lafayette, IN, September, 2013.
Polar bear stereotypic and general activity under fixed and variable time
schedules, 19th Annual Tri-State Conference on Learning and Behavior,
Indianapolis, IN, 2006.
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2. Fu S, O’Neal SL, Hong L, Jiang W, Zheng W (2015). Elevated Adult
Neurogenesis in Brain Subventricular Zone Following In Vivo Manganese
Exposure: Roles of Copper and DMT1. Toxicological Sciences 143(2):482-498.
3. Hong L, Xu C, O’Neal SL, Bi HC, Huang M, Zheng W, Zeng S (2014). Roles of
P-glycoprotein and multidrug resistance protein in transporting paraaminosalicylic acid and its N-acetylated metabolite in mice brain. Acta
Pharmacologica Sinica 35(12): 1577-85.
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4. O’Neal SL, Lee JW, Zheng W, Cannon JR (2014). Subchronic manganese
exposure in rats is a neurochemical model of early manganese toxicity.
NeuroToxicology 44:303-313.
5. O’Neal SL, Hong L, Fu S, Jiang W, Jones A, Nie LH, Zheng W(2014).
Manganese accumulation in bone following chronic exposure in rats: Steady-state
concentration and half-life in bone. Toxicology Letters 229:93-100.
6. Mason, A. O., Grieves, T. J., Scotti, M.-A. L., Levine, J., Frommeyer, S.,
Ketterson, E. D., Demas, G. E., Kriegsfeld, L. J., (2007). Suppression of
kisspeptin expression and gonadotropic axis sensitivity following exposure to
inhibitory day lengths in female Siberian hamsters. Hormones and Behavior, 492498.
ABSTRACTS & CONFERENCE PROCEEDINGS
1. Zheng W, Fu X, O’Neal SL (2015). Manganese-Copper Interaction: Effects on
Adult Neurogenesis and Stem Cell Migration. Toxicologist 144(1):2369. 54th
Annual Society of Toxicology conference, San Diego, CA March 22-26, 2015.
2. Jones A, O’Neal SL, Zheng W (2015) Intranasal Mn exposure Leads to a
Significant Accumulation of Mn in Bone. Toxicologist 144(1):330. 54th Annual
Society of Toxicology conference, San Diego, CA March 22-26, 2015.
3. O’Neal, SL, Fu S, Zheng W. (2015) Activated Adult Neurogenesis in the
Subventricular Zone Following Intranasal Manganese Exposure in Rats.
Toxicologist 144(1):962. 54th Annual Society of Toxicology conference, San
Diego, CA March 22-26, 2015.
4. O’Neal, S.L., Zheng, W. (2014) Absorbance and Distribution Characteristics of
Manganese: A Comparison of Three Dose Routes. Ohio Valley Society of
Toxicology Meeting 2014 [Health and Human Sciences Fall Research Day,
October 29, 2014]
5. O’Neal, S.L., Lee, J., Cannon, J.R., Zheng, W. (2014) Altered Neurotransmitter
Levels in Rats Exposed to Manganese: Relevance to Dopaminergic Dysfunction
and Neurodegeneration. Toxicologist 138(1):1361. 53rd National Society of
Toxicology conference, Phoenix, AZ March 22-27, 2014 [Health and Disease:
Science, Culture, and Policy Research Poster Session March 31, 2014 West
Lafayette, IN]
6. Zheng W, O’Neal SL, Hong L, and Jones AJ (2014). Half-life of manganese (Mn)
in murine bone following oral exposure. Toxicologist 138(1):1362. 53rd Annual
Society of Toxicology conference, Phoenix, AZ March 22-27, 2014
7. O’Neal, S.L., Cannon, J.R., Zheng, W. (Sep/Oct 2013) Altered Neurotransmitter
Levels in Rats Subchronically Exposed to Manganese: Relevance to
Dopaminergic Dysfunction and Neurodegeneration. Poster presented at Ohio
Valley Society of Toxicology Regional Meeting in Louisville, KY on September
23, 2013. [Indianapolis Society for Neuroscience October 18, 2013]
8. Zheng W, Hong L, O’Neal S, and Jiang W (2013). Bone as the storage site of
manganese (Mn) exposure: Relationship to Mn levels in brain. J Trace Elem Med
Biol 27S1: 24. 10th International Society of Trace Elements Research in Humans
conference, Tokyo, Nov 18-22, 2013
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9. Hong L, O’Neal SL, Nie L, Zheng W (2013). Bone manganese (Mn)
concentrations in Sprague-Dawley rats following subchronic manganese
10. exposure. Toxicologist 132(1):1864. 52nd National Society of Toxicology
conference, San Antonio, TX March 10-14, 2013.
11. O’Neal, S.L., Hong L, Zheng W. (Feb/April 2013) Accumulation of Manganese
(Mn) in Rat Brain Ventricular Region Following In Vivo Subchronic Mn
Exposure: Effect on Copper (Cu) Status. Toxicologist 132(1): 1520. 52nd National
Society of Toxicology conference, San Antonio, TX March 10-14, 2013. [WISP,
February 20, 2013] [Purdue Interdisciplinary Graduate Program Spring Reception
April 1, 2013].
12. Hong L, O’Neal S, Nie L, and Zheng W (2013). Bone manganese (Mn)
concentrations in Sprague–Dawley rats following subchronic manganese
exposure. Toxicologist 132(1):1864.
13. O’Neal, S.L., Hong L., Zheng W. (2012) Manganese is Sequestered in Rat Bone.
Poster presented at PULSe First Year Student Poster Session.
14. O’Neal, S. (2010). HydroGel is an Adequate Source of Hydration for Surgically
Modified Rat Models. Poster presented at the Academy of Surgical Research
Conference in Clearwater Beach, FL.
LEADERSHIP EXPERIENCE
Purdue University Graduate Student Government
Academic and Professional Development Committee—Chair
Academic and Professional Development Committee—Recorder

2012-2013
2011-2012

Department of Health Sciences Graduate Student Government
Vice President
Treasurer
President

2012-2013
2013-2014
2014-2015

TEACHING EXPERIENCE
Responsibilities include attending classes, taking attendance, preparing lecture materials,
holding office hours, holding weekly review sessions, proctoring exams, grading
assignments, reports and exams, individual tutoring and calculating course grades.
Teaching Assistant to Lisa Hilliard,
Medical Terminology HSCI 13100
Introduction to Medical Laboratory Sciences HSCI 13000
Immunology for Medical Laboratory Sciences HSCI 33300
Teaching Assistant to Dr. Wei Zheng,
Toxicology HSCI 56000
Teaching Assistant to Dr. Frank Rosenthal,
Introduction to the Health Science Professions HSCI 10100
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Industrial Hygiene Engineering Control HSCI 34600
Principles of Public Health Science HSCI 20100
Teaching Assistant to Dr. Neil Zimmerman,
Applied Industrial Hygiene HSCI 44600
Introduction to Environmental and Occupational Health Sciences HSCI 34500
Teaching Assistant to Dr. Craig E. Nelson,
Freshman Intensive Seminars, Indiana University
MENTORING EXPERIENCE
Supervising Honors Undergraduate Researchers in the School of Health Sciences
Alexander Jones: Pharmacokinetics of manganese exposure in bone
Vivien Lai: Aberrant migration of neural stem cells after manganese exposure
Erin Kay: Effects of manganese exposure in adult subgranular zone of the dentate gyrus

PROFESSIONAL SERVICE
Reviewer for Professional Journals
NeuroToxicology, Chemical Research in Toxicology, Biological Trace Element Research
Society of Toxicology
Metals Specialty Section- Elected Graduate Student Representative
Rapid Response Task Force- Appointed Graduate Student Representative
Graduate Student Leadership Council- Communications subcommittee member
CONFERENCES ATTENDED
Ohio Valley Society of Toxicology Student Meeting—Cincinnati, OH
Society of Toxicology 54rd Annual Meeting—San Diego, CA
Ohio Valley Society of Toxicology Annual Meeting—Dayton, OH
Ohio Valley Society of Toxicology Student Meeting—Louisville, KY
Society of Toxicology 53rd Annual Meeting—Phoenix, AZ
Alzheimer’s Disease Research Symposium—Indianapolis, IN
Society for Neuroscience Regional Meeting—Indianapolis, IN
Ohio Valley Society of Toxicology Regional Meeting—Louisville, KY
Ohio Valley Society of Toxicology Student Meeting—Cincinnati, OH
Society of Toxicology 52nd Annual Meeting—San Antonio, TX
Parkinson’s Disease Research Symposium—Indianapolis, IN
Academy of Surgical Research—Clearwater Beach, FL
American Association for Laboratory Animal Science—Indianapolis, IN
Animal Behavior Management Alliance—Houston, TX

2015
2015
2014
2014
2014
2013
2013
2013
2013
2013
2012
2010
2008
2005
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